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 Polyketides are a large and diverse family of natural products 
encompassing some of the most effective and valuable pharmaceuticals of all 
time, as well as some of the deadliest toxins.  These fascinating molecules are 
biosynthesized by some of nature’s largest and most complex enzymes, the 
polyketide synthases.  Because of their diverse biological activities, polyketide-
based natural products are an attractive target for biosynthetic engineering.  In 
order to effectively engineer polyketide synthases to produce novel compounds, 
we must understand the native enzymology of these molecular machines.  Since 
they consist of only a single set of catalytic domains, the fungal, iterative 
polyketide synthases are particularly challenging to decipher and engineer, 
relative to the assembly-line-like modular polyketide synthases.  In this work, 
biochemical and structural studies are performed to improve understanding of 
iterative polyketide synthase enzymatic programming.  By performing a screen 
of thirty unnatural starter units, the substrate specificity of the iterative 
polyketide synthase PksA was evaluated.  Characterization of enzymatic 
derailment products allowed for interrogation of the tolerance of specific 
catalytic domains to the unnatural substrates.  Through mechanism-based 
crosslinking of a closely related iterative polyketide synthase, CTB1, the structure 
of a polyketide synthase locked in a loading conformation was observed by cryo-
iii 
 
electron microscopy.  This first-ever multidomain structure of a non-reducing 
polyketide synthase may help to guide future engineering efforts, by beginning 
to establish what conformational changes polyketide synthases undergo during 
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Chapter 1: Introduction to polyketide natural products 
1.1.  Introduction 
 The polyketide class of natural products encompasses tens of thousands of 
diverse compounds with equally diverse biological activities (Figure 1.1).  Many 
polyketide-based natural products have been transformed into life-saving drugs, 
while others are deadly toxins.  One of the earliest and most well-studied is the 
antibiotic erythromycin 1, which is FDA approved in its native form as well as 
several synthetic derivatives (e.g. clarithromycin, azithromycin), and is on the 
World Health Organization’s List of Essential Medicines1-2.  Some of the most 
successful drugs of the 21st century, including the best-selling pharmaceutical of 
all time, atorvastatin (Lipitor), are the cholesterol-lowering, polyketide-based 
statins3.  The first statin to reach market was lovastatin 2, isolated from the 
fungus Aspergillus terreus4-5.  A fascinating example of the diversity of biological 
activities of polyketide-derived pharmaceuticals is the immunosuppressant 
rapamycin 3, which has also been shown to have anticancer and possibly 






Figure 1.1.  Examples of polyketide-based natural products. 
 
While many polyketide-based natural products have beneficial effects on 
human health, others are potent toxins of significant concern to the agricultural 
industry.  The hepatotoxin aflatoxin B1 4 is produced by Aspergillus parasiticus, a 
fungal pathogen of staple crops such as corn, wheat, and rice.  A. parasiticus 





































































































































supply directly through contaminated crops or through accumulation in 
livestock from contaminated feed6.  Since aflatoxin B1 is so potent, for example, 
causing carcinomas in all rats fed with 15 ppb, it is of significant concern to 
human health7-8.  Another potent polyketide-based toxin, cercosporin 5, is 
produced by the plant pathogens Cercospora spp.9.  Cercospora also infects a wide 
variety of agriculturally important crops, including sugar beets, corn, and rice, 
and causes millions of dollars in losses each year10. 
 Since the first characterization of a polyketide-like molecule by James 
Collie in 1893, the biosynthesis of this remarkable class of molecules has been of 
particular interest11.  After isolating orsinol 6 from a degradation reaction of 
dehydroacetic acid 7, Collie proposed it could be formed by way of a triketone 
intermediate 8 (Figure 1.2).  He further suggested that these polyketone 
intermediates may be involved in production of these molecules by living cells.  
Unfortunately, it was not until the 1950s that the true biosynthetic basis of 
polyketide synthesis was established, when Arthur Birch began researching 6-
methyl-salicylic acid (6-MSA) 9, the precursor to patulin 10, a fungal polyketide 
produced by Penicillium patulum.   
Figure 1.2.  Collie’s proposed formation of orsinol 6 through the triketide intermediate 8. 
O
O








Birch hypothesized that 6-MSA is synthesized by the ‘head-to-tail’ 
assembly of four acetate units.  Subsequent cyclization and aromatization steps 
could then yield the final product.  To prove this hypothesis, he fed radiolabeled 
acetate to the producing organism, and analyzed the resulting natural product 
for a specific labelling pattern12.  If his hypothesis was correct, the isolated 6-MSA 
would be labelled uniformly only at specific positions due to incorporation of the 
[1-14C]-acetate (Figure 1.3).  Through specific degradation of the labelled 
molecule, followed by measurement of radioactivity of each of the fragments, 
Birch was able to demonstrate isotopic enrichment at the predicted sites, 
validating his hypothesis.   
Figure 1.3.  Birch’s demonstration of the polyketide basis of 6-MSA by incorporation of [1-14C]-
acetate (indicated by dots). 
 
The success of Birch’s labelling experiments triggered a burst of similar 
studies to determine the biosynthetic origin of a number of natural products.  A 
further boon to the natural products field came in the 1970s, when Fourier-
transform nuclear magnetic resonance (NMR) spectroscopy became commonly 
available and was applied to polyketide biosynthesis.  This technique became 












commercially available.  Previously, labelling patterns were determined by 
months of labor-intensive degradation studies.  However, incorporation of these 
stable isotopes into polyketides by their producers allowed for determination of 
structures and labelling patterns in a single NMR experiment; therefore, much 
more complex molecules could be studied. 
Compared to early, simple polyketides such as orsinol and 6-MSA, the 
known scope of polyketide-based natural products is incredibly broad.  While 
the core reaction of polyketide biosynthesis - condensation of acetate units - 
yields a simple poly-β-ketone chain, a huge variety of tailoring reactions produce 
seemingly endless variations on the theme.  While some of these modifications 
are installed by domains within the polyketide synthase (PKS) itself (e.g. 
reduction, dehydration, methylation), many more are catalyzed by distinct 
tailoring enzymes.  Generally, the PKS and its associated tailoring genes are 
organized within a biosynthetic gene cluster13.  Biosynthetic gene clusters contain 
all of the genes required for biosynthesis of a given natural product, as well as 
genes involved in regulation of pathway expression or resistance.  With the 
advent of the genomic era of natural product biosynthesis, their fortunate 
organization into gene clusters has greatly increased the rate at which new 
natural product pathways have been identified. 
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Genetic techniques developed in the 1980s allowed for the 
characterization of the first PKS, a type II system responsible for the biosynthesis 
of the antibiotic actinorhodin 11.  The blue color of 11 provided an obvious 
screening method to identify genes involved in biosynthesis: mutants that 
abolish production lost their characteristic color and antibiotic activity14.  By 
sequencing the region of the genome identified by these mutational studies, the 
biosynthetic enzymes were localized and characterized.  Comparison of these 
enzymes to fatty acid synthase (FAS) sequences showed that they included FAS-
like domains: ketosynthase (KS), acyl-transferase (AT), acyl-carrier protein 
(ACP), and ketoreductase (KR).  Further genetic advances allowed specific 
removal of enzymes within the pathway and complementation of those genes 
through an added plasmid.  These techniques led to interrogation of the pathway 
in full by analyzing intermediates accumulated in vivo by various blocked 
mutants (Figure 1.4)15-16. 
Figure 1.4.  Biosynthesis of actinorhodin 11 by a type II PKS.  (a)  Organization of act genes 
involved in biosynthesis of 11 in Streptomyces coelicolor.  (b) Role of each act gene in 11 
biosynthesis, established by gene knockouts. 
















































1.2. Polyketide Synthases 
1.2.1.  The Polyketide Synthase Catalytic Cycle 
 Polyketides are synthesized by some of the world’s largest and most 
complex enzymes, the polyketide synthases (PKSs).  For example, MlsA1, which 
contains the first ten modules involved in biosynthesis of mycolactone, weighs in 
at 1.8 MDa17.  Since their discovery, understanding of PKSs has been based on the 
more well understood fatty acid synthase (FAS) from primary metabolism.  
Biosynthesis of fatty acids by FAS and polyketides by PKSs share a common core 
reaction: homologation of two-carbon units to form poly-β-ketone chains.  This 
core reaction is accomplished by three domains: an acyl-transferase (AT), a 
ketosynthase (KS), and an acyl-carrier protein (ACP) (Figure 1.5).  The ACP is 
post-translationally modified with a phosphopantetheine arm, which is an 
approximately 20 Å long flexible tether that allows for shuttling of substrates 
between the catalytic domains, while keeping the reactive poly-β-ketone 
intermediates covalently bound to the enzyme.  An acyl starter unit, typically 
acetyl-CoA or decarboxylated malonyl-CoA, is selected by the AT to initiate 
catalysis.  This starter unit is then loaded onto the KS, by way of the ACP.  The 
AT is then free to load an extender unit, typically malonyl-CoA, which is 
subsequently transferred to the ACP.  Finally, the KS catalyzes a decarboxylative 
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Claisen condensation between the starter unit and the ACP-bound extender unit, 














































































Figure 1.5.  General polyketide synthase catalytic cycle.  The core reaction of PKS biosynthesis is 
elongation via Claisen condensation, catalyzed by the KS.  The newly-installed β-ketone can then 
be optionally reduced by KR, DH, and ER domains.  All substrates and intermediates are 
covalently anchored to the enzyme by the ACP.  The TE catalyzes release of the final product. 
 
 In FAS, the β-ketone is fully reduced to a methylene after each round of 
elongation by a full suite of tailoring domains.  First, the keto group is reduced to 
a hydroxyl by the ketoreductase (KR).  This hydroxyl group is then eliminated as 
water, forming an alkene, by the dehydratase (DH), followed by a final reduction 
to the methylene by the enoyl reductase (ER).  PKSs may contain some, all, or 
none of these reductive domains, and the ketone installed by each elongation 
step can be optionally modified to any of these reduced states.  PKSs may also 
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contain a C-methyltransferase (MT) domain for installation of a S-adenosyl-
methionine (SAM) derived methyl group at the α-position following each round 
of extension.  Finally, the fully extended polyketide or fatty acid is specifically 
released from the enzyme by a thioesterase (TE).  This release is most commonly 
accomplished by hydrolysis, in the case of FAS, or macrolactonization, in the 
case of many modPKSs.  However, TEs also occasionally catalyze lactonization18 
or Claisen cyclization19-20. 
The non-reducing (NR)-PKSs contain two unique domains: a starter unit 
AT (SAT) and a product template (PT) domain.   In these systems, the SAT 
domain is responsible for specific selection of the starter unit, which can be more 
complex than the typical acetyl-CoA starter unit, and in some cases directly 
transferred from an upstream FAS or HR-PKS.  For example, the PksA SAT 
accepts a hexanoyl starter unit from a dedicated pair of yeast-like FASs21-23.  
Similarly, in asperfuranone biosynthesis, the NR-PKS AfoE accepts a 
dimethyloctadienone starter unit from the highly-reducing (HR)-PKS AfoG24.  
Hybrid systems in which the PKS accepts a starter unit from a non-ribosomal 
peptide synthetase further increase the diversity of polyketide-based natural 
products25-27.  In systems with a dedicated SAT, the extender unit loading AT is 
termed the malonyl-CoA AT (MAT).  The PT domain is responsible for 
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regiospecific cyclization of the fully oxidized, extended poly-β-ketone in NR-
PKSs28.   
1.2.2.  Classification of PKSs – Early lessons from modular PKSs 
 FASs and PKSs are closely related biosynthetic enzymes, both accomplish 
the condensation of acetate units into carbon chains, and share many 
biosynthetic domains.  FASs are broadly categorized based on their structural 
organization.  Type I FASs (fungal, mammalian) are multienzymes, where all 
domains are covalently linked in a single polypeptide.  Conversely, in type II 
FASs (bacterial), each domain is contained on its own discrete protein.  PKSs are 
also categorized based on this system, but include a third category – type III 
PKSs, which act on CoA- (rather than ACP-) bound substrates.  
Type I PKSs exist as both modular (modPKS) and iterative (iPKS) systems.  
ModPKSs, where each set of domains (module) canonically performs only a 
single elongation/modification reaction to extend the growing polyketide chain, 
are the most well understood class of PKSs.  Modules are organized in an 
assembly-line fashion, where the domains present in each module (generally) 
dictate the chemical modification at that stage of extension.  The first 
characterized type I PKS was the modPKS involved in biosynthesis of the 
antibiotic erythromycin by Saccharopolyspora erythraea, 6-deoxyerythronolide B 
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synthase (DEBS)29.  DEBS was independently identified by two labs using two 
distinct genetic approaches.  Peter Leadley’s group at Cambridge took advantage 
of the clustering of biosynthetic genes with those that confer self-resistance, and 
identified PKS genes in close proximity to the erythromycin resistance gene 
ermE30-32.  Conversely, Leonard Katz’s group at Abbott Laboratories identified 
mutations that abolished production of 6-deoxyerythronolide B, and found them 
to be located within PKS genes33-35. 
DEBS consists of six biosynthetic modules housed in three polypeptides.  
Each module contains, at minimum, the domains required to catalyze the 
condensation of propionate units into a polyketide chain – KS, AT, and ACP.  
Additionally, a variable selection of tailoring domains is present in each module, 
which determines the reductive modification of each β-ketone during elongation.  
For example, module 4 contains the whole suite of reductive domains – DH, ER, 
and KR – and thus the ketone installed by module 4 is fully reduced to the 
saturated thioester.  Conversely, module 1 contains only a KR, so the ketone 
should be reduced to a hydroxy group.  As expected, the PKS product 6-
deoxyerythronolide B has a structure fully consistent with the domain 
architecture of each module35.  Therefore, DEBS is the paradigm example of co-
linearity in modPKS biosynthesis, where products can be predicted based on 
which domains are present in each module, and domain architecture can be 
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predicted based on the structure of the polyketide product.  This concept of co-
linearity and the assembly-line nature of modPKSs make them much simpler to 
analyze and engineer than iPKSs. 
In contrast to the assembly-line architecture of modPKSs, where each 
module performs only a single round of extension, iPKSs consist of only a single 
set of domains, which act repeatedly during each catalytic cycle.  Therefore, 
while the enzymes themselves are smaller and simpler, the programming and 
prediction of iPKS products is considerably more difficult.  iPKSs are further 
categorized by the extent to which the polyketide is reduced, from highly-
reducing (HR)-PKSs with up to a full suite of reductive domains, to non-
reducing (NR)-PKSs which lack any reductive domains.  A prototypical example 
of NR-PKSs is PksA, responsible for the first step of aflatoxin biosynthesis in 
Aspergillus parasiticus.   
 
1.3.  Tools for understanding polyketide biosynthesis 
1.3.2.  Domain dissection for in vitro analysis 
 The iterative NR-PKSs are typically fungal and notoriously difficult to 
express in traditional heterologous bacterial hosts (e.g. E. coli), so traditional 
biochemical in vitro experiments on this class of PKS have been in short supply.  
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Due to their iterative nature, traditional in vivo mutagenesis experiments do not 
allow for detailed interrogation of the biosynthesis of iPKSs.  Inactivating a given 
catalytic domain through mutagenesis will completely abolish production in 
vivo, since each domain is used repeatedly throughout the catalytic cycle.  
Conversely, the activity of individual domains, or even full modules, of modPKS 
can be interrogated by inactivation and subsequent analysis of the accumulated 
product.  For example, when the KR of module 5 of DEBS is removed, an 
erythromycin analog is produced in which the keto group has been maintained 
at the expected position, rather than being reduced to a hydroxyl group35. 
 Limited proteolysis is commonly used to dissect multidomain enzymes 
into their individual domains36.  The relatively unstructured linker regions 
between the globular domains is proposed to be more accessible to proteases.  In 
early studies of FAS isolated from chicken, fortuitous proteolysis from native co-
purified proteases was observed under specific conditions37.  The susceptibility of 
the multidomain FAS to limited proteolysis could be used as a biochemical tool; 
for example, through controlled trypsinization, the TE was isolated and 
characterized38.  This technique was later used to dissect the modPKSs DEBS1, 2, 
and 3, and identify their linker regions by limited proteolysis followed by N-
terminal sequencing39-40.  Together, these two methods allowed for cloning and 
heterologous expression of isolated PKS and FAS domains, which can be 
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analyzed in vitro to determine catalytic activity or for structural studies.  
However, if native, intact protein cannot be expressed (as in the case of most NR-
PKSs), this technique is of little utility.  Instead, linker regions can be predicted 
based on primary structure, as they exhibit less sequence conservation than the 
catalytic domains.  Udwary and Merski improved upon this simple method of 
linker region prediction with their UMA algorithm, which also takes predicted 
local secondary structure and hydrophobicity into account41.  Their algorithm 
was validated with enzymes of known structure, such as methionine synthase 
(MetH) and DNA polymerase I.  It has since been used to successfully dissect a 
number of NR-PKSs, including PksA19 and PksCT42. 
 Dissection of iPKS catalytic domains has allowed for detailed 
characterization of fungal polyketide biosynthesis.  For instance, despite 
herculean efforts with a variety of heterologous expression systems, the NR-PKS 
PksA was not amenable to expression as an intact construct.  It was not until the 
UMA algorithm allowed dissection of PksA into smaller mono-, di- and tri-
domain constructs that its activity could be studied in vitro19.  By reconstituting 
various PksA domain combinations, the role of each domain in biosynthesis was 
defined (Figure 1.6).  The minimal PKS (SAT-KS-MAT + ACP), and the minimal 
PKS plus TE, produced only minute quantities of products.  However, addition 
of the PT domain to the minimal PKS resulted in significant production of the 
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regiospecifically cyclized product napthopyrone 12, demonstrating the PT’s role 
in cyclization.  Addition of the TE to this reaction nearly eliminated production 
of napthopyrone, instead producing the on-pathway product norsolorinic acid 
anthrone 13 and its oxidation product norsolorinic acid 14.  Therefore, domain 
dissection allows not only for in vitro analysis of PKSs that cannot be expressed 
in their entirety, but also allows for interrogation of activities of specific domains. 
SAT KS MAT PT ACP1 TE
SH SH OH OHSH























































Figure 1.6.  PksA biosynthetic scheme, determined by domain deconstruction.  (a)  Domain 
organization of PksA.  Cut sites for domain deconstruction are indicated by block arrows.  (b)  
Role of PksA domains in biosynthesis of 13, determined by in vitro reconstitution of dissected 
domains, as indicated. 
 
 A particularly powerful application of domain dissection is the ability to 
swap domains of different PKSs to further decipher their role in catalytic 
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programming, as well as synthesize novel polyketides.  By combinatorial 
reconstitution of domains from PKSs with products of defined chain length, 
cyclization pattern, and release mechanism, novel polyketides can be rationally 
designed and produced43-44.  Chain length was found to be strictly controlled by 
the KS: in all combinations of CTB1 minimal PKS and alternative PT and TE 
domains, a C14 polyketide was produced, regardless of the chain length 
specificity of the PT and TE domains44.  Cyclization register was faithfully 
determined by the PT domain, as long as the chain length was within one acetate 
unit of the PT’s native substrate.  For example, the ACAS PT combined with the 
CTB1 minimal PKS produced the C6-C11 cyclized pannorin.  Finally, the TE is 
crucial for product release and enzymatic turnover, and tends to be less tolerant 
to alternative substrates than the PT.  This observation is consistent with 
previous observations of TE-mediated editing of off-target or stalled enzymatic 
products45.  Productive biosynthesis of non-native products by combinatorial 
PKS reconstitution relies upon enzymatic cyclization and release occurring fast 
enough to overcome spontaneous cyclization and release, or TE editing.  These 
limitations can be partially overcome by fusing domain combinations into a 
single polypeptide43.  In both native and combinatorial PKSs, deconstruction 
imposes a biosynthetic penalty since domains must come together 
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intermolecularly to accomplish chemistry, as opposed to intramolecular reactions 
in the native system. 
1.3.2.  Structures of NR-PKS monodomains 
Other than the DEBS KS-AT didomain, structures of multidomain (or full-
length) PKS constructs have been difficult to obtain, likely due to their structural 
flexibility.  However, structures of each PKS domain have been elucidated as 
dissected monodomain constructs.  While many structures have been solved of 
modPKS domains (including reductive domains), this summary will focus on 
domains isolated from the NR-PKSs. 
 The first structure of an isolated NR-PKS domain, PksA PT, was reported 
fairly quickly after the UMA algorithm allowed successful deconstruction of 
PksA28.  The PT domain, a domain unique to NR-PKSs, catalyzes aldol 
cyclization and aromatization of the reactive poly-β-ketone intermediate.  In the 
case of PksA, cyclization occurs regiospecifically, first between C4 and C9, 
followed by C2-C11.  The mechanism by which this regiospecific cyclization is 
accomplished was an interesting enzymological problem.  The 1.8 Å resolution 
PT structure reveals a double hot dog fold, similar to that of the DH domains 
from mFAS and modPKSs (Figure 1.7).  Notably, the PT domain is located just 
downstream of the MAT domain in NR-PKS, analogous to the location of the DH 
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in mFAS and modPKS.  Palmitate (from E. coli heterologous expression) was 
found bound within a 30 Å deep pocket that can be divided into three regions.  
The deepest region of the pocket is lined with hydrophobic residues consistent 
with binding of the hexyl starter unit of the poly-β-ketone.  Next is a slightly 
wider cyclization chamber, which contains the His/Asp catalytic dyad.  Finally, a 
14 Å long tunnel leading to the cyclization chamber is proposed to bind the 
phosphopantetheine arm bearing the poly-β-ketone substrate.  The organization 
of the catalytic dyad and a corresponding oxyanion hole within the cyclization 
chamber are proposed to dictate the regiospecificity of PT cyclization. 
Figure 1.7.  1.8 Å crystal structure of PksA PT.  PksA PT forms a double hot dog dimer.  The two 
monomers are shown as ribbon diagrams in green and gray.  Palmitate visualized in the deep 
active site pocket is shown as magenta spheres.   
 
 Shortly after the PksA PT structure was solved, the X-ray crystal structure 
of PksA TE at 1.7 Å resolution was published20.  The PksA TE is distinct from 
mFAS and modPKS TEs, in that it catalyzes a C-C bond formation by way of 
Claisen cyclization, instead of thioester hydrolysis, to release the final PKS 
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product norsolorinic acid anthrone19.  Like other related TEs, monomeric PksA 
TE exhibits an α/β hydrolase fold and a helical lid region (Figure 1.8)46-50.  
Additionally, PksA TE contains the canonical Ser/His/Asp catalytic triad typical 
of TEs.  However, whereas modPKS TEs contain an open, hydrophilic, substrate-
binding channel, the substrate-binding region of PksA TE is deep and highly 
aromatic.  As this feature is conserved amongst TEs with Claisen cyclase activity, 
the hydrophobic nature of the PksA TE substrate-binding chamber appears to be 
characteristic of this class of TE domains. 
Figure 1.8.  1.7 Å crystal structure of PksA TE, shown as a ribbon diagram.  The α/β hydrolase 
core is shown in blue and the lid region is shown in yellow.  The catalytic triad residues 
(Ser1937/His2088/D1964) are shown as magenta spheres. 
 
 To round out the modifying region of PksA, the solution structure of PksA 
ACP was solved in 201051.  While type II FAS and PKS ACP structures have been 
extensively studied52-56, only a single other type I PKS ACP structure has been 
reported57.  PksA ACP was the first structure of an iPKS ACP, which is required 
20 
 
to shuttle a wide variety of intermediates throughout the catalytic cycle.  Like 
other type I and type II ACPs, PksA ACP consists of a four-helix bundle (Figure 
1.9).  However, helix III lies perpendicular to the other three parallel helices (I, II 
and IV), in contrast to the other structures.  This unusual conformation of helix 
III was attributed to its unusually hydrophobic nature, and resulting tight 
packing with the other helices.  In FAS ACPs, the more flexible helix III 
undergoes a conformational shift to allow for acyl chain binding55, 58-60.  While a 
slight conformational change was observed between holo PksA ACP and acylated 
(hexanoyl-loaded) holo PksA ACP, no analogous sequestration of the hexanoyl 
starter unit was observed.  ACP sequences are highly homologous amongst the 
NR-PKSs, suggesting these structural features may be conserved amongst this 
class of ACPs. 
Figure 1.9.  Solution structure of PksA ACP, shown as a ribbon diagram.  The 
phosphopantetheine attachment point (Ser1746) is shown as magenta spheres. 
 
 The most recent structure of a NR-PKS domain is that of the CazM SAT 
domain, involved in chaetoviridin 15 biosynthesis in Chaetomium globosum61.  NR-
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PKS SAT domains have the unique capability of accepting an acyl starter unit 
from an upstream FAS or PKS, as opposed to the more typical acetyl-CoA.  For 
example, PksA accepts its hexanoyl starter unit from a dedicated pair of yeast-
like FASs23.  Similarly, CazM utilizes a 4-methyl-hex-2-enoyltriketide starter unit 
16, synthesized by the HR-PKS CazF, and transferred by the CazM SAT domain 
(Figure 1.10a)62.  The structure of CazM SAT resembles other FAS and PKS AT 
domains, containing an α/β-hydrolase core and a small ferredoxin-like 
subdomain (Figure 1.10b).  A primarily hydrophobic active site cavity was 
observed in the interface between the α/β-hydrolase and ferredoxin subdomains.  
These hydrophobic residues likely contribute to CazM’s selectivity for its 
triketide substrate, in contrast to a more oxidized, tetraketide product of CazF.  
Comparison of crucial binding residues within CazM to other NR-PKS SAT 
domains may allow for rational engineering towards production of novel 











Figure 1.10.  (a)  Role of CazM SAT in biosynthesis of chaetoviridin 15 by the HR-PKS CazF and 
the NR-PKS CazM.  CazM accepts a starter unit synthesized by CazF to initiate NR-PKS 
biosynthesis.  (b)  1.6 Å crystal structure of CazM SAT.  The α/β hydrolase core is shown in 
purple, and the ferredoxin subdomain is shown in cyan.  The active site cysteine is shown as 
yellow spheres. 
 
1.3.3.  Full-length PKS structures and the rise of cryo-electron microscopy 
 As discussed previously, type I FAS has long been used as a basis for 
understanding type I PKS biochemistry.  This tactic is also applicable for 
understanding the structure of type I PKSs, since they share many of the same 
biosynthetic domains, organized in similar architectures.  The X-ray crystal 
structure of intact, porcine FAS (mFAS) was first reported in 2005 at 4.5 Å 





























dimeric FAS resembles a gingerbread man, with “legs” consisting of the KS-AT 
condensing region and “arms” containing the modifying region (DH, KR, ER, 
ACP, TE) (Figure 1.11).  The dimer is primarily mediated by the KS in the “leg” 
region, and the ER and DH in the “arm” region.  Presumably due to their 
inherent flexibility, neither the ACP nor the TE domains were resolved in either 
structure.  The approximate location of the TE at the end of each of the “arms” 
was inferred from EM images of guinea pig FAS labelled with anti-TE 
antibodies65. 
Figure 1.11.  3.2 Å crystal structure of porcine FAS.  Catalytic domains are color coded (from N- 
to C-terminus):  KS – orange, AT – orange, DH – light green, ψMT – purple, ER - green, KR – 
yellow.  Linker regions are shown in gray. 
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 Shortly after the first porcine FAS structure was published, the first hint 
towards PKS domain architecture emerged from the Khosla lab, which published 
the 2.7 Å crystal structure of the KS-AT didomain from DEBS module 566.  This 
structure closely resembled the corresponding domains in mFAS, in both overall 
topology and individual domain structures.  The KS domains form a tight dimer 
around the 2-fold axis, and are flanked on each side by the AT domains (Figure 
1.12).  Due to this similarity in structure and domain architecture, porcine FAS 
was validated as a model for type I PKS, both biochemically and structurally, 
and type I PKSs, both modular and iterative, were proposed to have a structure 
similar to that of mammalian FAS. 
Figure 1.12.  2.7 Å crystal structure of the KS-AT didomain from DEBS module 5.  Catalytic 
domains are color-coded as in Figure 1.11 (KS – orange, AT – red).  Linker regions are shown in 
gray. 
 In 2016, the relevancy of type I FAS as a model for type I PKS structures 
was further supported by the multidomain structure of an iterative HR-PKS, 
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mycoserosic acid synthase (MSA)67.  To achieve a hybrid crystal structure of the 
full-length enzyme, Maier and co-workers split MSA into a condensing region 
(KS-AT) and modifying region (DH-ER-KR).  The condensing region structure 
was solved to 2.2 Å resolution, and closely resembles that of DEBS KS-AT and 
mFAS.  The 3.75 Å resolution x-ray crystal of the modifying region also 
resembles that of mFAS, consisting of an overall dimeric organization mediated 
by the DH and ER domains.  When combined in silico, these structures yield an 
overall iPKS structure resembling that of mFAS, with modifying “arm” and 
condensing “leg” regions connected by a flexible “waist”.   
 Recently, advances in cryo-electron microscopy (EM) have provided new 
promise for elucidation of full-length PKS structures previously inaccessible by 
X-ray crystallography.  Previously, structure determination by cryo-EM was 
limited to relatively large and rigid proteins and biological particles, such as the 
ribosome and viral particles68-72.  Improvements in sample preparation and 
development of direct-electron detectors have pushed cryo-EM into the realm of 
high-resolution structure determination methods73-77.  These advances have 
allowed for the determination of a cryo-EM structure of an intact PKS module 
involved in pikromycin biosynthesis, PikAIII78.  This structure was surprising, in 
that its overall architecture deviates from the “gingerbread man” model 
developed based on the mFAS structure, which has thus far been consistent with 
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other modPKS and iPKS structures.  The PikAIII module is arch shaped, with a 
single reaction chamber at its center, rather than the dual reaction chambers 
observed in mFAS and HR-PKS.  This architecture represents a 120° rotation of 
the AT relative to the KS compared to other modPKS structures, and a 
completely distinct KS-AT interface.  Cryo-EM analysis of PikAIII also resulted 
in observation of substrate-dependent localization of the ACP domain79.   
 
1.4.  Outlook 
 Through advances in PKS deconstruction and structural elucidation over 
the past ten years, the “black box” of NR-PKS biosynthesis is beginning to be 
unpacked.  Activities of individual domains, and their role in programming 
biosynthesis, have been well studied.  Similarly, many monodomain structures 
have been determined, illuminating the structural basis for starter unit selection, 
cyclization, and product release.  However, the question remains as to how 
overall biosynthetic programming is achieved.  Engineering of PKSs to produce 
novel compounds with valuable bioactivity is an important goal of the PKS field.  
However, success in achieving this goal has been limited.  In order to 
successfully engineer PKSs, understanding of substrate tolerance and enzymatic 
programming must be improved.  In this thesis, studies to interrogate the 
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tolerance of PKS domains to non-native starter units demonstrate some 
capabilities and limitations of iPKS engineering.  Structures of full-length iPKSs 
will help decipher how individual domains interact to accomplish the complex 
series of reactions required by iterative polyketide biosynthesis.  In an important 
step toward this goal, we present a multidomain structure of an iPKS locked in 
its loading state by mechanism-based crosslinking. 
 
1.5.  References  
1. Staunton, J., Combinatorial biosynthesis of erythromycin and complex 
polyketides. Curr Opin Chem Biol 1998, 2 (3), 339-45. 
2. Staunton, J.; Wilkinson, B., Biosynthesis of Erythromycin and Rapamycin. 
Chemical reviews 1997, 97 (7), 2611-2630. 
3. Tobert, J. A., Lovastatin and beyond: the history of the HMG-CoA reductase 
inhibitors. Nature reviews. Drug discovery 2003, 2 (7), 517-26. 
4. McKenney, J. M., Lovastatin: a new cholesterol-lowering agent. Clin Pharm 1988, 
7 (1), 21-36. 
5. Sutherland, A.; Auclair, K.; Vederas, J. C., Recent advances in the biosynthetic 
studies of lovastatin. Curr Opin Drug Discov Devel 2001, 4 (2), 229-36. 
6. Jelinek, C. F.; Pohland, A. E.; Wood, G. E., Worldwide occurrence of mycotoxins 
in foods and feeds--an update. J Assoc Off Anal Chem 1989, 72 (2), 223-30. 
7. Newberne, P. M.; Butler, W. H., Acute and chronic effects of aflatoxin on the liver 
of domestic and laboratory animals: a review. Cancer research 1969, 29 (1), 236-50. 
8. Wogan, G. N.; Newberne, P. M., Dose-response characteristics of aflatoxin B1 
carcinogenesis in the rat. Cancer research 1967, 27 (12), 2370-6. 
9. Daub, M. E.; Ehrenshaft, M., THE PHOTOACTIVATED CERCOSPORA TOXIN 
CERCOSPORIN: Contributions to Plant Disease and Fundamental Biology. Annu 
Rev Phytopathol 2000, 38, 461-490. 
10. Farr, D. F.; Bills, G. F.; Chamuris, G. P.; Rossman, A. Y., Fungi on plants and plant 
products in the United States. APS Press: Minnesota, 1989. 
11. Collie, J. N.; Myers, W. S., VII. - The formation of orcinol and other condensation 
products from dehydracetic acid. J Chem Soc Trans 1893, 63, 122-128. 
28 
 
12. Birch, A. J.; Massy-Westropp, R. A.; Moye, C. J., Studies in relation to 
biosynthesis.  VII. 2-Hydroxy-6-methylbenzoic acid in Penicillium griseofulvum 
Australian Journal of Chemistry 1955, 8 (4), 539-44. 
13. Keller, N. P.; Hohn, T. M., Metabolic Pathway Gene Clusters in Filamentous 
Fungi. Fungal genetics and biology : FG & B 1997, 21 (1), 17-29. 
14. Malpartida, F.; Hopwood, D. A., Molecular cloning of the whole biosynthetic 
pathway of a Streptomyces antibiotic and its expression in a heterologous host. 
Nature 1984, 309 (5967), 462-4. 
15. McDaniel, R.; Ebert-Khosla, S.; Hopwood, D. A.; Khosla, C., Engineered 
biosynthesis of novel polyketides. Science 1993, 262 (5139), 1546-50. 
16. McDaniel, R.; Ebert-Khosla, S.; Fu, H.; Hopwood, D. A.; Khosla, C., Engineered 
biosynthesis of novel polyketides: influence of a downstream enzyme on the 
catalytic specificity of a minimal aromatic polyketide synthase. Proc Natl Acad Sci 
U S A 1994, 91 (24), 11542-6. 
17. Stinear, T. P.; Mve-Obiang, A.; Small, P. L.; Frigui, W.; Pryor, M. J.; Brosch, R.; 
Jenkin, G. A.; Johnson, P. D.; Davies, J. K.; Lee, R. E.; Adusumilli, S.; Garnier, T.; 
Haydock, S. F.; Leadlay, P. F.; Cole, S. T., Giant plasmid-encoded polyketide 
synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl 
Acad Sci U S A 2004, 101 (5), 1345-9. 
18. Newman, A. G.; Vagstad, A. L.; Belecki, K.; Scheerer, J. R.; Townsend, C. A., 
Analysis of the cercosporin polyketide synthase CTB1 reveals a new fungal 
thioesterase function. Chem Commun (Camb) 2012, 48 (96), 11772-4. 
19. Crawford, J. M.; Thomas, P. M.; Scheerer, J. R.; Vagstad, A. L.; Kelleher, N. L.; 
Townsend, C. A., Deconstruction of iterative multidomain polyketide synthase 
function. Science 2008, 320 (5873), 243-6. 
20. Korman, T. P.; Crawford, J. M.; Labonte, J. W.; Newman, A. G.; Wong, J.; 
Townsend, C. A.; Tsai, S. C., Structure and function of an iterative polyketide 
synthase thioesterase domain catalyzing Claisen cyclization in aflatoxin 
biosynthesis. Proc Natl Acad Sci 2010, 107 (14), 6246-51. 
21. Hitchman, T. S.; Schmidt, E. W.; Trail, F.; Rarick, M. D.; Linz, J. E.; Townsend, C. 
A., Hexanoate synthase, a specialized type I fatty acid synthase in aflatoxin B1 
biosynthesis. Bioorganic chemistry 2001, 29 (5), 293-307. 
22. Watanabe, C. M.; Townsend, C. A., Initial characterization of a type I fatty acid 
synthase and polyketide synthase multienzyme complex NorS in the 
biosynthesis of aflatoxin B(1). Chemistry & biology 2002, 9 (9), 981-8. 
23. Foulke-Abel, J.; Townsend, C. A., Demonstration of starter unit interprotein 
transfer from a fatty acid synthase to a multidomain, nonreducing polyketide 
synthase. Chembiochem : a European journal of chemical biology 2012, 13 (13), 1880-4. 
24. Chiang, Y. M.; Szewczyk, E.; Davidson, A. D.; Keller, N.; Oakley, B. R.; Wang, C. 
C., A gene cluster containing two fungal polyketide synthases encodes the 
biosynthetic pathway for a polyketide, asperfuranone, in Aspergillus nidulans. 
Journal of the American Chemical Society 2009, 131 (8), 2965-70. 
29 
 
25. Yoo, Y. J.; Kim, H.; Park, S. R.; Yoon, Y. J., An overview of rapamycin: from 
discovery to future perspectives. Journal of industrial microbiology & biotechnology 
2016. 
26. Gulder, T. A.; Moore, B. S., Salinosporamide natural products: Potent 20 S 
proteasome inhibitors as promising cancer chemotherapeutics. Angewandte 
Chemie 2010, 49 (49), 9346-67. 
27. Du, L.; Sanchez, C.; Shen, B., Hybrid peptide-polyketide natural products: 
biosynthesis and prospects toward engineering novel molecules. Metabolic 
engineering 2001, 3 (1), 78-95. 
28. Crawford, J. M.; Korman, T. P.; Labonte, J. W.; Vagstad, A. L.; Hill, E. A.; Kamari-
Bidkorpeh, O.; Tsai, S. C.; Townsend, C. A., Structural basis for biosynthetic 
programming of fungal aromatic polyketide cyclization. Nature 2009, 461 (7267), 
1139-43. 
29. Caffrey, P.; Bevitt, D. J.; Staunton, J.; Leadlay, P. F., Identification of DEBS 1, 
DEBS 2 and DEBS 3, the multienzyme polypeptides of the erythromycin-
producing polyketide synthase from Saccharopolyspora erythraea. FEBS letters 
1992, 304 (2-3), 225-8. 
30. Cortes, J.; Haydock, S. F.; Roberts, G. A.; Bevitt, D. J.; Leadlay, P. F., An unusually 
large multifunctional polypeptide in the erythromycin-producing polyketide 
synthase of Saccharopolyspora erythraea. Nature 1990, 348 (6297), 176-8. 
31. Malpartida, F.; Hopwood, D. A., Molecular cloning of the whole biosynthetic 
pathway of a Streptomyces antibiotic and its expression in a heterologous host. 
1984. Biotechnology 1992, 24, 342-3. 
32. Bevitt, D. J.; Cortes, J.; Haydock, S. F.; Leadlay, P. F., 6-Deoxyerythronolide-B 
synthase 2 from Saccharopolyspora erythraea. Cloning of the structural gene, 
sequence analysis and inferred domain structure of the multifunctional enzyme. 
Eur J Biochem 1992, 204 (1), 39-49. 
33. Weber, J. M.; Losick, R., The use of a chromosome integration vector to map 
erythromycin resistance and production genes in Saccharopolyspora erythraea 
(Streptomyces erythraeus). Gene 1988, 68 (2), 173-80. 
34. Tuan, J. S.; Weber, J. M.; Staver, M. J.; Leung, J. O.; Donadio, S.; Katz, L., Cloning 
of genes involved in erythromycin biosynthesis from Saccharopolyspora 
erythraea using a novel actinomycete-Escherichia coli cosmid. Gene 1990, 90 (1), 
21-9. 
35. Donadio, S.; Staver, M. J.; McAlpine, J. B.; Swanson, S. J.; Katz, L., Modular 
organization of genes required for complex polyketide biosynthesis. Science 1991, 
252 (5006), 675-9. 
36. Klenow, H.; Overgaard-Hansen, K., Proteolytic cleavage of DNA polymerase 
from Escherichia Coli B into an exonuclease unit and a polymerase unit. FEBS 
letters 1970, 6 (1), 25-27. 
37. Stoops, J. K.; Arslanian, M. J.; Oh, Y. H.; Aune, K. C.; Vanaman, T. C.; Wakil, S. J., 
Presence of two polypeptide chains comprising fatty acid synthetase. Proc Natl 
Acad Sci U S A 1975, 72 (5), 1940-4. 
30 
 
38. Smith, S.; Agradi, E.; Libertini, L.; Dileepan, K. N., Specific release of the 
thioesterase component of the fatty acid synthetase multienzyme complex by 
limited trypsinization. Proc Natl Acad Sci U S A 1976, 73 (4), 1184-8. 
39. Aparicio, J. F.; Caffrey, P.; Marsden, A. F.; Staunton, J.; Leadlay, P. F., Limited 
proteolysis and active-site studies of the first multienzyme component of the 
erythromycin-producing polyketide synthase. The Journal of biological chemistry 
1994, 269 (11), 8524-8. 
40. Staunton, J.; Caffrey, P.; Aparicio, J. F.; Roberts, G. A.; Bethell, S. S.; Leadlay, P. F., 
Evidence for a double-helical structure for modular polyketide synthases. Nat 
Struct Biol 1996, 3 (2), 188-92. 
41. Udwary, D. W.; Merski, M.; Townsend, C. A., A method for prediction of the 
locations of linker regions within large multifunctional proteins, and application 
to a type I polyketide synthase. Journal of Molecular Biology 2002, 323 (3), 585-598. 
42. Storm, P. A.; Herbst, D. A.; Maier, T.; Townsend, C. A., Functional and Structural 
Analysis of Programmed C-Methylation in the Biosynthesis of the Fungal 
Polyketide Citrinin. Cell Chem Biol 2017, 24 (3), 316-325. 
43. Newman, A. G.; Vagstad, A. L.; Storm, P. A.; Townsend, C. A., Systematic 
domain swaps of iterative, nonreducing polyketide synthases provide a 
mechanistic understanding and rationale for catalytic reprogramming. Journal of 
the American Chemical Society 2014, 136 (20), 7348-62. 
44. Vagstad, A. L.; Newman, A. G.; Storm, P. A.; Belecki, K.; Crawford, J. M.; 
Townsend, C. A., Combinatorial domain swaps provide insights into the rules of 
fungal polyketide synthase programming and the rational synthesis of non-
native aromatic products. Angewandte Chemie 2013, 52 (6), 1718-21. 
45. Vagstad, A. L.; Bumpus, S. B.; Belecki, K.; Kelleher, N. L.; Townsend, C. A., 
Interrogation of global active site occupancy of a fungal iterative polyketide 
synthase reveals strategies for maintaining biosynthetic fidelity. Journal of the 
American Chemical Society 2012, 134 (15), 6865-77. 
46. Tsai, S. C.; Lu, H.; Cane, D. E.; Khosla, C.; Stroud, R. M., Insights into channel 
architecture and substrate specificity from crystal structures of two macrocycle-
forming thioesterases of modular polyketide synthases. Biochemistry 2002, 41 (42), 
12598-606. 
47. Tsai, S. C.; Miercke, L. J.; Krucinski, J.; Gokhale, R.; Chen, J. C.; Foster, P. G.; 
Cane, D. E.; Khosla, C.; Stroud, R. M., Crystal structure of the macrocycle-
forming thioesterase domain of the erythromycin polyketide synthase: versatility 
from a unique substrate channel. Proc Natl Acad Sci U S A 2001, 98 (26), 14808-13. 
48. Bruner, S. D.; Weber, T.; Kohli, R. M.; Schwarzer, D.; Marahiel, M. A.; Walsh, C. 
T.; Stubbs, M. T., Structural basis for the cyclization of the lipopeptide antibiotic 
surfactin by the thioesterase domain SrfTE. Structure 2002, 10 (3), 301-10. 
49. Samel, S. A.; Wagner, B.; Marahiel, M. A.; Essen, L. O., The thioesterase domain 
of the fengycin biosynthesis cluster: a structural base for the macrocyclization of 
a non-ribosomal lipopeptide. J Mol Biol 2006, 359 (4), 876-89. 
31 
 
50. Frueh, D. P.; Arthanari, H.; Koglin, A.; Vosburg, D. A.; Bennett, A. E.; Walsh, C. 
T.; Wagner, G., Dynamic thiolation-thioesterase structure of a non-ribosomal 
peptide synthetase. Nature 2008, 454 (7206), 903-6. 
51. Wattana-amorn, P.; Williams, C.; Ploskon, E.; Cox, R. J.; Simpson, T. J.; Crosby, J.; 
Crump, M. P., Solution structure of an acyl carrier protein domain from a fungal 
type I polyketide synthase. Biochemistry 2010, 49 (10), 2186-93. 
52. Crump, M. P.; Crosby, J.; Dempsey, C. E.; Parkinson, J. A.; Murray, M.; 
Hopwood, D. A.; Simpson, T. J., Solution structure of the actinorhodin 
polyketide synthase acyl carrier protein from Streptomyces coelicolor A3(2). 
Biochemistry 1997, 36 (20), 6000-8. 
53. Li, Q.; Khosla, C.; Puglisi, J. D.; Liu, C. W., Solution structure and backbone 
dynamics of the holo form of the frenolicin acyl carrier protein. Biochemistry 2003, 
42 (16), 4648-57. 
54. Findlow, S. C.; Winsor, C.; Simpson, T. J.; Crosby, J.; Crump, M. P., Solution 
structure and dynamics of oxytetracycline polyketide synthase acyl carrier 
protein from Streptomyces rimosus. Biochemistry 2003, 42 (28), 8423-33. 
55. Zornetzer, G. A.; Fox, B. G.; Markley, J. L., Solution structures of spinach acyl 
carrier protein with decanoate and stearate. Biochemistry 2006, 45 (16), 5217-5227. 
56. Sharma, A. K.; Sharma, S. K.; Surolia, A.; Surolia, N.; Sarma, S. P., Solution 
structures of conformationally equilibrium forms of holo-acyl carrier protein 
(PfACP) from Plasmodium falciparum provides insight into the mechanism of 
activation of ACPs. Biochemistry 2006, 45 (22), 6904-16. 
57. Alekseyev, V. Y.; Liu, C. W.; Cane, D. E.; Puglisi, J. D.; Khosla, C., Solution 
structure and proposed domain domain recognition interface of an acyl carrier 
protein domain from a modular polyketide synthase. Protein science : a publication 
of the Protein Society 2007, 16 (10), 2093-107. 
58. Roujeinikova, A.; Baldock, C.; Simon, W. J.; Gilroy, J.; Baker, P. J.; Stuitje, A. R.; 
Rice, D. W.; Slabas, A. R.; Rafferty, J. B., X-ray crystallographic studies on 
butyryl-ACP reveal flexibility of the structure around a putative acyl chain 
binding site. Structure 2002, 10 (6), 825-35. 
59. Roujeinikova, A.; Simon, W. J.; Gilroy, J.; Rice, D. W.; Rafferty, J. B.; Slabas, A. R., 
Structural studies of fatty acyl-(acyl carrier protein) thioesters reveal a 
hydrophobic binding cavity that can expand to fit longer substrates. J Mol Biol 
2007, 365 (1), 135-45. 
60. Upadhyay, S. K.; Misra, A.; Srivastava, R.; Surolia, N.; Surolia, A.; Sundd, M., 
Structural insights into the acyl intermediates of the Plasmodium falciparum 
fatty acid synthesis pathway: the mechanism of expansion of the acyl carrier 
protein core. The Journal of biological chemistry 2009, 284 (33), 22390-400. 
61. Winter, J. M.; Cascio, D.; Dietrich, D.; Sato, M.; Watanabe, K.; Sawaya, M. R.; 
Vederas, J. C.; Tang, Y., Biochemical and Structural Basis for Controlling 
Chemical Modularity in Fungal Polyketide Biosynthesis. Journal of the American 
Chemical Society 2015, 137 (31), 9885-93. 
32 
 
62. Winter, J. M.; Sato, M.; Sugimoto, S.; Chiou, G.; Garg, N. K.; Tang, Y.; Watanabe, 
K., Identification and characterization of the chaetoviridin and chaetomugilin 
gene cluster in Chaetomium globosum reveal dual functions of an iterative 
highly-reducing polyketide synthase. Journal of the American Chemical Society 
2012, 134 (43), 17900-3. 
63. Maier, T.; Jenni, S.; Ban, N., Architecture of mammalian fatty acid synthase at 4.5 
A resolution. Science 2006, 311 (5765), 1258-62. 
64. Maier, T.; Leibundgut, M.; Ban, N., The crystal structure of a mammalian fatty 
acid synthase. Science 2008, 321 (5894), 1315-22. 
65. Kitamoto, T.; Nishigai, M.; Sasaki, T.; Ikai, A., Structure of fatty acid synthetase 
from the Harderian gland of guinea pig. Proteolytic dissection and electron 
microscopic studies. J Mol Biol 1988, 203 (1), 183-95. 
66. Tang, Y.; Kim, C. Y.; Mathews, II; Cane, D. E.; Khosla, C., The 2.7-Angstrom 
crystal structure of a 194-kDa homodimeric fragment of the 6-
deoxyerythronolide B synthase. Proc Natl Acad Sci U S A 2006, 103 (30), 11124-9. 
67. Herbst, D. A.; Jakob, R. P.; Zahringer, F.; Maier, T., Mycocerosic acid synthase 
exemplifies the architecture of reducing polyketide synthases. Nature 2016, 531 
(7595), 533-7. 
68. Armache, J. P.; Jarasch, A.; Anger, A. M.; Villa, E.; Becker, T.; Bhushan, S.; 
Jossinet, F.; Habeck, M.; Dindar, G.; Franckenberg, S.; Marquez, V.; Mielke, T.; 
Thomm, M.; Berninghausen, O.; Beatrix, B.; Soding, J.; Westhof, E.; Wilson, D. N.; 
Beckmann, R., Cryo-EM structure and rRNA model of a translating eukaryotic 
80S ribosome at 5.5-A resolution. Proc Natl Acad Sci U S A 2010, 107 (46), 19748-
53. 
69. Gilbert, R. J.; Fucini, P.; Connell, S.; Fuller, S. D.; Nierhaus, K. H.; Robinson, C. V.; 
Dobson, C. M.; Stuart, D. I., Three-dimensional structures of translating 
ribosomes by Cryo-EM. Mol Cell 2004, 14 (1), 57-66. 
70. Baker, M. L.; Zhang, J.; Ludtke, S. J.; Chiu, W., Cryo-EM of macromolecular 
assemblies at near-atomic resolution. Nat Protoc 2010, 5 (10), 1697-708. 
71. Sirohi, D.; Chen, Z.; Sun, L.; Klose, T.; Pierson, T. C.; Rossmann, M. G.; Kuhn, R. 
J., The 3.8 A resolution cryo-EM structure of Zika virus. Science 2016, 352 (6284), 
467-70. 
72. Zhang, X.; Jin, L.; Fang, Q.; Hui, W. H.; Zhou, Z. H., 3.3 A cryo-EM structure of a 
nonenveloped virus reveals a priming mechanism for cell entry. Cell 2010, 141 
(3), 472-82. 
73. Campbell, M. G.; Cheng, A.; Brilot, A. F.; Moeller, A.; Lyumkis, D.; Veesler, D.; 
Pan, J.; Harrison, S. C.; Potter, C. S.; Carragher, B.; Grigorieff, N., Movies of ice-
embedded particles enhance resolution in electron cryo-microscopy. Structure 
2012, 20 (11), 1823-8. 
74. Li, X.; Mooney, P.; Zheng, S.; Booth, C. R.; Braunfeld, M. B.; Gubbens, S.; Agard, 
D. A.; Cheng, Y., Electron counting and beam-induced motion correction enable 




75. Henderson, R., Structural biology: Ion channel seen by electron microscopy. 
Nature 2013, 504 (7478), 93-4. 
76. Kuhlbrandt, W., Biochemistry. The resolution revolution. Science 2014, 343 (6178), 
1443-4. 
77. Kuhlbrandt, W., Cryo-EM enters a new era. Elife 2014, 3, e03678. 
78. Dutta, S.; Whicher, J. R.; Hansen, D. A.; Hale, W. A.; Chemler, J. A.; Congdon, G. 
R.; Narayan, A. R.; Hakansson, K.; Sherman, D. H.; Smith, J. L.; Skiniotis, G., 
Structure of a modular polyketide synthase. Nature 2014, 510 (7506), 512-7. 
79. Whicher, J. R.; Dutta, S.; Hansen, D. A.; Hale, W. A.; Chemler, J. A.; Dosey, A. M.; 
Narayan, A. R. H.; Hakansson, K.; Sherman, D. H.; Smith, J. L.; Skiniotis, G., 
Structural rearrangements of a polyketide synthase module during its catalytic 




Chapter 2:  Starter unit flexibility for engineered product 
synthesis by the non-reducing polyketide synthase PksA  
 
This chapter was adapted with permission from Huitt-Roehl, C.R., Hill, E.A., 
Adams, M.M., Vagstad, A.L., Li, J.W. and Townsend, C.A., ACS Chem Biol, 2015, 
10(6), 1443-9 
 
2.1.  Introduction 
Fatty acid synthases (FASs) and all but one clan of the related polyketide 
synthases (PKSs) exemplify the rare catalytic strategy of iteration; that is, the 
catalytic domains of these large proteins are re-used, typically a fixed number of 
times, and can accommodate substrates as small as two carbons to as large as 20 
or more1-3.  Thus, unlike the acute substrate discrimination associated with highly 
evolved primary metabolic enzymes, the potential synthetic hazards of substrate 
promiscuity are overcome by deeply buried active sites accessible to 
intermediates borne on carrier proteins and intraprotein transfers that confer 
high effective concentrations.  Such intrinsic plasticity in iterative systems raises 
the fundamental question of whether these active sites can more readily 
accommodate alternative building blocks to synthesize non-native products.  
Previous studies of modular PKSs, where each module canonically catalyzes a 
single set of elongation and tailoring steps during biosynthesis, have shown 
limited tolerance to a narrow range of both non-native starter4-8 and extender 
35 
 
units9-10.  The fungal non-reducing PKSs (NR-PKSs) mediate the simplest chain 
extension chemistry to a classical poly-β-ketone intermediate with no processing 
at the β-carbon during elongation, which distinguishes the other partially and 
highly reducing PKSs and all FASs11-14.  
NR-PKSs contain two domains unique among PKSs: a starter unit acyl-
transferase (SAT) that brings the chain initiating component onto the enzyme15, 
and a product template (PT) domain that controls the cyclization of the fully 
elongated, highly reactive poly--ketone intermediate to specific aromatic and 
fused aromatic products3, 16-17.  Combinatorial assemblies of heterodomains from 
a selection of NR-PKSs have shown that polyketide chain length is largely 
controlled by the ketosynthase (KS) domain, and the cyclization pattern is 
determined by the PT domain18-19.  The enzyme responsible for the biosynthesis 
of norsolorinic acid anthrone 2 in Aspergillus parasiticus, the precursor to aflatoxin 
B1 1, PksA20, accepts an unusual hexanoyl starter unit from a dedicated pair of 
yeast-like FASs (HexA/B, Figure 2.1a,b)21-23.  The SAT domain of most NR-PKSs 
prefers acetyl-CoA from common cellular metabolism and shows strong 
selection against even propionyl-CoA24.  However, there are similar enzyme 
pairs such as Hpm8 and Hpm3, where the highly-reducing PKS Hpm8 
synthesizes a relatively large partially-reduced starter unit, which is then 
transferred to the NR-PKS Hpm3 for further elongation25. 
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 In this work we combine the SAT-KS-MAT (malonyl-CoA acyl-
transferase) tridomain and the PT-ACP (acyl-carrier protein) didomain of PksA 
to examine the ability not only of the SAT to accept non-native starter units but 
also the KS and the PT to perform their central tasks in product synthesis as a 
more complete measure of both starter unit tolerance and NR-PKS synthetic 
function.  To simplify the analysis, the thioesterase (TE) domain, which catalyzes 
a further (Claisen) cyclization to anthrone 2, is not present and we rely on the 
facile self-enol lactonization of the PT-cyclized product 3 to release pyrone 4 or 





Figure 2.1.  PksA biosynthetic scheme.  (a)  Domain organization of PksA.  Active site residues 
are indicated.  (b)  PksA synthesizes the first intermediate in aflatoxin 1 biosynthesis – 
norsolorinic acid anthrone 2.  Bonds/moieties installed by each catalytic domain are color-coded 





2.2.  Results 
 
2.2.1.  Alternative starter unit in vitro assays.   
The C-terminal His6-tagged PksA SAT-KS-MAT tridomain and PT-ACP 
didomain were over-produced in E. coli and purified by Co2+-affinity 
chromatography as previously described18.  Potential starter units were 
presented as N-acetylcysteamine (SNAC) thioesters (Figure 2.1c), which were 
prepared by coupling of N-acetylcysteamine to commercially-available or readily 
synthesized carboxylic acids (see Appendix B).  Each substrate (1 mM) was 
assayed under uniform conditions in phosphate buffer at pH 7 containing 
glycerol (10%), malonyl-SNAC (1 mM), TCEP (1 mM), PksA SAT-KS-MAT and 
PT-ACP (10 μM), and incubated at room temperature for 4 hours. Products were 
extracted into ethyl acetate, separated by HPLC, and the UV-Vis spectrum of 
each was recorded (200-800 nm).  Exact masses were determined by UPLC-ESI-
MS. In all instances the naphthopyrone products gave a characteristic absorbance 
signature. 
2.2.2.  Linear acyl-SNAC starter units.   
Early examination of PksA starter unit preferences of the SAT domain 
indicated modest selectivity for hexanoyl over butanoyl or octanoyl15.  In a first 
set of experiments, systematic examination of the homologous series of linear C4–
C8 SNAC thioesters (5–9) was undertaken in the synthesis of norpyrone 4 and its 
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structural variants.  The non-native C5 fatty acid thioester was incorporated with 
comparable efficiency to the native hexanoyl starter (Figure 2.2, Appendix 
Figures B.2, B.4), but reactions of C4, C7 and C8 chain lengths were still evident.  
To facilitate comparison among the C4–C8 thioesters, the naphthopyrone product 
peak intensities were plotted relative to that of hexanoyl in Figure 2.2.  Starter 
units longer than C8 were not tested owing to their limited solubility under the 
assay conditions. Reactions of 6, 8, and 9 were less efficient in naphthopyrone 
product formation and correspondingly gave increased shunt and truncation 
products appearing at early retention times in the HPLC chromatogram 
(Appendix Figures B.3, B.5, B.6).  Recent deconstruction and domain “swapping” 
or heterodomain combinatorial experiments have revealed tight control of 
overall polyketide chain length to largely ± one ketide (C2) extension, while the 
PT domain exerts strict programming of ring formation despite receiving chain 
lengths both shorter and longer than wild-type18-19.  Reactions utilizing the C8 
starter unit 9 exemplify this tight chain length control, as one fewer ketide 
extension was performed to give a naphthopyrone product with the native C20 
chain length.  Similarly, one extra ketide extension occurred in the reaction of the 
C4 starter unit 6 to yield a C20 product.  In the case of the C7 starter unit 8, both C21 
and C19 products were observed, whereas only the C19 product was produced 
from the C5 starter unit 7.  This overall chain-length constraint in PksA likely 
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Figure 2.2.  Relative production of on-target naphthopyrones from linear acyl-SNAC starter units.  
Products are indicated on the y-axis and starter units are indicated on the right side of each bar.  
In the case of starter unit 8, where two naphthopyrone products of different chain lengths were 
produced, the peak areas of both products have been combined for this chart. 
 
 
To analyze the pattern of truncation and derailment products observed in 
all reactions, these off-target products have been categorized by basic core 
structures corresponding to known chromophores (Figure 2.3a, see Appendix 
Figure B.1 for full structures of all characterized products)19, 26.  Control reactions 
containing malonyl-SNAC as the sole substrate produced primarily the 
naphthopyrone 42 (Figure 2.3b) in which decarboxylated malonyl-SNAC was 
41 
 
used as the starter unit.  Monitoring the steady-state population of intermediates 
bound to the PksA ACP by mass spectrometry revealed acetyl in addition to the 
expected hexanoyl and malonyl27.  One can visualize that the appearance and 
inefficient utilization of an acetyl starter could arise by direct transfer from 
acetyl-SNAC, but more likely by transfer from malonyl-SNAC to the MAT 
domain and then to the ACP, followed by decarboxylation.  In the case of the 
linear C4–C8 SNAC thioesters 5–9, the primary derailment products observed 
were the tri- and tetra-ketide lactones having core structure C, while only small 
amounts of improperly cyclized but fully extended and cyclodehydrated SEK4 
and SEK4b analogs were produced (cores D and E).  Therefore, extension by the 
KS domain may be the limiting factor in productive biosynthesis with linear 
starter units shorter or longer than the native hexanoyl primer, rather than 
cyclization in the proper register by the PT domain. As expected, the product 
profile for the reaction of C8 -ketothioester 10 is similar to that of the native 
hexanoyl starter unit.  While the observed products were nearly identical for the 
two reactions, efficiency was lower in the non-native case (Appendix Figure B.7).  
As this starter unit represents the first intermediate product of elongation, the 
reason for decreased productivity presumably owes to reduced binding 




Figure 2.3.  Core structures of observed derailment products.  (a)  Derailment product cores were 
determined based on exact mass and known chromophores.  (b)  Major product observed in 
control reactions containing malonyl-SNAC as the sole substrate. 
 
2.2.3.  Halogenated acyl-SNAC starter units.   
Experiments conducted to evaluate the efficiency of naphthopyrone 
production by PksA utilizing substituted acyl-SNAC thioesters demonstrated 
that modifications at the distal end of the thioester were well tolerated by the 
enzyme, particularly halogenation and methylation (Figure 2.4).  Starter units 
halogenated at the remote end of the acyl chain (11–14) were relatively well 
accepted, resulting in high product formation, albeit accompanied by significant 
amounts of derailment products, primarily the triacetic acid lactone analog (core 
C).  The product profiles among the four tested halogenated starter units were 
similar, although relative and absolute amounts of on-target and derailment 
products varied depending on chain length and identity of the halogen 
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substituent.  Similar to the linear, un-substituted starter units, reactions of the 
longer 7-atom halogenated substrates resulted in higher derailment production 
and lower naphthopyrone production.  Additionally, brominated products were 
produced in smaller amounts than chlorinated products, presumably owing to 
the relative steric bulk of the halogen substituent (Figure 2.4, Appendix Figures 
B.8–B.11).  
 
Figure 2.4.  Relative production of on-target naphthopyrones from halogenated acyl-SNAC 
starter units.  Products are indicated on the y-axis and starter units are indicated on the right side 








2.2.4.  Methylated acyl-SNAC starter units.   
Biosynthetic production and catalytic efficiency decrease with chain 
branching close to the thioester, as exemplified with reactions utilizing 
methylated starter units 15, 16, 17, and 18 (Figure 2.5).    Starter units with 
substituents at the 2- and 3- position were particularly unfavored, while starter 
units substituted at the 4- and 5- position were significantly better tolerated.  In 
the case of 2-branched 15, the major product was 42 (Figure 2.3b, Appendix 
Figure B.12), suggesting this starter unit is so poorly tolerated that inefficient 
priming and extension using decarboxylated malonyl-SNAC took place.  
Similarly, the reaction utilizing 16 also produced 42, albeit in a smaller 
proportion.  The fully extended but improperly cyclized SEK4/SEK4b analogs 
86a,b (cores D and E) were the major derailment products in reactions with 16, 
suggesting the KS domain is significantly more tolerant of substitution at the C-3 
position than the PT (Appendix Figure B.13).  Although only a small difference in 
naphthopyrone production was observed between reactions utilizing 17 and 18 
(Figure 2.5, Appendix Figures B.14, B.15), there was a marked difference in the 
ratio of naphthopyrone to derailment products. Thioester 17 gave a significant 
amount of the SEK4/SEK4b analogs 91a,b (Appendix Figure B.14).  While it was 
expected that a five-carbon long starter unit branched near its terminus, 19, 
would give an outcome comparable to 17 based on the location of the methyl 
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group, production of naphthopyrone product was significantly lower (Figure 2.5, 
Appendix Figure B.16).  These results indicate that branched starter units, 
especially if proximal to the thioester, can impede the ability of the PT domain to 
properly cyclize the mature polyketide chain. 
 
Figure 2.5.  Relative production of on-target naphthopyrones from methylated acyl-SNAC starter 
units.  Products are indicated on the y-axis and starter units are indicated on the right side of each 
bar. 
 
2.2.5.  Unsaturated acyl-SNAC starter units.   
Analogous to the methyl-branched starter units, desaturation was 
relatively well tolerated at the alkyl terminus of the acyl chain (starter unit 22), 
while the α,β-unsaturated SNAC thioester 20 reacted poorly (Figure 2.6).  This 
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reduced reactivity may owe to the intrinsically greater stability of a conjugated 
thioester slowing each acyl transfer step, or enzyme inhibition by this 
electrophilic species.  Three unsaturated starter units were tested for 
incorporation into naphthopyrone products.  The reaction utilizing 22 resulted in 
moderate production of the on-target final product and few derailment products 
(Figure 2.6, Appendix Figure B.19).  Conversely, reactions of 20 produced in the 
main the spontaneously cyclized SEK4/SEK4b analogs 104a,b (Appendix Figure 
B.17).  No significant peaks representing truncation products were observed in 
this reaction, suggesting the α,β-alkene was problematic for processing by the PT 
domain, but not the KS domain.  Unexpectedly, production of the 
naphthopyrone in the reaction of 21 was approximately equal to that of 20, but a 
more diverse profile of derailment products was observed with 20 (Figure 2.6, 
Appendix Figure B.18).  These included both improperly or partially cyclized, 
but fully extended products as well as truncation products.  As was the case of 
the methyl-branched starter units, the relative rigidity afforded by the alkene 








Figure 2.6.  Relative production of on-target naphthopyrones from unsaturated acyl-SNAC 
starter units.  Products are indicated on the y-axis and starter units are indicated on the right side 




2.2.6.  Heteroatom-substituted acyl-SNAC starter units.   
PksA is capable of incorporating oxyether- and thioether-containing 
starter units into naphthopyrone products (e.g. 23–28), but significant decreases 
in production and efficiency were observed (Figure 2.7).  Reactions utilizing 
methylthioether 23 resulted in product formation comparable to the analogous 
six-carbon starter unit 5, with only a slight increase in derailment products 
(Figure 2.7, Appendix Figure B.20).  The major derailment product observed for 
this reaction was the triketide lactone 114 (core C), while no significant peak 
intensities correlating to the SEK4/SEK4b analogs were observed.  Processing of 
23 into the naphthopyrone product 116 (Figure 2.7, Appendix Figure B.20) is, 
therefore, as efficient as that of the native starter unit.  Reactions of five- and 
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four-atom thioethers (24, 25, 26) resulted in lower product formation than the 
comparable carbon-only starter units (Figure 2.7, Appendix Figures B.21-B.23).  
This effect is particularly evident with starter unit 26, which produced 
significantly less product than its analogous carbon-only starter unit 6 (Figures 
2.2, 2.7, Appendix Figure B.23).  Derailment product types C, D and E were 
prevalent in these reactions, suggesting interference with the activity of both the 
KS and the PT domains.  As in the case of starter unit 6, reactions utilizing four-
atom thioethers underwent one extra extension to maintain the native C20 chain 
length, providing further evidence for tight chain length control by the KS 
domain.  Additionally, an eight-atom oxyether starter unit 27 produced a C20 
chain length product, analogous to the C8 alkane starter unit 9.  Surprisingly, 
production of the naphthopyrone product 129 containing this starter unit was 
significantly greater than that from starter unit 9, with correspondingly lower 
levels of derailment products (Figures 2.2, 2.7, Appendix Figure B.24).  The 
seven-atom oxyether starter unit 28 produced much less naphthopyrone product 
than 27, and increased amounts of the spontaneously cyclized derailment 
product 130a,b (cores D and E) (Appendix Figure B.25).   
Starter units amenable to downstream coupling strategies, such as those 
containing terminal cyano- and azido- groups (e.g. 29 and 30), were accepted by 
the enzyme, albeit with relatively low targeted product formation.  In both cases, 
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significant amounts of triketide and tetraketide truncation products were 
produced (Appendix Figures B.26, B.27).  In the case of starter unit 29, fully 
extended but improperly cyclized products 134a,b (Appendix Figure B.26) were 
observed as well. 
Figure 2.7.  Relative production of on-target naphthopyrones from heteroatom-substituted acyl-
SNAC starter units.  Products are indicated on the y-axis and starter units are indicated on the 
right side of each bar.  In the case of starter unit 27, where two naphthopyrone products of 





2.2.7.  Sterically constrained acyl-SNAC starter units.   
To test the tolerance of PksA to bulkier, more rigid substrates, SNAC-
thioesters containing cyclopropyl groups (31, 32), an alkyne (33) and a benzyl 
group (34) were assayed.  In the case of 31 and 32, a small amount of 
naphthopyrone product containing the cyclopropyl group was detected in both 
reactions (Figure 2.8).  Production with these starter units was extremely low, 
and all domains of the enzyme presumably had difficulty accommodating the 
cyclopropyl group within their active sites.  Compound 42 was the dominant 
product of these reactions, suggesting decarboxylated malonyl-SNAC is a more 
favorable primer for these reactions than 31 and 32 (Appendix Figures B.28, 
B.29).  This product was also observed in other reactions where production is 
poor, including starter units 6 and 15, as noted above, and 2-butynoyl-SNAC (33) 
(Appendix Figure B.30). Control reactions where malonyl-SNAC alone was 
provided to the enzyme in the absence of a candidate acyl-SNAC starter unit 
gave similar results (Appendix Figure B.32).  Conversely, benzoyl-SNAC 
reactions did not produce naphthopyrone product (Appendix Figure B.31).  
However, a very small amount of the triketide lactone (core C) was observed in 
the reaction of benzoyl-SNAC, suggesting some tolerance of this starter unit by 





Figure 2.8.  Relative production of on-target naphthopyrones from sterically constrained acyl-
SNAC starter units.  Products are indicated on the y-axis and starter units are indicated on the 
right side of each bar.  The x-axis has been split for clarity due to exceptionally low production of 
140 and 141. 
 
2.2.8.  SAT active site mutants.   
A series of SAT active site (Cys117) mutants was tested for product 
formation to further evaluate the role of the SAT domain in starter unit selection.  
Mutants were initially selected to mimic the other two naturally-occuring SAT 
active site motifs (GXSXG as in Giberella zeae Pks13 and GXGXG as in Aspergillus 
terreus ACAS)28-29 as well as another non-nucleophilic mutant (C117A).  Against 
expectation, presumably inactive C117A formed comparable levels of product to 
wild-type enzyme, as depicted in Figure 2.9.  Furthermore, the C117G mutant 
produced notably more product than wild-type.  Reactions with C117S, however, 
resulted in extremely low product formation.  This pattern was consistent among 
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all starter units tested and owes to hydrolysis of SNAC thioesters before 
inefficient acyl transfer to the ACP can take place (Figure 2.10).   
Figure 2.9.  Comparison of hexyl-naphthopyrone (4) production by PksA-SAT active site 
mutants. 
Figure 2.10.  Ellman’s reagent (DTNB) assay for detection of SNAC hydrolysis by PksA SAT 
active site mutants.  PksA SAT C117S hydrolyzes hexanoyl-SNAC to the free thioester (detected 
by Ellman’s reagent at 412 nm).  Control reactions lack hexanoyl-SNAC substrate. 
 
 
Given the largely unaltered reaction profiles with C117A and C117G 
variants, other SAT active site mutants were constructed to probe whether non-
covalent binding was responsible for increased production in C117A and C117G 
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mutants.  C117L, C117Q and C117N mutations were attempted in an effort to 
partially occlude the active site.  Soluble SAT-C117N-KS-MAT was obtained and 
evaluated for naphthopyrone product formation.  Production by this mutant was 
comparable to that of the wild-type enzyme and the C117A mutant, suggesting 
any non-covalent binding to the active site likely plays a small role, if any (Figure 
2.9).  It is worth noting, however, that production from C117G was still higher 
than the other variants, consistent with the possibility that non-covalent 
recognition and transfer may yet play a role in bringing starters onto the enzyme.  
 
2.3.  Discussion 
PksA can accept and utilize a circumscribed selection of acyl-SNAC 
substrates as starter units to support naphthopyrone biosynthesis.  The enzyme 
is tolerant to minor modifications in chain length and constitution of the thioester 
starter unit, especially at the distal end of the acyl chain, including substituents 
that allow subsequent modification of the resulting tricyclic product; for example 
“Click” chemistry30.  However, significant losses in production efficiency are 
observed with longer chain lengths or substitutions proximal to the thioester.  
Recent experimental advances have allowed production of full-length NR-
PKSs, albeit in much lower yields than smaller multi-domain constructs19.  As a 
control to measure the synthetic penalty, if any, exacted by dissection into a 2-
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part combination of SAT-KS-MAT and PT-ACP tri- and didomains, the 
corresponding fully intact 5-domain construct of PksA was prepared.  Owing to 
low protein yields, in vitro reactions were performed with 1 μM PksA SAT-KS-
MAT-PT-ACP, but under otherwise identical conditions to the previous 
experiments.  Three starter units (hexanoyl-SNAC [5], pentanoyl-SNAC [7], and 
benzoyl-SNAC [34]) were selected to compare production from both efficient and 
inefficient substrates.  For the former two efficient substrates, presuming 
reasonably that product formation tracks linearly with pentadomain enzyme 
concentration, production by the two-part combination lagged the intact 
construct by only a factor of 1.5 in the case of 5 and 1.2 in the case of 7 (Figure 
2.11).  As seen above in experiments with the two-part system, no 
naphthopyrone product containing the benzyl ring was observed in reactions of 
34.  This finding was in complete accord with similar comparisons of intact vs. 
domain combinations determined recently, and confirms the validity of the 







Figure 2.11.  Comparison of intact pentadomain (blue) and dissected two-part (black) reactions.  
(a)  Reaction of starter unit 5 (S-(2-acetamidoethyl) hexanethioate).  (b)  Reaction of starter unit 7 
(S-(2-acetamidoethyl) pentanethioate).  (c)  Reaction of starter unit 34 (S-(2-acetamidoethyl) 
benzothioate). 
 
The SAT active site mutants tested in this study gave unanticipated 
results.  While some native SAT domains contain a glycine substitution of the 
active site cysteine, these have previously been presumed to be inactive and 
compensated for by the activity(ies) of another domain(s).  Our experiments, 
however, suggest that at sufficiently high concentrations of starter unit, the KS 
can recognize the SNAC thioester as an adequate mimic of the normal ACP-
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delivered starter unit to be loaded directly.  Additionally, the possibility remains 
that even in the absence of a covalent bond between the SAT domain and a 
starter unit, non-covalent binding may increase effective concentrations 
sufficiently for efficient biosynthesis.  Although an active SAT domain is 
required for starter unit transfer within the HexA/HexBPksA complex22, under 
the super-physiological conditions utilized in this in vitro study, the SAT appears 
to be bypassed by some starter units and directly loaded on to the KS.  Such 
relatively facile utilization of non-native starter units is fortuitous but useful 
from the perspective of synthetic biology and rationally-directed biosynthesis. 
 Unlike other SAT domains that scavenge acetyl-CoA from their cellular 
environment, PksA receives its hexanoyl starter unit directly in complex with 
HexA/B and thus may have less pressure to be discriminating in its starter unit 
selection.  Analogous observations have been made in the case of the HR-
PKSNR-PKS pair Hpm3 and Hpm8, where a SNAC mimic of the starter unit can 
rescue production in the absence of an active SAT domain25.  Based on the 
limited data from these two examples, it can be anticipated that when SAT 
domains exist in FASNR-PKS or HR-PKSNR-PKS complexes, their primary 
function is interprotein transfer of a relatively large and/or complex starter unit 
and they are likely to be additionally flexible in the modified primers they accept 
and/or can be bypassed to directly load the KS.  Diversity of production is then 
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determined by the tolerance of the KS and PT to provide full polyketide chain 
elongation and correct cyclization register.  Recently, an X-ray structure of a SAT 
domain has been elucidated, which may facilitate to mutagenesis experiments to 
remodel a SAT active site with the goal of efficient uptake of altered starter units 
and transfer to sustain directed biosynthesis in a physiological context31. 
 
2.4.  Experimental Methods 
2.4.1.  Cloning 
Cloning details for all constructs used in this study are provided in 
Appendix B.  All plasmids used are summarized in Appendix Table B.1, and 
primers are given in Appendix Table B.2. 
 
2.4.2.  Protein Expression and Purification 
All proteins were heterologously expressed in E. coli BL21(DE3) and 
isolated as described previously27, with the exception that Co2+-TALON resin 
(GoldBio) was used in place of Ni2+-NTA resin.  Expression of soluble 
pentadomain PksA SAT-KS-MAT-PT-ACP was achieved by an additional one-
hour cold shock in ice water prior to induction with 1 mM IPTG.  Following 
purification, proteins were dialyzed against assay buffer (100 mM potassium 
phosphate pH 7, 10% glycerol) and optionally frozen at –80 °C prior to use.  If 
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necessary, proteins were concentrated using 10K Molecular Weight Amicon 
Ultra Centrifugation Filters (Millipore).  Protein concentration was measured in 
triplicate using the Bradford assay (Bio-Rad) and bovine serum albumin as a 
standard (New England Biolabs). 
 
2.4.3.  In vitro assays 
Purified SAT-KS-MAT tridomain (10 μM) and PT-ACP didomain (10 μM) 
were combined with 1 mM malonyl-SNAC in assay buffer (100 mM potassium 
phosphate, pH 7.0, 10% glycerol, 1 mM TCEP).  Reactions were initiated by 
addition of 1 mM acyl-SNAC starter unit and allowed to run for 4 h at room 
temperature.  The 500 μL reactions were quenched with 10 μL hydrochloric acid 
and extracted three times with 500 μL ethyl acetate.  Extractions were pooled and 
evaporated to dryness using a Speed-Vac.  Enzymatic products were 
resuspended in 300 μL 40% aqueous acetonitrile for HPLC analysis. 
 
2.4.4.  HPLC and UPLC-ESI-MS analysis of enzymatic products 
100 μL injections of enzymatic products were analyzed over a Prodigy 
ODS3 analytical column (4.6 x 250 mm, 5 μ, Phenomenex) by a gradient HPLC 
method using an Agilent 1200 instrument equipped with an autosampler.  
Bisolvent method: linear gradient of 20% A/80% B to 90% A over 35 min, hold 
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90% A for 10 min, followed by re-equilibration to 20% A over 5 minutes with a 10 
minute hold, where solvent A is acetonitrile + 0.1% formic acid and solvent B is 
0.1% formic acid.  UV-vis spectra were recorded over a range of 200-800 nm, and 
chromatograms recorded at 280 nm.  High-resolution mass data were obtained 
by UPLC-ESI-MS on a Waters Acquity/Xeno-G2 in positive ion mode. 
 
2.4.5.  Synthesis of acyl-SNAC substrates 
Malonyl-SNAC was produced using the malonyl-CoA synthetase MatB 
from Rhizobium leguminosarum and HPLC purified as described previously26, 32.  
The synthesis of all acyl-SNAC starter units used in this study is described in 
Appendix B. 
 
2.4.6.  Ellman’s reagent assay for acyl-SNAC hydrolysis 
 Ellman’s reagent (5,5-dithio-bis-(2-nitrobenzoic acid), DNTB) was used to 
detect the free thiol of SNAC released by SAT-catalyzed hydrolysis.  5 μM SAT, 
0.2 mM DTNB, and 1 mM hexanoyl-SNAC were combined in 100 mM potassium 
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Chapter 3:  The structural organization of substrate loading 
in iterative polyketide synthases 
 
This chapter was adapted with permission from Herbst, D.A., Huitt-Roehl, C.R., 
Jakob R.P., Kravetz, J.M., Storm, P.A., Alley, J.R., Townsend, C.A., and Maier, T. 
Nat Chem Biol, submitted. 
 
3.1.  Introduction 
 Polyketide synthases (PKS) are large, multi-domain enzymes involved in 
the biosynthesis of a wide variety of pharmaceutically and agriculturally 
important natural products1.  Because of the value of many polyketide-based 
natural products, including lovastatin, erythromycin, and rapamycin, polyketide 
biosynthesis has been studied in great detail over the past several decades2.  Of 
particular interest to the Townsend lab are the fungal type I iterative non-
reducing polyketide synthases (NR-PKS)3.  In contrast to modular PKS 
(modPKS), in which multiple sets of catalytic domains, called modules, act 
sequentially in an assembly-line fashion4, the iterative PKSs (iPKSs) consist of a 
single set of domains.  This single polypeptide iteratively catalyzes substrate 
loading and elongation, with each domain catalyzing multiple reactions to form 
the polyketide.  iPKSs can be most closely compared to mammalian fatty acid 
synthase (FAS), which also acts in an iterative fashion to condense two carbon 
units into an acyl chain5.  In both cases, a ketosynthase (KS) domain catalyzes a 
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series of decarboxylative Claisen condensations to homologate 2-carbon units, 
provided as malonyl-CoA by an acyltransferase (AT, termed the malonyl-CoA 
AT (MAT) in iPKS).  All intermediates are covalently tethered to the enzyme 
through the phosphopantetheine arm of an acyl-carrier protein (ACP), which is 
post-translationally installed6.  In FAS, the polyketide is fully reduced after each 
extension by the reductive domains within the modifying region: a ketoreductase 
(KR), dehydratase (DH), enoyl-reductase (ER).  However, NR-PKSs lack any 
reductive domains, instead the reactive, poly--ketone intermediate is regio-
specifically cyclized by a product template (PT) domain7.   In addition to the PT, 
NR-PKSs contain another unique domain, the starter unit acyl-transferase (SAT), 
which selects an acyl-thioester starter unit to initiate biosynthesis8-10.  Finally, in 
both FAS and PKS, the thioesterase (TE) releases the fatty acid or cyclized 
polyketide, most commonly through hydrolysis11. 
These multidomain enzymes are incredibly challenging to study.  
Classical mechanistic enzymology cannot be employed, as PKSs contain multiple 
active sites, catalyze multiple discrete chemical reactions, and act 
intramolecularly on covalently-tethered substrates.  Furthermore, due to their 
large size and inherent structural flexibility, they are difficult to express in 
traditional heterologous hosts (e.g. E. coli) as intact constructs.  In order to 
circumvent these limitations, much of the biochemical and structural work to 
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date on PKS has been accomplished by utilizing a dissection approach, where 
domains are excised at the genetic level and expressed as smaller constructs 
consisting of 1-3 domains12.  The primary hurdle in successful dissection of PKS 
domains is determination of N- and C-terminal cut sites that will yield stable, 
active protein.  Early dissection attempts relied on limited proteolysis, where the 
relatively unstructured linker regions between domains are more readily 
proteolyzed13.  The cut sites of the resulting fragments can then be identified by 
N-terminal sequencing14.  More recently, linker regions were approximated by 
multiple sequence alignments, as their sequences are less conserved than those of 
the catalytic domains.  Ultimately, an algorithm was developed by Udwary and 
Merski to accurately predict linker regions based on sequence conservation, 
secondary structure prediction, and hydrophobicity15. 
 This domain dissection approach has allowed the functions of individual 
PKS domains to be deduced by in vitro reconstitution.  Furthermore, the 
structures of isolated monodomains have been solved for nearly all NR-PKS 
domains (SAT16, PT7, ACP17, and TE18).  Although structures of KS-AT didomains 
from modPKSs have been determined19-20, NR-PKS KS and MAT have never been 
successfully expressed as excised mono- or di-domains, despite extensive efforts.  
While isolated monodomain structures provide valuable insight into the 
mechanism of individual domains, the question remains how the domains are 
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integrated into the larger multienzyme, and how they coordinate their actions for 
the complex programming required for polyketide synthesis.  
 The X-ray crystal structure of animal FAS was first reported at 4.5 Å 
resolution in 200621, and refined to 3.2 Å in 200822.  Animal FAS forms a 
gingerbread man shaped dimer, with the ‘arms’ and ‘legs’ connected by a flexible 
linker region.  The condensing region (KS-AT) dimer, mediated by the KS, forms 
the ‘legs’, while the modifying region (DH-ER-KR-ACP-TE) dimer, mediated by 
the DH, forms the ‘arms’.  As the domain order and catalytic mechanisms are 
very similar, this breakthrough allowed the development of models of PKS 
architecture23.  Structures of isolated PKS domains, such as the DEBS KS-AT 
didomain19, resemble their FAS counterparts, further supporting animal FAS as a 
structural model for type I PKS. 
 Recently, advances in cryo-electron microscopy (EM) have pushed the 
capabilities of the technique closer to atomic resolution.  Cryo-EM, as well as 
another solution-based technique, small-angle X-ray scattering (SAXS), are well 
suited to elucidation of large PKS structures.  The inherent structural flexibility of 
PKSs has thus far precluded successful crystallization, prohibiting structure 
determination by X-ray crystallography.  However, cryo-EM and SAXS can 
accommodate more structural heterogeneity, and can be used to visualize 
enzymes in distinct conformational states24-25.  Previously, high-resolution cryo-
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EM structures were limited to large, comparatively rigid macromolecular 
complexes, such as the ribosome26-27.  However, development of direct-electron 
detectors has allowed for high-resolution structures of smaller enzymes by 
limiting noise and blurring in image collection28-29.  Recently, these advances 
allowed for the determination of a cryo-EM reconstruction of an entire PKS 
module, PikAIII30-31. 
The inherent flexibility of NR-PKSs makes crystallization or even high-
resolution structural elucidation by cryo-EM very challenging.  The resolution of 
cryo-EM is limited by the “biological resolution” of the molecule, including its 
inherent dynamics and conformational heterogeneity.  To limit structural 
flexibility, we utilized a mechanism-based crosslinking approach to lock the 
enzyme into a single conformation, as well as to observe specific ACP-client 
domain interactions32-35.  Using a selectively reactive substrate mimic, the ACP 
can be covalently crosslinked to the active site of select client domains, without 
off-target reactions.  This technique has been used previously to observe the 
interaction between an AT and an ACP involved in vicenistatin biosynthesis at 
2.3 Å resolution36.  Similarly, a mechanism-based crosslinker was used to 
interrogate residues involved in PT-ACP binding in an NR-PKS37. 
CTB1 is the NR-PKS involved in the first step of cercosporin 1 
biosynthesis in the fungal plant pathogens Cercospora spp., which cause 
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hundreds of millions of dollars in agricultural loss each year38-39.  Cercosporin is a 
perylenequinone natural product that facilitates Cercospora infection by acting as 
a photosensitizer, producing reactive oxygen species upon activation with visual 
light40-42.  The domain architecture and chemistry of CTB1 is prototypical of a NR-
PKS, as described above, with the exception of an additional ACP domain and 
unusual TE activity (Figure 3.1a).  The CTB1 TE catalyzes lactonization, rather 
than the more typical hydrolysis, to release the pyrone nor-toralactone 2 (Figure 
3.1b)43. 
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Figure 3.1.  CTB1 biosynthesis.  (a) Domain organization of CTB1.  Active site residues are 
indicated within each domain.  Wavy bonds on ACPs indicate the post-translationally installed 
phosphopantetheine arm.  (b) Synthesis of nor-toralactone by CTB1.  Bonds formed by specific 




3.2.  Results 
3.2.1.  Mechanism-based crosslinking of CTB1 
 In this study, we chose to crosslink the CTB1 SAT-KS-MAT to its cognate 
ACP at the KS active site.  The SAT-KS-MAT, or loading and condensing region, 
is catalytically active as the isolated tridomain in cognate and non-native 
reactions44-45.  ACP2 was selected over ACP1 as it shares a higher sequence 
identity to PksA ACP (40% for ACP2, 30% for ACP1), for which a solution 
structure has been determined17.  Additionally, the ACP1 monodomain shows 
poor expression and stability, even following cut-site optimization.  ACP1 and 
ACP2 were shown to be biosynthetically equivalent in vitro in minimal PKS 
reactions (SAT-KS-MAT + ACP) (Figure 3.2).  Both ACPs produce identical 
product profiles, and although ACP1’s overall production is slightly lower (likely 











COMPOUND [M+H]+ (FOUND) [M+H]+ (CALC) 
MOLECULAR 
FORMULA 
3 127.0402 (5.3 PPM) 127.0395 C6H6O3 
4 259.0608 (0.6 PPM) 259.0607 C14H10O5 
5 233.0819 (2.2 PPM) 233.0814 C13H12O4 
6 259.0608 (0.6 PPM) 259.0607 C14H10O5 












































Figure 3.2.  Comparison of biosynthetic capabilities of CTB1 ACP1 and ACP2.  (a) HPLC 
chromatograms (280 nm) of product profiles of minimal CTB1 reactions with ACP1 (10 μM), 
ACP2 (10 μM), or both (5 μM each).  (b) UV-vis spectra of select derailment products.  When 
possible, products were characterized on the basis of exact mass and UV-vis chromophore.  (c) 
Exact masses of select derailment products determined by UPLC-ESI-MS. 
 
 
 To covalently attach CTB1 ACP2 to its client domain(s), a mechanism-
based crosslinker mimicking the native acetyl-phosphopantetheine substrate was 
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prepared.  In the native system, an acetyl starter unit is selected from the pool of 
primary metabolites as acetyl-CoA by CTB1 SAT and loaded onto the post-
translationally installed phosphopantetheine arm of the ACP (holo-ACP) (Figure 
3.3a).  For crosslinking, we prepared an α-bromoacetyl aminodephospho-CoA 
substrate mimic 8, where the native thioester has been substituted by an amide 
for stability, and an α-bromo group has been installed to facilitate irreversible 
attack by the active site cysteine, covalently linking the ACP to its client domain.  
Unfortunately, the acetyl substrate mimic proved to be too reactive, likely due to 
the primary halogen, and could not be loaded onto CTB1 ACP2 (Figure 3.3b).  A 
less reactive α-bromopropionyl aminodephospho-CoA 9 was used in place of 8, 
as CTB1 SAT has been shown to transfer propionyl groups, albeit at a lower rate 




















Figure 3.3.  Loading of ACP with its native acetyl-CoA substrate (a), an α-bromo-acetyl substrate 
mimic (b) and an α-bromo-propionyl substrate mimic (c). 
 
 
All crosslinkers were prepared synthetically to the acyl aminopantetheine 
stage 10, followed by enzymatic transformation to the dephospho-CoA 9, by way 
of an aminophosphopantetheine intermediate 11 (Figure 3.4).   This enzymatic 
transformation is accomplished by two enzymes involved in CoA  
biosynthesis: pantetheine kinase (PanK)46 and phosphopantetheine 
adenyltransferase (PPAT)47.  A promiscuous phosphopantetheinyl transferase 
involved in surfactin biosynthesis (Sfp) is then used to transfer the crosslinker 
onto apo ACP48.  The α-bromopropionyl crosslinker 9 was successfully loaded 
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onto apo CTB1 ACP2, however, a significant amount of optimization of the 
process was required.  Intermediates, particularly the phosphopantetheine mimic 
11, were difficult to isolate.  High-performance liquid chromatography (HPLC) 
purification of 11 resulted in <10% recovery, likely because the phosphates 
cannot be fully protonated under typical HPLC conditions (0.1% TFA).  
Therefore, a one-pot enzymatic process was developed.  First, the synthetically 
prepared α-bromopropionyl aminopantetheine 10 was phosphorylated with 
PanK.  Once this reaction went to completion (as determined by UPLC-MS), 
PPAT, Sfp, and CTB1 ACP2 were added to adenylate the phosphopantetheine 
mimic 11 and load it onto the ACP.  Phosphorylation of the 3’ position of the 
ribose ring, to fully mimic native CoA, was eliminated.  The required enzyme 
(dephospho-CoA kinase, DPCK) was found to be difficult to work with, and the 












Figure 3.4.  Enzymatic preparation of crosslinker-loaded ACP. 
 
 
Crosslinker-loaded CTB1 ACP2 was successfully crosslinked to two of its 
client domains within the loading and condensing region: SAT and KS.  
However, no crosslinking to the MAT was observed, likely due to the lesser 
nucleophilicity of the active site serine in comparison to cysteine.  In order to 
ensure selective crosslinking to a single client domain, double active-site mutants 
were prepared (C119A-S1010A (SAT°-KS-MAT°) for KS crosslinking, and 
H688A-S1010A (SAT-KS°-MAT°) for SAT crosslinking).  The cysteine to alanine 
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mutation in the KS yielded insoluble protein, so alanine and more conservative 
glutamine mutations to the other two members of the catalytic triad (H688 and 
H733) were attempted.  Of these mutations, one (H688A) was found to block 
crosslinking to the KS domain.  Selective crosslinking with this mutant was 
confirmed by attempted crosslinking to the C119A-H688A-S1010A mutant, 
which was completely blocked. 
 Crosslinking to the SAT domain is markedly slower than to the KS 
domain, likely due to both the inherent reactivity of the domains, and the non-
native propionyl substrate mimic.  Consequently, preparation of 100% 
crosslinked sample was more straight forward in the case of KS crosslinking, and 
the KS crosslinked sample (SAT°-KS-MAT°=ACP2, = denotes crosslinking) was 
chosen to move forward with structural elucidation.  To achieve 100% 
crosslinking, extended (16 h) treatment of the client domains with reductant and 
a large excess of ACP2 was required.  When CTB1 SAT-KS-MAT is in its native 
dimeric state (in the presence of 250 mM NaCl), 50% crosslinking is favored (1:2 
ACP:SKM stoichiometry) (Figure 3.5). 
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Figure 3.5.  Crosslinking time course.  Crosslinking of ACP2 to SAT°-KS-MAT° in presence (a) or 
absence (b) of 250 mM NaCl.  (c) Quantification of extent of crosslinking by densitometry measurements.  
Data presented as mean +/- s.e.m. 
 
 
 Selective crosslinking to the KS active site, rather than non-specific 
crosslinking to a surface residue, was confirmed by a competition assay with 
radiolabeled acetyl-CoA.  CTB1 SAT-KS-MAT was incubated with crosslinker-
loaded ACP (or α-bromopropionyl aminophosphopantetheine 11) for one hour 
prior to treatment with [1-14C]-acetyl-CoA.  Pre-incubation with 11 or crosslinker-
loaded ACP blocked radiolabeling of the protein, suggesting specific crosslinking 
to the KS active site (Figure 3.6).  Additionally, only a single crosslinking event 
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was observed by SDS-PAGE (Figure 3.5), confirming a single ACP covalently 
crosslinked specifically to the KS active site of each SAT-KS-MAT monomer. 
Figure 3.6.  [1-14C]-acetyl-CoA competition assay.  Incubation with crosslinker 11 or crosslinker-




 To obtain a more complete picture of the loading and condensing region’s 
interaction with ACP2, CTB1 SAT-KS°-MAT° crosslinked at the SAT domain was 
prepared for structural elucidation.  Based on the prior observation of preferred 
single-site ACP binding, we sought to prepare a sample in which only a single 
ACP2 is bound to each SAT-KS-MAT dimer.  To accomplish this task, 
crosslinking was performed in the absence of salt, at a slightly lower 
concentration of ACP2, for one hour.  At this point, approximately 50% of the 
SAT-KS-MAT monomer had been crosslinked (as determined by SDS-PAGE), 
and 250 mM NaCl was added to the reaction to significantly slow the rate of 
crosslinking.  Rather than the multi-step purification performed on the KS-
crosslinked sample, a streamlined, one step purification was utilized for the SAT-
crosslinked sample, since removal of free SAT-KS-MAT was unnecessary (see 
Methods for details).  The crosslinking reaction was purified by size-exclusion 
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chromatography, removing all free ACP2 or other contaminants.  SDS-PAGE of 
the final crosslinked protein following purification confirms the desired 
stoichiometry of 1:2 ACP2:SAT-KS-MAT.  This optimization of the preparation of 
crosslinked material increased final protein yield from 4% to 50%. 
 
3.2.2.  Structure of CTB1 SAT-KS-MAT 
 The structure of CTB1 SAT-KS-MAT was solved by X-ray crystallography 
to 2.8 Å (Figure 3.7, Appendix Table C.1).  The dimeric protein is compact and of 
rhomboid shape.  Dimerization is primarily mediated by the KS domains, each of 
which is connected to its MAT domain through a small linker domain (LD) 
(Figure 3.7a).  The architecture of the KS-LD-MAT domains, as well as their 
individual structures, is consistent with related structures solved by X-ray 
crystallography: mammalian FAS (mFAS)22, 49, fully-reducing iPKS50, and several 
modPKSs19-20, 51.  However, the arrangement of these domains is markedly 
different in the structure of the PikAIII modular PKS, determined by cryo-EM at 
intermediate resolution30-31. 
 The SAT resembles other ATs, containing an α/ hydrolase core fold and a 
ferredoxin-like subdomain, between which lies a cleft containing the active site.  
The SAT domains form a pseudo-dimer, arranged at 35° relative to the KS-MAT 
dimer (Figure 3.7b), where the direct interface of 324 Å2 is hydrophobic, lacking 
any hydrogen bonds or salt bridges (Appendix Table C.2).  However, 
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interactions with surrounding domains considerably stabilize this pseudo-dimer.  
The 26 amino acid (aa) linker between the C-terminus of the SAT and N-terminus 
of the KS binds a surface groove on the opposite SAT, adding 493 Å2 to the 
interface (Figure 3.7c).  While 9 aa of this linker is disordered and thus not 
visualized in the crystal structure, its connectivity is unambiguous based on 
relative distances to the resolved portions.  An additional 957 Å2 interface is 
formed between the SAT and the MAT of the opposite protomer, containing at 
least two salt bridges and five hydrogen bonds.  The SAT also interfaces with the 
opposite KS domain (184 Å2), however, it does not contact the opposite LD.  
Notably, the SAT domain is located within the cleft formed by the KS and MAT 
of the opposite protomer, in a position analogous to proposed interactions of 
upstream ACPs with KSs in modPKSs (Figure 3.7d)52.  The entrance to each SAT 
active site points into this cleft, at a distance of 56 Å from the opposite KS active 




Figure 3.7.  Crystal structure of CTB1 SAT-KS-MAT. (a) Cartoon representation of the SAT-KS-
MAT crystal structure (front view); the intertwined domain connectivity is indicated in the inset.  
Active sites and N- and C-termini are indicated by circles. (b) Top view of SAT-KS-MAT, 
domains are shown in surface representation, linkers as cartoon.  Active sites, termini, and 
twofold axis are indicated as in (a), the angle between the longest axes of the KS-LD-MAT and 
SAT (pseudo-) dimers is indicated.  (c) The SAT-KS linker.  Bottom view of the crystal structure 
as in (b) highlighting the connectivity of the SAT-KS linker and Euclidean distances.  The inset 
provides a close-up view from the side of the C-terminal region of the SAT-KS linker involved in 
contacts to KS’ and SAT.  An Fo-Fc shaked omit difference map is shown at 2.5.  (d) Interdomain 
interfaces between the SAT domains and the KS-LD-MAT region of CTB1 are mapped onto a 
split-surface representation of the SAT-KS-MAT structure by coloring according to the interaction 
partner.  The SAT domains have been separated from the KS-LD-MAT for representation. 
 
The N-terminus of the SAT and C-terminus of the MAT are located close 
to the twofold axis on opposite ends of the molecule (Figure 3.7a).  Therefore, 
while CTB1 functions as an isolated iPKS, its domain arrangement is consistent 
with that required for connectivity in an assembly line.  The only other known 
structure of a NR-PKS SAT, CazM SAT, shows similar domain connectivity to 
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that of CTB1 SAT16.  The structure of CazM SAT, determined by X-ray 
crystallography as an isolated monodomain, shows its C-terminal linker 
terminating close to the position of CTB1 SAT’s, despite a lack of sequence 
conservation (Appendix Figure C.1).  This linker architecture is notably distinct 
from that of the isolated loading AT domain from the avermectin modPKS 
(AVES1)53, which has a distinct domain organization where the loading AT 
connects to an ACP, rather than a KS.  In fact, the AVES1 loading AT linker 
architecture more closely resembles the post-MAT linker in PKS and FAS 
condensing regions.  These domain arrangements and distinct linker 
architectures support a specific, conserved organization among NR-PKS loading 
domains. 
 
3.2.3.  Structure of CTB1 SAT-KS-MAT=ACP2 
 Through mechanism-based crosslinking, CTB1 SAT°-KS-MAT° was 
covalently linked with CTB1 ACP2 to observe specific KS-ACP interactions and 
observe the impact of this interaction on the overall domain architecture.  
Crosslinked CTB1 SAT°-KS-MAT°=ACP2 was visualized by cryo-EM at 7.1 Å 
resolution (Figure 3.8, Appendix Table C.1).  This map was interpreted by rigid 
body and real space refinement using an all-atom model based on the crystal 
structure of CTB1 SAT-KS-MAT and a homology model of CTB1 ACP2 based on 
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the PksA ACP solution structure17.  Due to the limited resolution, and the 
absence of an authentic high-resolution structure, the analysis for ACP2 is 
restricted to conserved structural elements (Appendix Figure C.2, see Methods 
for details).  Single-particle processing including reference-free maximum 
likelihood classification provided a single, predominant conformation of SAT°-
KS-MAT°=ACP2 (for details see Methods).  Surprisingly, while the SAT°-KS-
MAT° was approximately 95% crosslinked to ACP2 (as determined by SDS-
PAGE), only a single ACP was resolved in the structure (Figure 3.8a-c, Appendix 
Figure C.3).  Additionally, the overall structure is asymmetric, with changes in 
domain architecture varied between the apparent crosslinked- and non-
crosslinked protomers (Figure 3.8a-c).  ACP2 is bound in a cleft between the LD 
and the KS/KS’ dimer, with the DSL motif bearing the aminophosphopantetheine 
substrate mimic (located at the N-terminal end of helix II) in close proximity to 
the KS active site entrance (Figure 3.8d).  While no ACP was resolved at the 
second KS active site entrance, the binding surface residues of the second KS are 
more disordered (Appendix Figure C.4), consistent with disordered binding of 
the second ACP.   
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Figure 3.8.  Asymmetric cryo-EM structure of CTB1 SAT°-KS-MAT°=ACP2. (a) Reconstructed 
volume and model of SAT°-KS-MAT°=ACP2 in front and top view.  The canonical four helix 
bundle of CTB1 ACP2 is shown.  All maps are contoured at 7.1.  (b,c) Close-up of the active site 
(indicated in (a)) regions of the two KS domains with (b) or without (c) resolved ACP2.  (d) 
Location of residues on SAT°-KS-MAT° interacting with ACP2 as structure and schematic 
representation.  In the scheme, the approximate position of the KS active site tunnel and the 
crosslinker-modified serine in ACP2 are indicated.  (e) Functional analysis of CTB1 SAT-KS-MAT 
mutants of ACP2 interacting residues.  Nor-toralactone production was quantified by integrated 
peak areas of HPLC chromatograms at 280 nm (mean +/- s.e.m.).    
 
 
 The structure of SAT°-KS-MAT°=ACP2 is considerably more asymmetric 
than the SAT-KS-MAT crystal structure, strongly suggesting ACP2 binding 
causes an asymmetrical conformational shift across the SAT-KS-MAT dimer.  In 
the crosslinked structure, the individual SAT domains are translocated towards 
the KS domains (Appendix Figure C.5).  The proximal SAT moves towards the 
KS by 6.9 Å, while the opposite SAT moves 4.5 Å towards the opposite KS-MAT 
region.  Additionally, the LD and MAT closest to the resolved bound ACP move 
upward by 4.4 Å and 8.4 Å, respectively (Figure 3.10).  Together, these 
movements open the interface between the proximal SAT and MAT domains and 
enlarge the SAT-KS interface (Appendix Figure C.5).  Since only one ACP is 
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resolved in the cryo-EM structure of the 95% crosslinked sample, these 
asymmetric conformational changes upon the first ACP binding likely disfavor 
ordered and competent binding of the second ACP.  This negative feedback is 
consistent with the observed kinetic preference for 50% crosslinking (Figure 3.5), 
as well as activity assays of crosslinked samples of a related NR-PKS.  When 50% 
crosslinked, Pks4 exhibits only 20% activity instead of the expected 50%, relative 
to a non-crosslinked sample32. 
 
3.2.4.  Mutagenic validation of KS-ACP binding region 
  Using the higher resolution crystal structure of SAT-KS-MAT, amino 
acids involved in ACP binding can be identified on the KS and LD.  However, 
the limited resolution of the crosslinked EM structure makes assignment of 
interface amino acids of ACP2 less well defined.  Three positively charged 
residues were identified on the SAT-KS-MAT surface and proposed to interact 
with acidic patches on ACP2 (Figure 3.8d).  Residue R879, located within the LD, 
interacts with the loop connecting helix I and II in ACP2.  Consistent with this 
proposal, production of nor-toralactone in in vitro reconstitution experiments 
with R879A and R879E is reduced, but not completely abolished (Figure 3.8e).  
Conversely, the KS-ACP interaction mediated by two arginines at the KS/KS’ 
active site entrance appears to be more crucial for productive biosynthesis.  R461 
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is strictly conserved in NR-PKSs (Appendix Figure C.6), and may interact with 
the acidic patch consisting of E1794 and E1795.  Mutation of R461 to alanine 
reduces nor-toralactone production, while mutation to glutamate completely 
abolishes it (Figure 3.8e).  R658’ is proposed to interact with D1815 within the 
DSL motif and/or the phosphate of the phosphopantetheine arm, and is 
conserved as a positively charged residue in the CTB1 clade (Appendix Figure 
C.6).  This residue appears to be most critical in mediating ACP binding, as the 
R658A mutation drastically reduces nor-toralactone production, while 
production in reactions with R658E is abolished (Figure 3.8e).  Analysis of 
mutations to proposed binding residues within ACP2 is more complicated, as the 
ACP must interact with multiple client domains, even in a minimal PKS reaction 
(SAT-KS-MAT + ACP).  However, we can infer perturbation of KS-ACP 
interaction if the minimal reconstituted PKS is capable of synthesizing short-
chain (e.g. triacetic acid lactone 3), but not fully extended derailment products 
(e.g. 4-7).  Mutagenesis of proposed binding residues of ACP2 demonstrated only 
two residues that perturb KS-ACP binding when individually mutated, E1794 
and D1815 (Figure 3.9).  However, these residues exist in acidic patches on the 
ACP2 surface, and multiple ACP residues are likely involved in interactions with 
a single residue on the KS/LD. 
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Figure 3.9.  Quantification of derailment product production by ACP2 mutants in a minimal PKS 
reaction.  Integrated peak areas were calculated from HPLC chromatograms at 280 nm in 




 Two previous examples of KS-ACP interaction within a multienzyme 
have been visualized: a crystal structure of yeast FAS (yFAS) at 3.1 Å resolution54 
and a cryo-EM reconstruction of a modPKS, PikAIII, at 8.6 Å and 7.3 Å30.  In both 
structures, the observed ACP interactions were strictly symmetrical, in contrast 
to the asymmetric interactions observed in CTB1 SAT°-KS-MAT°=ACP2.  Only 
the heterododecameric yFAS fulfills the distance restraints for symmetric ACP 
interaction, with solvent accessible surface (SAS) distance from the ACP serine 
bearing the phosphopantetheine arm to the KS active site cysteine of 
approximately 27 Å, similar to the corresponding distance in SAT°-KS-
MAT°=ACP2 of 28 Å (Appendix Figure C.7c, f-i).  Conversely, the SAS distances 
between ACP and KS in PikAIII are non-productive (45.2 Å and 43.3 Å) 
(Appendix Figure C.7h, i).  Consistent with this observation, the position and 
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orientation of ACP relative to KS is conserved between yFAS and CTB1 
(Appendix Figure C.7b), but is considerably different between PikAIII and CTB1 
(Appendix Figure C.7d,e).  The ACP docking surface observed in CTB1, and 
verified by mutant activity assays in reconstitution experiments, is partially 
blocked in PikAIII due to the divergent location of the LD domain (Appendix 
Figure C.7d,e).  The PikAIII structure also reveals symmetric large scale 
conformational transitions with the requirement for partial refolding of 
conserved domains, in contrast to asymmetric conformational changes derived 
by local hinge-bending or shear motions observed in CTB1 SAT°-KS-
MAT°=ACP2, as well as a highly-reducing iPKS and modPKS50.  These latter 
conformational changes maintain the individual domain structures, key 
conserved interfaces, and the overall interdomain architecture. 
Given the asymmetric conformational changes observed upon ACP 
binding, we propose that the loading and condensing region acts analogously to 
a V-twin engine, where conformational coupling between the two sets of active 
sites in the dimer is mediated by ACP binding (Figure 3.10).  ACP binding to the 
KS of one protomer within the SAT-KS-MAT dimer results in an asymmetric 
conformational change which disfavors binding to the KS of the second 
protomer.  This conformational coupling is consistent with biochemical 
demonstration of preferential single-site ACP loading in CTB1 and Pks432.  
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Furthermore, a related seesaw-type conformational coupling has been observed 
in FabZ, a hexameric dehydratase involved in fatty acid biosynthesis55.  In this 
system, the dehydratase binds ACPs in a 6:3 ratio.  We propose that this 
conformational change favors ACP binding to one of the other client domains, to 
allow for controlled programming of loading and condensing, where substrate 
(malonyl-CoA) loading by the MAT alternates with elongation by the KS on 
either side of the PKS dimer.  Since domains (including SAT-KS-MAT 
tridomains) can be productively swapped between NR-PKS in in vitro 
reconstitution experiments, this V-twin engine-like mechanism of ACP-mediated 
conformational coupling may be representative of many NR-PKS44-45. 
 
Figure 3.10.  Schematic illustration of suggested modes of conformational coupling in CTB1.  
ACP2 preferentially binds to a single KS active site.  ACP2 binding results in coupled 
conformational changes across the dimeric CTB1, disfavoring productive KS-ACP2 interaction in 
the other ptotomer and re-aligning active sites for ACP2 interaction and substrate shuttling.  Such 
conformational coupling resembles a V-twin engine mechanism for alternating KS-ACP2 
interactions.  Additional regions of complete CTB1 and other NR-PKS, in particular the dimeric 




3.4.  Experimental Methods 
3.4.1.  Preparation of expression constructs 
All plasmids used in this study are summarized in Appendix Table C.3.  
The plasmids for expression of wild-type CTB1 SAT-KS-MAT (pECTB1-NKA6), 
PT (pECTB1-PT), and TE (pECTB1-TE) have been previously described43.  
Primers used for assembly of new plasmids in this study are detailed in 
Appendix Table C.4.  All expression constructs were prepared and maintained in 
E. coli BL21(DE3).  Cut sites for CTB1 ACP2 deconstruction were chosen based on 
the PksA ACP solution structure17.  CTB1 ACP2 was cloned as an N-terminal 
Thrombin-cleavable His6-tagged construct to allow for differential purification 
throughout the crosslinking process.  The desired gene sequence was amplified 
by PCR from pECTB1-ACP (tandem ACP, previously described)43 using CTB1-
ACP2-5 and CTB1-ACP2-stop-3, and ligated into pET-28a at NdeI and NotI sites 
using T4 DNA ligase.  Active-site mutations for selective crosslinking were 
introduced into pECTB1-NKA6 by Gibson assembly56 of PCR-amplified 
fragments using standard protocol, giving pECTB1-SKM-C119A-S1010A and 
pECTB1-SKM-H688A-S1010A.  Mutations to CTB1 SAT-KS-MAT and ACP2 for 
interface validation were introduced via Gibson assembly in the same manner.  
Assembled plasmids were screened by restriction digestion and sequences 
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confirmed by the Johns Hopkins Synthesis and Sequencing Facility (Baltimore, 
MD).  Sequencing revealed the point mutation T321A (compared to Uniprot 
Q6DQW3) in all SAT containing constructs. 
 
3.4.2.  Protein expression and purification for crosslinking and interface 
validation 
 
All proteins were expressed in E. coli BL21(DE3).  One liter Terrific Broth 
cultures supplemented with 25 μg/mL kanamycin (GoldBio) were inoculated 
with overnight starter cultures, and grown at 37 °C with shaking at 250 rpm until 
OD600 reached 0.7.  Cultures were cold-shocked in ice water for 1 h prior to 
induction with 0.5 mM IPTG (GoldBio).  Expression was carried out at 19 °C with 
shaking at 250 rpm for approximately 16 h.  Cells were harvested by 
centrifugation at 4,000 x g for 15 min and flash frozen in liquid nitrogen for 
storage at -80 °C. 
Cell pellets were thawed in lysis buffer A (50 mM potassium phosphate, 
pH 8, 300 mM NaCl, 10% (v/v) glycerol) and lysed by sonication.  Lysate was 
cleared by centrifugation at 27,000 x g for 25 min.  The resulting supernatant was 
batch bound to Co2+-TALON resin (Clontech) at 4 °C, typically for 1 h.  The 
protein-bound resin was applied to a gravity-flow column and washed and 
eluted with lysis buffer containing increasing concentrations of imidazole (0-100 
mM), as directed by the manufacturer.  Fractions containing the protein of 
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interest were pooled and dialyzed against the appropriate buffer (50 mM Tris pH 
7.5, 5% (v/v) glycerol unless otherwise indicated) at 4 °C.  For dialysis of CTB1 
SAT°-KS-MAT°, 1 mM DTT was included to maintain the KS active-site cysteine 
in its reduced form.  If necessary, the protein was concentrated in Amicon Ultra 
centrifuge filters of appropriate molecular weight cut-off (Millipore).  Protein 
concentration was quantified based on absorbance at 280 nm on a Cary 50 UV-
Vis spectrophotometer and extinction coefficients calculated using Expasy 
ProtParam (Appendix Table C.3). 
 
3.4.3.  Expression and purification of CTB1-SAT-KS-MAT for crystallization 
C-terminal hexa-histidine (His6) tagged CTB1 SAT-KS-MAT (pECTB1-
NKA6, aa 1-1293) was overexpressed with Streptomyces chaperonins (pETcoco-
2A-L1SL2 plasmid)57 in E. coli BL21(DE3) pRIL.  Cells were cultured in 2xYT 
medium, supplemented with 0.5 % (v/v) glycerol, NPS (25 mM (NH4)2SO4, 50 
mM KH2PO4, 50 mM Na2HPO4), kanamycin (100 μg/mL), chloramphenicol (34 
μg/mL), and ampicillin (100 μg/mL).  An expression culture (1.5 L) was 
inoculated (1:20), grown at 37 °C for 2 h, cooled to 20 °C, and induced with IPTG 
(0.1 mM) at an OD600 of 1.0.  Cells were harvested after 12 h by centrifugation 
(7,000 x g) and resuspended in lysis buffer B (50 mM HEPES pH 7.4, 200 mM 
NaCl, 2.5mM MgCl2, 40 mM imidazole, 10% (v/v) glycerol, 5 mM β-
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mercaptoethanol), supplemented with protease inhibitors (200 μM 
phenylmethylsulfonyl fluoride, 20 μM bestatin, 4 μM E64, 2 μM pepstatin A, 20 
μM phenantrolin, 2 μM phosphoramidon) as well as DNase I, RNase A, and 
lysozyme.  Cells were placed on ice and lysed by sonication.  The lysate was 
cleared by centrifugation (100,000 x g, 30 min) and immobilized by metal-affinity 
chromatography on a 25 mL Ni-affinity column (GenScript) pre-equilibrated 
with lysis buffer.  Unbound protein was eluted with five column volumes (CV) 
of HisA buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 2.5mM MgCl2, 40 mM 
imidazole, 10% (v/v) glycerol, 5 mM β-mercaptoethanol, protease inhibitors).  
The sample was eluted with a linear gradient to 100% HisB buffer (50 mM 
HEPES pH 7.4, 500 mM imidazole, 50 mM NaCl, 10%(v/v) glycerol, 2.5 mM β-
mercaptoethanol, and protease inhibitors) and directly loaded on a strong anion 
exchange column (PL-SAX 4,000 Å, 10 μm, Agilent).  The protein was eluted with 
a linear gradient from 0% AIC-A (50 mM HEPES pH 7.4, 50 mM NaCl, 10% (v/v) 
glycerol, 2.5 mM β-mercaptoethanol) to 100% AIC-B (50 mM HEPES pH 7.4, 1 M 
NaCl, 10% (v/v) glycerol, 2.5 mM β-mercaptoethanol).  The protein was 
concentrated using Amicon Ultra centrifuge filters (10K MWCO, Millipore) and 
subjected to size exclusion chromatography (SEC) (Superdex 200 16/60, GE 
Healthcare) using 20 mM HEPES pH 7.4, 250 mM NaCl, 5% glycerol (v/v), 1 mM 
dithiothreitol.  Protein-containing fractions were pooled and concentrated in 
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Amicon Ultra centrifuge filters (10K MWCO, Millipore) to 10-15 mg/mL and 
frozen in liquid nitrogen. 
 
3.4.4.  Proteolysis of tag from CTB1-ACP2-His 
To facilitate separation of ACP2 from both crosslinker loading reactions 
and crosslinking reactions, the N-terminal His6-tag was removed by thrombin 
proteolysis using a Thrombin CleanCleave Kit (Sigma Aldrich).  The thrombin 
agarose resin was washed with reaction buffer (50 mM Tris pH 8, 10 mM CaCl2) 
and conditions were optimized as recommended by the manufacturer.  Complete 
cleavage was achieved using approximately 100 μL thrombin agarose resin per 
50 mg CTB1-ACP2 at 2 mg/mL CTB1-ACP2 in reaction buffer.  Reactions were 
rotated for 3 h at 25 °C.  Cleavage was monitored by SDS-PAGE and confirmed 
by MALDI-TOF (Bruker Auto Flex III).  Cleaved CTB1-ACP2 was isolated by 
brief centrifugation at 500 x g to pellet the thrombin resin and dialyzed in 50 mM 








3.4.5.  Synthesis of α-bromopropionyl aminopantetheine (10) 
Figure 3.11: Synthesis of crosslinker 10. 
 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise indicated. 
Benzyl tert-butyl ethane-1,2-diyldicarbamate (12):  In a 500 mL round-bottomed 
flask, N-Boc-ethylenediamine (14 mL, 88.5 mmol) was stirred in anhyd. DCM 
(200 mL) under argon.  Triethylamine (16 mL, 113.9 mmol) was added, followed 
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by slow addition of Cbz-Cl (15 mL, 105 mmol).  DMAP (1.1 g, 8.9 mmol) was 
added, and the solution was stirred at room temperature overnight.  The reaction 
was quenched by the addition of a saturated aqueous solution of NH4Cl (100 
mL).  The aqueous layer was washed with EtOAc (3×50 mL).  The combined 
organic extracts were dried over anhyd. Na2SO4.  Crystallization proceeded 
spontaneously upon concentration on a rotary evaporator and the resulting solid 
was filtered on a glass frit to give N-Boc,N’-Cbz-ethylenediamine 12 (23.1 g, 79.7 
mmol, 90%) as a white solid.  1H NMR (400 MHz, CDCl3): δ 7.35-7.33 p.p.m. (m, 
5H), 5.09 (s, 2H), 3.29-3.24 (m, 4H), 1.42 (s, 9H).  13C{1H} NMR (101 MHz, CDCl3): 
δ 136.41, 128.44, 128.04, 128.01, 79.46, 66.65, 45.71, 41.38, 40.52, 28.29, 8.51.  UPLC-
HRMS (ESI) calc’d for C15H22N2O4Na+ 317.1472; found 317.1471 [M+Na]+. 
(S)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanoic acid (13): D-
pantothenic acid hemicalcium salt (11 g, 46.2 mmol) and p-toluene sulfonic acid 
hydrate (17 g, 100 mmol) were added to acetone (200 mL) in a flame-dried, 
round-bottomed flask under argon.  Molecular sieves (4 Å, 200 g) were added, 
and the reaction mixture was stirred vigorously enough to break up the sieves.  
The reaction was run overnight at room temperature.  The sieves were filtered off 
through a bed of Celite.  The solution was concentrated by rotary evaporation 
and the resulting syrup was redissolved in EtOAc (100 mL).  The organic 
solution was washed with brine (2×50 mL) and dried with anhyd. Na2SO4.  The 
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solution was concentrated partially in vacuo, and hexanes were added.  The ketal-
protected pantothenic acid 13 (7.64 g, 29.4, 64%) precipitated as a white solid 
upon concentration to dryness.  1H NMR (400 MHz, CDCl3): δ 7.06 p.p.m. (t, J = 
5.6 Hz, 1H), 4.10 (s, 1H), 3.67 (d, J = 11.6 Hz, A of ABq, 1H), 3.61-3.56 (m, 1H), 
3.50-3.44 (m, 1H), 3.27 (d, J = 11.6 Hz, B of ABq, 1H), 2.59 (t, J = 6.0 Hz, 2H), 1.39 (s, 
3H), 1.37 (s, 3H), 0.96 (s, 3H), 0.91 (s, 3H).  13C{1H} NMR (101 MHz, CDCl3): δ 
176.32, 170.22, 99.04, 77.00, 71.35, 34.08, 33.77, 32.92, 29.34, 21.96, 18.78, 18.66.   
UPLC-HRMS (ESI) calc’d for C12H21NO5Na+ 282.1312; found 282.1312 [M+Na]+. 
Benzyl (2-aminoethyl)carbamate (14):  To a 250 mL round-bottomed flask 
containing DCM:TFA (30 mL:15 mL) was added 12 (10 g, 34 mmol).  The solution 
was stirred for 2 h at room temperature.  The reaction mixture was diluted with 
toluene, and concentrated by rotary evaporation three times to give Cbz-
ethylenediamine 14 (6.27 g, 32.3 mmol, 95%) as a yellow oil, which was taken 
directly to the next reaction.  The observed spectral data matched those data 
reported previously58. 
Benzyl (S)-(2-(3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido) 
ethyl)carbamate (15):  In a flame-dried, round-bottomed flask, 13 (8 g, 30.6 
mmol), 14 (6.6 g, 34 mmol) and triethylamine (9.48 mL, 68 mmol) were dissolved 
in DCM (300 mL).  The solution was cooled to 0 ℃ in an ice bath.  PyBOP (19.45 
g, 37.4 mmol) was added in one portion.  The reaction mixture was stirred for 3 
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h, and allowed to warm to room temperature.  The reaction was quenched by the 
addition of a saturated aqueous solution of NH4Cl (150 mL).  The aqueous layer 
was extracted with EtOAc (2×100 mL) and the combined organic extracts were 
dried over anhyd. Na2SO4, followed by concentration by rotary evaporation.  A 
white solid precipitated from the solution and was filtered off.  The remaining oil 
was fractionated by flash silica chromatography (100% EtOAc) to afford pure, 
diprotected Cbz-aminopantetheine 15 (9.32 g, 21.4 mmol, 70%) as a colorless 
solid, which was recrystallized from EtOAc/Hexanes.  1H NMR (400 MHz, 
CDCl3): δ 7.25 p.p.m. (m, 5H), 7.05-7.02 (m, 2H), 5.92 (s, 1H), 5.00 (s, 2H), 3.98 (s, 
1H), 3.57 (d, J = 11.7 Hz, A of ABq, 1H), 3.42 (septet, J = 6.6 Hz 2H), 3.30-3.21 (m, 
4H), 3.17 (d, J = 11.7 Hz, B of ABq, 1H), 2.33 (t, J = 6.4 Hz, 2H), 1.38 (s, 3H), 1.32 (s, 
3H), 0.92 (s, 3H), 0.88 (s, 3H).  13C{1H} NMR (101 MHz, CDCl3): δ 171.69, 170.39, 
157.04, 136.37, 128.49, 128.14, 128.10, 99.09, 77.09, 71.32, 66.81, 40.81, 40.13, 36.12, 
34.79, 32.90, 29.40, 22.05, 18.81, 18.64.  UPLC-HRMS (ESI) calc’d for C22H34N3O6+ 
436.2442; found 436.2443 [M+H]+. 
(S)-N-(3-((2-aminoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamide (16):  Compound 15 (7 g, 18.4 mmol) was added to MeOH (10 mL) 
in a 100 mL Parr bomb flask.  The reaction mixture and flask were purged with 
argon.  10% Pd/C (700 mg) was added.  The reaction vessel was placed under a 
H2 atmosphere (50 bar), and shaken for 3 h.  The reaction mixture was filtered 
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over Celite to remove the catalyst and the Celite washed with MeOH (3×10 mL).  
The filtrate was concentrated by rotary evaporation to afford ketal-protected 
aminopantetheine 16 (5.5 g, 18.3 mmol, 99%) as a pale yellow oil, which was 
taken directly to the next step.  1H NMR (400 MHz, CDCl3): δ 7.07 p.p.m. (t, J = 
8.0 Hz, 1H), 6.88 (s, 1H), 4.04 (s, 1H), 3.65 (d, J = 15.6 Hz, A of ABq, 1H), 3.52-3.46 
(m, 3H), 3.42 (s, 1H), 3.38-3.37 (m, 2H), 3.24 (d, J = 15.6 Hz, B of ABq, 1H), 2.86 (t, J 
= 7.5 Hz, 2H), 2.42 (t, J = 8.7 Hz, 2H), 1.44 (s, 3H), 1.40 (s, 3H), 0.98 (s, 3H), 0.93 (s, 
3H).  13C{1H} NMR (101 MHz, CDCl3): δ 171.51, 170.05, 98.90, 76.96, 71.19, 41.54, 
41.02, 35.81, 34.86, 32.75 29.26, 21.95, 18.70, 18.51.  UPLC-HRMS (ESI) calc’d for 
C14H28N3O4+ 302.2074; found 302.2079 [M+H]+. 
(4S)-N-(3-((2-(2-bromopropanamido)ethyl)amino)-3-oxopropyl)-2,2,5,5-
tetramethyl-1,3-dioxane-4-carboxamide (17):  In a round-bottomed flask under 
argon, 16 (1.77 g, 5.87 mmol) was added to DCM (20 mL).  To this solution was 
added triethylamine (1.82 mL, 12.9 mmol).  The temperature of the solution was 
lowered to 0 ℃ in an ice bath.  Bromopropionyl bromide (0.645 mL, 6.16 mmol) 
was added dropwise.  The initially milky solution was stirred at 0 ℃ for 1 h and 
became clear.  The reaction was quenched by the addition of a saturated aqueous 
solution of NH4Cl (30 mL), and the organic layer was washed with saturated 
aqueous Na2CO3 (15 mL) and brine (15 mL).  The organic layer was concentrated 
by rotary evaporation.  The resulting off-white solid was purified by flash silica 
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chromatography (1:9 MeOH:EtOAc) to give 2-bromopropionyl 
aminopantetheine 17 (2.13 g, 4.87 mmol, 83%) as a colorless solid.  The isolated 
mixture of diastereomers gave the following analytical data: 1H NMR (400 MHz, 
CDCl3): δ 7.11 p.p.m. (s, 1H), 7.02 (t, J = 5.6 Hz, 1H), 6.57 (br s, 1H), 4.39/4.38 (2×q, 
J = 7.0 Hz, 1H), 4.09/4.07 (2×s, 1H), 3.68 (d, J = 12.0 Hz, A of ABq, 1H), 3.59-3.52 
(m, 2H), 3.43-3.38 (m, 4H), 3.28 (d, J = 12.0 Hz, B of ABq, 1H), 2.46 (t, J = 6.2 Hz, 
2H), 1.85/1.84 (2×d, J = 7.0 Hz, 3H), 1.46 (s, 3H), 1.42 (s, 3H), 1.02 (s, 3H), 0.97/0.96 
(2×s, 3H).  13C{1H} NMR (101 MHz, CDCl3): δ 172.10/172.07, 170.42, 170.10/170.07, 
98.90/98.90, 76.95, 71.12, 43.81/43.80, 40.12/40.05, 38.93, 35.81/35.75, 34.85, 
32.74/32.73, 29.26, 22.31/22.82, 21.96/21.95, 18.72, 18.53.  UPLC-HRMS (ESI) calc’d 
for C17H31BrN3O5+ 436.1442; found 436.1433 [M+H]+. 
(2S)-N-(3-((2-(2-bromopropanamido)ethyl)amino)-3-oxopropyl)-2,4-dihydroxy-
3,3-dimethylbutanamide (10):  To DCM (2 mL) stirring in a 25 mL round-
bottomed flask, 17 (25 mg, 0.06 mmol) was added.  4 mL of deionized water, and 
0.1 mL of TFA were added to the reaction mixture.  The solution was allowed to 
stir at room temperature for 60 min.  The reaction mixture was diluted with 1:1 
H2O:toluene and concentrated by rotary evaporation three times to remove 
residual TFA.  The resulting pale yellow oil was purified by reverse-phase (C18) 
flash silica chromatography (gradient: 5-95% ACN in H2O) to afford 2-
bromopropionyl aminopantetheine 10 (15 mg, 1.2 mmol, 63%) as a white solid 
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after lyophilization.  1H NMR (400 MHz, MeOD): δ 4.47 p.p.m. (q, J = 6.8 Hz, 1H), 
3.91 (s, 1H), 3.50-3.47 (m, 2H), 3.48 (d, J = 10.8 Hz, A of ABq, 1H), 3.40 (d, J = 10.8 
Hz, B of ABq, 1H), 3.36-3.32 (m, 4H), 2.43 (t, J = 6.8 Hz, 2H), 1.77 (d, J = 6.8 Hz, 
3H), 0.93 (s, 6H).  13C{1H} NMR (101 MHz, MeOD): δ 176.00, 174.17, 172.76, 77.30, 
70.28, 43.97, 40.32, 40.30, 39.70, 36.58, 36.38, 22.41, 21.35, 20.88.  UPLC-HRMS 
(ESI) calc’d for C14H27BrN3O5+ 396.1129; found 396.1120 [M+H]+. 
 
3.4.6.  Phosphorylation of α-bromopropionyl aminopantetheine (10) 
α-Bromopropionyl aminopantetheine 10 was phosphorylated 
enzymatically under the following conditions: 0.25 mg/mL PanK, 2 mM 10, 5 mM 
ATP, 20 mM KCl, 10 mM MgCl2, 50 mM Tris pH 7.5 at room temperature for 
approximately 20 h.  Complete phosphorylation to yield 11 was confirmed by 
UPLC-ESI-MS (Waters Acquity/Xevo-G2, negative ion mode).  All protein was 
removed from the reaction with a 3K MWCO Amicon Ultra centrifuge filter 
(Millipore).  The flow-through was flash frozen in liquid nitrogen and 
lyophilized to dryness.  The resulting white powder was resuspended in 5% 
aqueous acetonitrile.  11 was HPLC purified on an Agilent 1100 equipped with a 
Kinetex C18 semi-prep column (250 x 10 mm, 5 μ, Phenomenex) using the 
following method at 4 mL/min: hold 5% solvent A/95% solvent B for 3 minutes, 
5-35% solvent A over 17 minutes, 35-95% solvent A over 5 minutes, followed by 
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re-equilibration to 5% solvent A, where solvent A is acetonitrile + 0.1% 
trifluoroacetic acid and solvent B is 0.1% trifluoroacetic acid.  Purity and identity 
of the isolated compound was confirmed by UPLC-ESI-MS as above, and the 
pooled fractions were lyophilized to dryness. 
 Due to poor recovery of 11 from HPLC purification, preparation of 11 for 
crosslinking to CTB1 SAT-KS°-MAT° was optimized.  The phosphorylation of 10 
was performed as before, and used directly in the next step (adenylation and 
ACP loading), once the reaction was complete. 
 
3.4.7.  Loading of ACP2 with α-bromoacyl crosslinker 
α-Bromopropionyl aminophosphopantetheine 11 was adenylated to yield 
9 and subsequently loaded onto CTB1 ACP2 in a one-pot enzymatic reaction 
under the following conditions: 0.5 mM 11, 0.5 mg/mL PPAT, 5 μM Sfp, 0.5 mM 
CTB1 ACP2, 5 mM ATP, 10 mM MgCl2, 20 mM KCl, 50 mM Tris pH 7.5, 10% 
glycerol.  Reactions were run at room temperature and monitored by MALDI-
TOF (Bruker AutoFlex III).  Once loading was complete, the His-tagged Sfp and 
PPAT were separated from untagged CTB1 ACP2 by passing the reaction 
solution through an equilibrated Co2+-TALON column (Clontech) and recovering 
the flow-through.  Additionally, any unreacted crosslinker was removed by 
repeated concentration and dilution with a 3K MWCO Amicon Ultra centrifuge 
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filter (Millipore).  Complete removal of free crosslinker was confirmed by UPLC-
ESI-MS analysis. 
 
3.4.8.  Crosslinking of CTB1 SAT°-KS-MAT° to ACP2 
CTB1 SAT°-KS-MAT° was combined with 20-fold excess CTB1 ACP2 
bearing the α-bromoacyl crosslinker in 50 mM Tris pH 7.5, 10% glycerol (v/v) at 
room temperature for 1 h.  Crosslinking was monitored by SDS-PAGE, and 
found to be approximately 95% complete after 1 h.  Crosslinked CTB1 SAT°-KS-
MAT°=ACP2 was separated from remaining free CTB1 SAT°-KS-MAT° by anion 
exchange chromatography.  Q-Sepharose Fast Flow resin (GE Healthcare) was 
equilibrated with 50 mM Tris pH 7.5, 10% glycerol, and the crosslinking reaction 
mixture was applied to the column.  CTB1 SAT°-KS-MAT° and CTB1 SAT°-KS-
MAT°=ACP2 were eluted using a gradient of potassium chloride from 0-500 mM.  
To remove free CTB1 ACP2 from the crosslinked protein, fractions containing 
CTB1 SAT°-KS-MAT°=ACP2 were pooled and applied to an equilibrated Co2+-
TALON column.  CTB1 ACP2 was removed in the flow-through, and pure CTB1 






3.4.9.  Crosslinking of CTB1 SAT-KS°-MAT° to ACP2 
CTB1 SAT-KS°-MAT° was combined with 10-fold excess CTB1 ACP2 
bearing the α-bromoacyl crosslinker in 50 mM Tris pH 7.5, 10% glycerol (v/v) at 
room temperature for 1 h to reach 50% crosslinking.  NaCl was added to a final 
concentration of 250 mM to impede further crosslinking.  CTB1 SAT-KS°-
MAT°=ACP2 was isolated from free ACP2 by size-exclusion chromatography 
using a Bio-Rad NGC fitted with an ENrich SEC650 column (10 x 300 mm, Bio-
Rad).  Fractions containing CTB1 SAT-KS°-MAT°=ACP2 were pooled and 
concentrated using an Amicon Ultra centrifuge filter (10K MWCO, Millipore). 
 
3.4.10.  In vitro reactions of CTB1 for interface validation and comparison of 
ACP1 and ACP2 
 
CTB1 SAT-KS-MAT (wild-type and select mutants of proposed interface 
residues), PT, ACP2 (wild-type and select mutants of propose interface residues), 
and TE were purified as described above, and dialyzed into 100 mM potassium 
phosphate pH 7, 10% glycerol.  ACP2 mutants were additionally purified by size 
exclusion chromatography (ENrich SEC 70, 10 x 300 mm, Bio-Rad) using 100 mM 
potassium phosphate pH 7, 10% glycerol.  ACP2 was activated enzymatically 
with CoA under the following conditions: 2 μM Sfp, 0.5 mM CoA, 10 mM MgCl2, 
200 μM ACP2, 100 mM potassium phosphate pH 7, 10% glycerol.  Activation 
reactions were run at 25 °C for 1 h, and complete conversion to holo-ACP2 was 
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confirmed by UPLC-ESI-MS (Waters Acquity/Xevo-G2, positive ion mode) and 
MALDI-TOF (Bruker AutoFlex III).  For full PKS reconstitution, 10 μM CTB1-
SAT-KS-MAT, PT, ACP2 and TE were combined in assay buffer (100 mM 
potassium phosphate pH 7, 10% glycerol, 1 mM TCEP).  Minimal PKS reactions 
excluded PT and TE.  Reactions were initiated by addition of 0.5 mM acetyl-S-N-
acetylcysteamine (SNAC) and 2 mM malonyl-SNAC, and incubated for 4 h at 25 
°C.  The 250 μL reactions were quenched with 10 μL hydrochloric acid and 
extracted thrice with ethyl acetate.  Extracts were pooled, dried, and resuspended 
in 250 μL 20% aqueous acetonitrile for HPLC analysis. 
Product profiles of each enzyme mutant were analyzed on an Agilent 1200 
equipped with a Prodigy ODS3 analytical column (4.6 x 250 mm, 5 μ, 
Phenomenex).  100 μL injections were separated by a bisolvent method at 1 
mL/min: 5-85% solvent A over 40 min, 85-95% solvent A over 10 min, re-
equilibrate to 5% solvent A over 10 min, where solvent A is acetonitrile + 0.1% 
formic acid, and solvent B is 0.1% formic acid.  Chromatograms were recorded at 
280 nm, and UV-vis spectra were recorded over a range of 200-800 nm.  Exact 
masses of derailment products were obtained by UPLC-MS (Waters 





3.4.11.  Crystallization, data collection and structure determination of CTB1 
SAT-KS-MAT 
 
CTB1 SAT-KS-MAT plate-like crystals were obtained by the sitting drop vapor 
diffusion method in 0.2 M MgCl2, 0.1 M Bis-Tris Propane pH 6.5, 18% (v/v) 
PEG3350 at 4 °C, a drop ratio of 1.0 μL + 0.5 μL and further optimized by 
seeding.  Crystals grew to a final size of 0.4×0.04×0.04 mm3 within one week.  The 
crystals were dehydrated and cryo-preserved by successively increasing the 
concentration to 0.5 M MgCl2, 0.1 M Bis-Tris Propane pH 6.5, 25% PEG3350, 22% 
ethylene glycol.  Diffraction data of crystals in space group C2221 (a= 108.1 Å, 
b= 230.2 Å, c= 253.8 Å) and 56% solvent content were collected at the Swiss Light 
Source (SLS, Villigen, Switzerland) at beamline X06SA, a temperature of 100 K 
and a wavelength of 1.000 Å.  Data reduction was performed using XDS and 
XSCALE59 and data were analyzed using phenix.xtriage60.  The structure was 
solved with PHASER61 using molecular replacement and the KS and AT domains 
of DEBS module five19 as well as the AT domain of CurL51 as search models.  An 
initial model was obtained in iterative cycles of rebuilding with BUCCANEER62 
and density modification using solvent flattening and histogram matching in 
PARROT63.  Iterative cycles of manual model building and real space refinement 
in Coot64 and TLS refinement in Phenix60 yielded a high quality model with 
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Rwork/Rfree values of 0.21/0.24 at 2.8 Å resolution with excellent geometry 
(Ramachandran favored/outliers: 97.07%/0.00%) (Appendix Table C.1a).  
 
3.4.12.  EM sample preparation and data collection. 
Initial sample quality was evaluated by conventional negative-stain EM.  
Initial cryo-EM analysis revealed a monomer-dimer equilibrium, which has 
previously been observed for PKS and FAS fragments30, 50-51, 65-66.  The oligomeric 
state of the CTB1 SAT-KS-MAT was analyzed by analytical size-exclusion 
chromatography (SEC) (4.6/250 Superose 6 Increase, GE Healthcare), using 
buffers with different salt concentrations and a flow rate of 0.1 mL/min.  The 
results indicated a fast equilibrium and a mostly dimeric species in low salt 
buffer (20 mM Tris pH 7.4, 50 mM NaCl, 2.5 mM tris(2-carboxyethyl)phosphine 
(TCEP)) (Appendix Figure C.3c).  For cryo-EM, crosslinked sample was 
concentrated to 15-16 mg/mL, applied to analytical SEC and collected in fractions 
of 50 μL.  For grid preparation 4 μL of individual fractions were applied to glow 
discharged (30 s) lacey carbon grids (300 mesh, copper), immediately blotted for 
2 s and plunge-frozen in liquid ethane using a Vitrobot (FEI, Vitrobot III).  An 
incubation step was omitted due to fast adsorption of the particles to the carbon.  
The integrity of the crosslinked sample was analyzed by denaturating 
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polyacrylamide gel electrophoresis (PAGE) of the remaining sample after grid 
preparation (Appendix Figure C.3d). 
Grid quality was analyzed using a Philips CM200 FEG cryo-transmission 
electron microscope, operated at an acceleration voltage of 200 kV.  Optimal 
conditions were identified for peak fractions diluted to 270 μg/mL, in a trade-off 
between low particle density (approx. 70 particles per micrograph), monomer 
formation and particle adsorption to carbon.  Final data were collected using a 
Titan Krios electron microscope (FEI), operated at 300 kV, a GIF Quantum LS 
imaging filter (Gatan) and a K2 Summit (Gatan) operating in counting mode.  
Images were acquired at 0.8-4.5 μm defocus and a nominal magnification of 
105,000x, corresponding to a pixel size of 1.326 Å (Appendix Table C.1b).  Movies 
were collected with a total dose of approx. 90 e-/Å2 per 18 s exposure, 
fractionated over 60 frames. 
 
3.4.13.  EM data processing and analysis 
Drift correction of dose fractionated frames28 was performed using Zorro67 
and global contrast transfer function (CTF) parameters were determined using 
CTFFIND4.168.  Particles were picked from aligned dose-filtered averages using 
the swarm semi-automated procedure as implemented in e2boxer.py69, followed 
by extraction from unfiltered averages using Relion-2 70 and local CTF parameter 
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refinement using Gctf v1.06 71.  Single particle analysis included several rounds 
of reference-free maximum a posteriori-2D classification70 to remove junk particles 
and monomers, which revealed a clearly distinguishable shape and could be 
reconstructed at low resolution (Appendix Figures C.2a, C.3b).  For 
reconstruction of the dimeric, crosslinked CTB1 SAT°-KS-MAT°=ACP, an initial 
volume was generated using e2initialmodel.py69 and low-pass filtered to 50 Å.  
Exhaustive global followed by local reference-free 3D classification and 
alignment without symmetry were applied, yielding highly similar classes that 
were combined in a consensus refinement prior to movie refinement and particle 
polishing as implemented in Relion-270.  Parameters for B-factor fitting as 
function of movie frames have been carefully examined as well as the different 
number of frames in the particle movie stacks.  At this stage all 60 frames were 
included in the weighted particle movie stacks as no significant difference 
between including different amounts of frames per movie could be identified 
after applying weighting.  Another round of 2D and 3D classification yielded 
three almost identical volumes that were refined as individual classes and in all 
possible combinations of classes.  The combination of two classes (Appendix 
Figure C.2a) resulted in a slightly improved model at 7.3 Å resolution (25,107 
particles) as compared to all three classes at 7.5 Å (44,859 particles).  For the 
refinement of the final map at 7.1 Å resolution weighted particle averages of 27 
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movie frames were used, corresponding to a total dose of 41 e-/Å2.  All reported 
resolution estimates are based on the 0.143 threshold criterion of the Fourier 
Shell Correlation (FSC)72 between two halves of the dataset refined 
independently in RELION-2, after accounting for correlations introduced by 
masking73.  Throughout all refinements in Relion-270, particles were grouped by 
k-mean clustering of their CTF parameters with a minimum of 50 particles per 
group.  The alignment was not significantly influenced by a preferred 
orientation74 (Appendix Figure C.2b, c), which was assessed by reducing the 
number of particles per angular sampling group to the mean of all groups by 
random subset deletion in four independent refinements.  Later refinements 
were carried out using a soft mask and solvent corrected FSC during the 
refinement73.  Final maps were sharpened with a sharpening B-factor of -350 Å2.  
Local resolution was calculated with ResMap75 and indicated higher resolution 
for secondary structure elements in the center of the particle (Appendix Figure 
C.2d, e).  Therefore, masked 3D classification and refinement after signal 
subtraction76 was carried out, resulting in slightly improved resolution, but 
without significant differences in the electron density map.  Map generation from 
coordinates as well as filtering and file type conversion was done using EMAN2 
tools69.  For analysis, map transformations were applied using the CCP4 tool 
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maprot77.  Maps were resampled using UCSF Chimera78 and difference maps 
were calculated Python Numpy and MRCZ79. 
 
3.4.14.  Cryo-EM structure refinement and modelling 
Modelling of the cryo-EM structure was started by rigid body fitting of 
individual domains of the CTB1 SAT-KS-MAT crystal as well as of an ACP2 
homology model in Coot64.  The model for CTB1 ACP2 was generated using 
SwissModel80 based on PksA ACP17, which shares 40% sequence identity and can 
be functionally replaced with the CTB1 tandem ACPs in in vitro assays44-45.  Initial 
B-factors of the model were scaled relative to B-factors of atomic displacement 
parameter (ADP) refined crystal structures structures in the PDB at similar 
resolution.  Prior to map-based real-space refinement, the model was protonated 
using phenix.reduce and geometry minimization with secondary structure 
restraints and reference coordinate restraints was applied using 
phenix.geometry_minimization60.  Afterwards global minimization and ADP 
refinement with reference structure restraint was carried out against the 
unsharpened cryo-EM map in phenix.real_space_refine60.  Reference structure 
and nonbonded distance restraint weights were carefully monitored and 
optimized.  As the local resolution around the resolved ACP2 is not sufficient to 
unambiguously interpret possible conformational changes of loop regions 
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relative to the isolated PksA ACP NMR structure, the loop regions were 
excluded from the final model after all atom refinement, without affecting model 
statistics (Appendix Table C.1b).  The resulting model contained the regions 
corresponding to the canonical ACP four helix bundle (residues: 1782-1796, 1816-
1828, 1839-1842, 1846-1854) and was validated using phenix.molprobity81 with 
Ramachandran plot statistics of  “favored/outliers”: 96.47%/0.12%.  A position for 
a second crosslinked ACP2 could not be undoubtedly resolved in any 
intermediate or final EM map.  The sample has been analyzed after grid 
preparation and is approximately 95% crosslinked (Appendix Figure C.3d).  
Due to residual noise around the putative second ACP2 binding site the presence 
of a second ACP2 in a mostly disordered state without a solid interface, tethered 
only by covalent crosslinking (Appendix Figure C.4a,b) cannot be strictly 
excluded.  However, we cannot exclude the possibility that effects of selective 
adsorption of partially or fully crosslinked CTB1 SAT°-KS-MAT°=ACP2 or of 
selective destabilization under grid preparation also contribute to selective 
imaging of a single-crosslinked state with low population in the sample used for 






3.4.15.  Structure analysis and visualization 
Related structures were identified using PDBeFold (20% query / 10% 
target)82 and interfaces were analyzed using QtPISA v2.1.083.  Transformations 
and coordinate manipulations were carried out using CCP484 tools and 
MOLEMAN85.  Bias-removal for crystallographic Fobs-Fcalc omit maps was 
achieved by applying a random perturbation to coordinates (Δ0.2 Å) and B-
factors (Δ20% of the mean overall B-factor) with MOLEMAN285 prior to 
refinement.  Cα-r.m.s.d. between domains of the crystal and cryo-EM structure 
were calculated using LSQMAN86.  Structures of PikAIII were modeled 
according to Dutta et al.30 using Chimera78.  Solvent accessible surface distances 
(SAS) between Cα residues of ACP phosphopantetheinylation and KS active site 
residues were calculated using Xwalk87.  Figures, movies and plots were 
generated using Pymol88 and Python Matplotlib. 
 
3.4.16.  Sequence analysis 
Sequence alignments were generated using Clustal Omega89.  A 
Phylogenetic tree was generated using the neighboring joining algorithm in 
Geneious v8.1.690.  
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Chapter 4:  Cercosporin biosynthesis: Expansion of the 
biosynthetic gene cluster and scope of production by plant 
pathogens 
 
Adapted with permission from de Jonge, R.*, Ebert, M.K.*, Huitt-Roehl, C.R.*, 
Pal, P., Suttle, J.C., Neubauer, J.D., Jurick II, W.M., Secor, G.A., Thomma, B.P.H.J., 
Van de Peer, Y., Townsend, C.A., Bolton, M.D.   Ancient duplication and 
horizontal transfer of a toxin gene cluster reveals novel mechanisms in the 
cercosporin biosynthesis pathway.  Manuscript in preparation.   *Indicates co-first-
authorship 
 
4.1.  Introduction 
 The fungal plant pathogens Cercospora spp. infect hundreds of 
agriculturally and economically important crops1, including soy bean, sugar beet, 
tobacco, maize, and rice, causing hundreds of millions of dollars in damage each 
year.  Cercosporin 1, a perylenequinone toxin produced by Cercospora spp., has 
been shown to be the primary virulence factor involved in infectivity.   
Cercosporin was first isolated from C. kikuchii, a pathogen of Japanese soy 
bean, in 1957.  It was shown to be a crystalline red pigment with a quinone core, 
and proposed to be symmetrical, but with optical activity2-3.  This interesting 
finding led to extensive investigation into the stereochemistry of cercosporin, 
ultimately revealing that it is indeed an atropisomer4.  The helical configuration 
of this atropisomer was unambiguously determined by X-ray crystallography5.  
Cercosporin’s perylenequinone core acts as a potent photosensitizer, with 
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quantum yields >0.86.  Following activation to a long-lived triplet state by visible 
light, cercosporin reacts with molecular oxygen, releasing reactive oxygen 
species (ROS), specifically singlet oxygen and superoxide radical7.  The activity of 
cercosporin is photodynamic, and the relative production of singlet oxygen and 
superoxide is modulated by the presence of various reducing agents, allowing 
for a wider scope of reactivity8.  Therefore, cercosporin does not have a specific 
cellular target, but rather causes non-specific damage to DNA, lipids, proteins, 
and other targets.  For example, cercosporin-induced ROS have been shown to 
cause epoxidation of lipids9, resulting in cell membrane damage within minutes 
of exposure10 as well as changes in membrane composition and structure11.  
Damage to the plant’s cell membrane causes leakage of nutrients, feeding the 
fungus and allowing for further penetration of the leaves.  Cercosporin is also 
toxic to mammals and bacteria, in a light- and oxygen-dependent manner12. 
Cercospora spp. resist the non-specific toxic effects of the cercosporin they 
produce through several mechanisms, primarily maintaining cercosporin in an 
inactive, reduced state (2) prior to active secretion (Figure 4.1).  The quantum 
yield of 2 is dramatically lower than that of cercosporin (0.02-0.04 in water), 
significantly diminishing its ability to form ROS13.  Cercosporin-resistant species 
of Cercospora and Alternaria were shown to contain primarily reduced 
cercosporin within their hyphae, while cercosporin-sensitive fungi were not 
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capable of reducing cercosporin14-15.  To date, two cercosporin-specific resistance 
genes have been identified in cercosporin producers.  Cercosporin facilitator 
protein (CFP), a major facilitator superfamily (MFS) transporter, is required for 
virulence and cercosporin secretion, as well as cercosporin resistance in C. 
kikuchii16-17.  Heterologous expression of CFP in a cercosporin-sensitive fungus 
can induce cercosporin resistance18.  Cercosporin resistance gene 1 (crg1), is a 
zinc-finger transcription factor involved in cercosporin resistance and 
biosynthesis19-20.  Introduction of these cercosporin resistance genes into crops 
could be a viable strategy to prevent or mitigate Cercospora infections without the 
use of harmful pesticides21-24. 
Figure 4.1. Cercosporin is maintained in a reduced state by producers until it is actively exported. 
 
 
 Despite extensive research on cercosporin resistance and mechanism of 
action, little is known about the chemical details of its biosynthesis.  Cercosporin 
is a polyketide-derived natural product25-26, however, the complete biosynthetic 
pathway has yet to be conclusively elucidated.  A series of oxidations, 
reductions, methylations, and a dimerization transform the polyketide synthase 
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(PKS) product into the final perylenequinone product.  Many of the 
intermediates of the pathway are unstable and prone to oxidation, impeding 
elucidation of the pathway by traditional biological methods, such as analyzing 
accumulated intermediates in gene knockout strains27.   
 The gene cluster was first identified in C. nicotianae, a pathogen of tobacco, 
in 200728.  The cluster was found to contain six biosynthetic genes, a zinc-finger 
transcription factor (CTB8), and a MFS transporter involved in cercosporin 
secretion (CTB4)29.  These two regulatory and resistance genes are distinct from 
crg1 and CFP, and are pathway specific.  As expected, the previously identified 
non-reducing (NR)-PKS, CTB1, is included in the cluster26.  Also included in the 
cluster are CTB2, an O-methyltransferase30; CTB3, a didomain O-
methyltransferase/FAD-dependent monooxygenase31; and three oxidoreductases, 
CTB5-732.  All eight genes are regulated by light, and feedback inhibition of 
transcription of other genes in the cluster was shown in response to knockouts of 
each biosynthetic gene28, 32.  A tentative biosynthetic pathway was proposed 














Figure 4.2.  Proposed biosynthesis of cercosporin based on putative enzyme functions of cluster 
identified in C. nicotianae by Chen et al (2007). 
 
 
 However, the biosynthetic pathway had to be reconsidered when the on-
pathway product of CTB1 was found to be nor-toralactone 3, not the carboxylic 
acid 433.  In vitro characterization of reconstituted CTB1 showed that the NR-PKS 
homologates an acetyl starter unit and six malonyl extender units to form a 
heptaketide.  The heptaketide is regiospecifically cyclized by the product 
template (PT) domain (C4-C9 and C2-C11) and finally released by the thioesterase 
(TE).  Rather than more traditional TE chemistry (e.g. hydrolysis), the CTB1 TE 
catalyzes lactonization to form nor-toralactone.  This lactonization mechanism 
was confirmed by 18O-acetyl-CoA labelling, where retention of the labelled acetyl 
carboxyl group was observed in the final product33.  The observed product of 
CTB1 is not consistent with the previously proposed biosynthetic pathway, 
requiring an updated proposal (Figure 4.3). 
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Figure 4.3.  Revised biosynthetic proposal based on characterization of CTB1 and CTB3 by 
Newman et al (2016). 
 
 
 Analysis of intermediates accumulated by the knockouts of each 
biosynthetic gene in C. nicotianae allowed for a revised proposal of the 
biosynthetic pathway27.  Given the unexpected tricyclic structure of nor-
toralactone 3, an enzyme is needed to open the pyrone ring.  CTB3 was proposed 
to be the second enzyme in the pathway responsible for this ring opening step.  
CTB3 is an unusual didomain, bifunctional enzyme, containing a N-terminal O-
methyltransferase and a C-terminal flavin-dependent monooxygenase.  In vitro 
analysis confirmed CTB3 catalyzes two modifications of nor-toralactone, O-
methylation and oxidative ring opening.  A selection of unusual, off-pathway 
quinones were isolated from knockouts of CTB3, CTB5, and CTB6, while no 
soluble intermediates could be isolated from ΔCTB2 or ΔCTB7.  These quinones 
were rationalized as spontaneous oxidation products of the true on-pathway 
intermediates, and a revised biosynthetic pathway was proposed (Figure 4.3), 
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where CTB2 methylates the product of CTB3 (5) to form the doubly-methylated 
(6), which is reduced by CTB6 to form the hydroxyl (7)27.  Finally, dimerization 
and methylenedioxy ring formation is proposed to be catalyzed by CTB5 and 
CTB7. 
 
4.2.  Results 
4.2.1.  Identification of new cercosporin biosynthetic genes 
 Following publication of this revised biosynthetic pathway, five new 
genes were discovered in the cercosporin gene cluster in C. beticola, a pathogen of 
sugar beets, using an evolutionary genomics approach (Figure 4.4).  These genes 
were not identified with the original eight-gene cluster, as they are separated by 
two open reading frames that are not regulated by light or the transcription 
factor CTB8, and whose knockouts still produce cercosporin28.  One of the newly 
identified genes is cercosporin facilitator protein (CFP), a MFS transporter that 
has previously been identified in C. kikuchii, but thought to lie outside the 
cluster16.  Additionally, four new biosynthetic genes were identified: an α-
ketoglutarate dependent oxygenase (CTB9), an EthD-domain containing protein 
(CTB10), a β-IG-h3 fasciclin (CTB11), and a laccase (CTB12).  All five genes 




Figure 4.4.  Revised cercosporin biosynthetic gene cluster in C. beticola 
 
 
Figure 4.5.  HPLC analysis of C. beticola mutants.  280 nm chromatograms are shown.  Scale bar 






4.2.2.  Characterization of pre-cercosporin (8) 
Two knockouts of the new biosynthetic genes (CTB9 and CTB10) 
accumulated a red, cercosporin-like pigment.  However, this pigment had a 
different retention time by HPLC and migrated differently in potato dextrose 
agar (PDA).  To characterize the red metabolite that accumulated in ΔCTB9 and 
ΔCTB10 mutants, an ethyl acetate extract of the collected mycelia was analyzed 
by reverse-phase HPLC.  At 280 nm, a single peak was observed in both mutant 
extracts with identical retention times (Figure 4.5) and UV-Vis spectra (Figure 
4.6b,c).  This peak was compared to a reference sample of cercosporin produced 
by wild-type C. beticola (Figure 4.6a).  The retention time of this peak was shorter 
than that of cercosporin suggesting a more polar metabolite.  Comparison of the 
UV-vis spectra (Figure 4.6a-c) of the unknown compound and cercosporin 
revealed nearly identical chromophores, suggesting close structural relation.  The 
exact mass of the metabolite from the mutants was determined (∆CTB9: m/z = 
537.1762, ∆CTB10: m/z = 537.1757, [M+H+]), consistent with the elemental 
composition C29H28O10.  This mass is 2 Da greater than that of cercosporin (+2 
hydrogens), which led to a proposed structure for pre-cercosporin (Figure 4.6d).  
Alternative hydroquinones of cercosporin could be excluded simply on the basis 
of the UV-vis spectral information and chemical instability.  The presence of a 
free phenol in pre-cercosporin in place of the unusual 7-membered 
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methylenedioxy of cercosporin is consonant with the red shift of the long 
wavelength λmax and the shorter HPLC retention time. 
Figure 4.6.  UV-vis spectra of cercosporin (a), pre-cercosporin produced by C. beticola ∆CTB9 (b), 
and pre-cercosporin produced by C. beticola ∆CTB10.  Structures and mass spectrometry data for 
pre-cercosporin and cercosporin are shown in (d). 
 
 
To firmly support the tentative structure of pre-cercosporin, the crude 
extract of ∆CTB9 was further purified by reverse-phase HPLC.  Isolation of 
sufficient amounts of pre-cercosporin to characterize by NMR proved difficult 
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due to its instability and tendency to polymerize.  The relative instability of pre-
cercosporin compared to cercosporin suggests a possible role for the 
methylenedioxy bridge in overall stability.  Several large-scale purifications were 
attempted by HPLC, but in all cases the small amount of pre-cercosporin 
obtained (< 1 mg in all cases) was too unstable to characterize by NMR.  
Attempts to acetylate the five free hydroxyls on pre-cercosporin were primarily 
unsuccessful.  Complete acetylation of all positions was not achieved, and a 
mixture of pre-cercosporin with varied numbers of acetyl groups was isolated 
(Figure 4.7b).  This mixture also appeared to be unstable, and could not be 
characterized by NMR.  Extracts of liquid cultures of C. beticola ∆842 were 
relatively complex, in contrast to extracts of solid cultures which consist of pre-
cercosporin and little else, as determined by absorbance at 210 nm.  However, 
liquid cultures can be grown at significantly larger scales than solid culture.  
Therefore, attempts to clean up the liquid culture extracts using size exclusion 
chromatography (Sephadex LH20) prior to HPLC were attempted.  
Unfortunately, this step did not result in more effective HPLC purification, likely 
due to pre-cercosporin degrading and/or polymerizing on the Sephadex LH20 
column or during evaporation of the collected fractions (Figure 4.7c).  Finally, we 
opted to isolate pre-cercosporin from solid cultures, and perform the extractions 
as quickly as possible in the dark (previous extractions were run for 24 h).  This 
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method yielded a very clean crude extract (Figure 4.7a), and allowed isolation of 
enough pre-cercosporin for 1H-NMR analysis. 
Figure 4.7.  Large-scale HPLC purification of pre-cercosporin.  Only extracts of solid cultures 
were clean enough to isolate pure pre-cercosporin.  a) Solid (top) and liquid (bottom) cultures of 
C. beticola ∆842, extracted with ethyl acetate, quickly and in the dark.  b) Crude C. beticola ∆842 
extract acetylated with acetic anhydride.  A mixture of acetylated pre-cercosporin products was 
obtained.  c) C. beticola ∆842 extract purified by Sephadex LH20. 
 
1H-NMR analysis confirmed the proposed structure of pre-cercosporin 
based on the earlier HPLC and UPLC-MS data.  The spectrum lacked a 
methylenedioxy singlet at δ5.74, diagnostic of cercosporin, and instead contained 
a new methoxyl signal at δ4.28 and a phenol at δ9.25.  While we did not isolate 
enough material to definitively determine the stereochemistry of the atropisomer 
by X-ray crystallography, the 1H-NMR spectrum suggests a single atropisomer.  
Presumably the helical configuration of pre-cercosporin is identical to 
cercosporin, however we cannot rule out the possibility that the final 
stereochemistry is set by CTB9 or CTB10.   
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4.2.3.  Identification of cercosporin production by Colletotrichum fioriniae 
To date, cercosporin production has only been observed by Cercospora spp. 
and the closely related pathogen Pseudocercosporella capsellae34-35.  However, 
evolutionary genomics revealed the presence of cercosporin biosynthetic gene 
clusters in multiple species of Colletotrichum, another fungal genus with 
significant agricultural impacts, as well as Sclerotinia sclerotiorum and the rice 
pathogen Magnaporthe oryzae.  Colletotrichum, like Cercospora, infects hundreds of 
agriculturally and economically important crops, including fruits such as apple, 
avocado, citrus, and banana.  For example, Colletotrichum fioriniae is one of the 
top pre- and post-harvest pathogens of apples, causing significant losses in fresh 
and dried apple products36. 
Since our phylogenomic analyses suggested that several Colletotrichum 
spp. harbor cercosporin biosynthetic gene clusters, we questioned whether any 
Colletotrichum spp. can produce cercosporin.  To initially assess this, two 
Colletotrichum fioriniae strains (HC89 and HC91) isolated from apple were 
assayed for cercosporin production using the KOH assay26.  No cercosporin-like 
pigment was observed in the media under the same conditions that stimulate 
cercosporin production in C. beticola.  However, the addition of the epigenetic 
modifier trichostatin A37, a histone deacetylase inhibitor, induced production of a 
red cercosporin-like compound into the medium.  To characterize this red 
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metabolite, mycelia from both Co. fioriniae strains were extracted with ethyl 
acetate.  Reverse-phase HPLC analysis as before revealed a peak with a retention 
time and UV-vis spectrum consistent with cercosporin in both extracts (Figure 
4.8a, b).  The presence of cercosporin was confirmed by UPLC-ESI-MS (Figure 
4.8c). 
 
Figure 4.8.  Analysis of Colletotrichum fiorinae extracts.  a) HPLC chromatograms at 280 nm.  b) 
UV-visual spectra of cercosporin produced by Co. fiorinae HC89 and HC91.  c)  Extracted ion 




4.3.  Discussion 
Given the discovery of four new biosynthetic genes within the cercosporin 
gene cluster, the proposed biosynthetic pathway needs to be revised.  
Unfortunately, instability of pathway intermediates and feedback inhibition of 
gene expression have impeded efforts to elucidate the middle steps of the 
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pathway, including the cryptic dimerization to form the unusual atropisomer.  
However, we have now identified the final step in the biosynthetic pathway, 
oxidative closure of the 7-membered methylenedioxy bridge.  Isolation of pre-
cercosporin from both ∆CTB9 and ∆CTB10 shows that two genes are involved in 
this reaction, in contrast to 5-membered methylenedioxy bridge formation, 
which is catalyzed by a single P450 enzyme in plant alkaloid biosynthesis38-39. 
CTB9 is an α-ketoglutarate dependent oxygenase, and presumably 
oxidizes the methoxyl position, analogous to the methylenedioxy forming P450s 
(Figure 4.9).  Since in all known cases of methylenedioxy ring formation, only a 
single enzyme (a P450) is required, the role of CTB10 (an EthD-domain 
containing protein) is less clear.  However, given the unfavorable 7-membered 
ring being formed, it may be required to facilitate closure of the ring.  EthD-
domain containing proteins are very small (~100 amino acids), poorly 
understood proteins, generally implicated as accessory proteins having no true 
catalytic function40.  For example, in aflatoxin biosynthesis, the EthD-domain 
containing HypE is required for the oxidation of 9 to 10 by a cytochrome P450 
(Figure 4.10)41-42.  Therefore, the possibility remains that CTB10’s role is purely 





Figure 4.9.  Proposed role of CTB9 and CTB10 in cercosporin biosynthesis. 
 
Figure 4.10.  Role of an EthD-domain containing protein (HypE) in aflatoxin biosynthesis. 
 
Two new additional biosynthetic genes have been identified in this study: 
CTB11, a putative β-IG-h3 fasciclin, and CTB12, a putative laccase.  As no 
intermediates are accumulated in either knockout, the precise role of CTB11 and 
CTB12 remains unknown.  Both enzymes are predicted to be extracellular, with 
small signal peptides, and, in the case of CTB11, a transmembrane domain.  
Fasciclin domain proteins are membrane-anchored, extracellular proteins 
involved in cell adhesion43-44.  Laccases are multicopper oxidases involved in a 
variety of cellular processes, including fungal pigment biosynthesis, lignification, 
and delignification45.  One possible role for these extracellular enzymes is to 
facilitate adhesion of the fungus to the host plant, and subsequently degrade the 
plant’s cell wall through delignification to allow cercosporin access to the cell 
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membrane.  Alternatively, CTB12 may be involved in the dimerization step of 
cercosporin biosynthesis. 
Characterization of the cercosporin biosynthetic pathway through 
identification of accumulated intermediates from gene knockouts has thus far 
proven to be problematic.  With the exception of nor-toralactone 3 and pre-
cercosporin 8, all isolated intermediates have been apparent oxidation products 
of true on-pathway intermediates.  Therefore, the true on-pathway intermediates 
have been logically inferred.  Additionally, many knockouts of cercosporin 
biosynthetic genes do not accumulate isolable intermediates, likely due to 
feedback inhibition of expression of earlier genes in the pathway.  Alternatively, 
the unstable, oxidatively-sensitive intermediates may be polymerizing, forming 
an insoluble compound(s) that is not readily extracted using traditional methods.  
Isolated pre-cercosporin appeared to dimerize over time (as detected by UPLC-
MS), and earlier, monomeric intermediates in the pathway are likely to be even 
more susceptible to oxidative polymerization.  Therefore, alternate methods, 
such as in vitro reconstitution of enzymes, need to be implemented to fully 
characterize cercosporin biosynthesis. 
The identification of cercosporin production in two isolates of Co. fioriniae 
has significant implications for the apple packing, storage, and processing 
industries.  Bitter rot, caused by Colletotrichum spp., is one of the top pre- and 
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postharvest pathogens of apple36.  This disease is a major problem for the apple 
industry as it limits fresh fruit in the field and during storage, and has a 
quiescent stage allowing decay to occur on seemingly high quality apples, only 
to come out of storage rotten.  Hence, contamination of processed apple products 
with cercosporin could be a significant health hazard.  For example, other fungal-
produced toxins (e.g. patulin, citrinin, penicillic acid) can contaminate processed 
apple products46.  Patulin, produced by Penicillium spp., is the most troubling as it 
is carcinogenic and consequently the United States and Europe have strict 
patulin limits in fruit juices and processed pome fruit products47.  Future studies 
will focus on the role of cercosporin production during the Colletotrichum-apple 
fruit interactions in addition to assaying processed fruit products made from 
apples with bitter rot symptoms to determine levels of the toxin in 
fruit.  Although only Co. fioriniae strains were analyzed for the ability to produce 
cercosporin, the identification of highly similar CTB clusters in other 








4.4.  Experimental Methods 
4.4.1.  Pre-cercosporin isolation and characterization 
Mycelial plugs of C. beticola ΔCTB9 were placed on top of eight “thin” 
PDA (Difco) plates (3.0 mL PDA per 50 mm Petri plate).  Cultures were 
incubated at 22 °C for one week under continuous light.  Three separate methods 
were attempted to prepare crude secondary metabolite extractions.  1) PDA and 
mycelia were extracted with ethyl acetate for 4 min.  The resulting supernatant 
was collected and frozen for further analysis.  2) PDA and mycelia were placed 
into a GenElute Maxiprep binding column (Sigma Aldrich) and centrifuged at 
3500 x g for 10 min.  The flow-through was collected and frozen for further 
analysis.  3) PDA and mycelia were placed into a GenElute Maxiprep binding 
column along with 15 mL ethyl acetate.  After a 30 s incubation, the column was 
centrifuged at 2400 x g for 10 min.  The flow-through was collected and frozen 
for further analysis.  To obtain sufficient pre-cercosporin for isolation and NMR 
analysis, primary extracts from all three methods were combined. 
The combined extracts were re-suspended with water and acidified with conc. 
HCl.  Pre-cercosporin was extracted quickly from this aqueous solution by 
partitioning thrice with ethyl acetate in the dark, wrapping the glassware with 
aluminum foil.  The combined ethyl acetate fractions were washed with brine, 
dried over anhydrous sodium sulfate and evaporated under vacuum at 30 °C.  
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The reddish-brown residue was resuspended in methanol and filtered through 
0.2 μm PTFE filters.  The methanol extracts were initially analyzed by reverse 
phase HPLC on an Agilent model 1200 fitted with a Kinetex XB-C18 column (4.6 
mm x 75 mm, 2.6 μm, Phenomenex).  Injections of 1 μl were run at 1.25 mL/min 
on a linear gradient of 5% solvent C/95% solvent D to 95% solvent C/5% solvent 
D over 10.8 min, where solvent C was 0.1% formic acid and solvent D was 
acetonitrile + 0.1% formic acid.  Chromatograms were monitored at 436, 280, and 
210 nm, and UV-vis spectra were recorded over a range of 210-800 nm.  High-
resolution mass data were obtained from a Waters Acquity/Xevo-G2 UPLC-ESI-
MS in positive ion mode. 
 To isolate sufficient pre-cercosporin for 1H-NMR analysis, the filtered 
methanol extract prepared above was purified by reverse-phase HPLC on an 
Agilent model 1100 fitted with a Kinetex XB-C18 semi-prep column (10 mm x 250 
mm, 5 μm, Phenomenex).  The crude extract (10 mg/mL in methanol) was 
injected (generally 500 μL) and run at 4 mL/min using the following method: 
20% solvent C/80% solvent D for 3 min, 20-70% solvent C over 17 min, 70-95% 
solvent D over 5 min, where solvent C and D were as above.  Chromatograms 
were recorded at 436, 280, and 210 nm.  The metabolite of interest was collected 
from multiple injections, combined, and lyophilized to dryness.  The purified 
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pre-cercosporin was analyzed by UPLC-ESI-MS as described above and 1H-
NMR.  
 
4.4.2.  Pre-cercosporin purification by Sephadex LH20 
C. beticola ∆842 total culture mass (mycelia and agar) was ground under 
liquid nitrogen twice and lyophilized to dryness.  The resulting powder was 
resuspended in acidified water (pH < 2) and extracted thrice with ethyl acetate.  
The ethyl acetate extractions were pooled, washed with brine, and evaporated to 
dryness.  The crude extract was resuspended in methanol. 
A Sephadex LH20 column (5.25 g) was prepared by swelling in excess methanol 
for five hours.  The resin was poured into a glass fritted column (1.5 cm 
diameter) and packed at 3 mL/min until the volume stabilized.  300 μL aliquots 
of the crude extract were chromatographed over the column at 1.3 mL/min.  
Fractions were collected and analyzed for pre-cercosporin by HPLC on an 
Agilent 1200 as above.  Fractions containing pre-cercosporin were pooled, 
evaporated to dryness, and resuspended in methanol for HPLC purification on 






4.4.3.  Colletotrichum spp. cercosporin assay 
To determine whether Colletotrichum species were able to produce cercosporin, 
two monoconidial isolates C. fioriniae (HC89 and HC91) were grown on 9 cm 
Petri plates containing 15 mL of PDA as described above to replicate conditions 
that were conducive for cercosporin production in vitro.  Seven-day old cultures 
of each isolate were grown in a temperature controlled incubator at 25 °C with 
natural light.  A pinkish to dark red color was visible in the media for all isolates 
except HC75, which had a yellow-colored pigment.  Using a #2 cork borer, three 
plugs were removed from each isolate from the edge, middle and center of each 
colony and placed in small screw cap glass vials.  Three plugs were also removed 
from an uncolonized PDA plate and included as a negative control.  Cercosporin 
(Sigma-Aldrich) was dissolved in acetone to 100 mM and used as a positive 
control.  5N KOH was added to each vial to cover the surface of the plugs and 
incubated on a shaking incubator at room temperature for 4 h.  Supernatants 
were examined for cercosporin spectrophotometrically.  To induce cercosporin 
production, we followed the procedures described by Shwab et al. except 10 μM 
trichostatin A (TSA; Sigma) was used37.  Cercosporin production by C. fioriniae 
HC89 and HC91 was confirmed by HPLC and UPLC-ESI-MS analysis as 
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Appendix A:  General Experimental Methods 
A.1.  Cloning 
When necessary, genes are isolated from genomic DNA by PCR using 
primers lacking any restriction enzyme cut sites.  This allows for more efficient 
binding of the primers to the genomic DNA.  Introns are identified based on 
NCBI gene prediction, as well as Softberry’s FGENESH gene prediction 
algorithm.  When available, cDNA sequences greatly simplify this task.  cDNA 
constructs are then put together using overlap extension PCR or Gibson 
assembly. PCR products are gel purified by running on standard agarose gels 
and extracted. 
 New primers containing appropriate restriction enzyme cut sites, or with 
overlap to the target plasmid are then used to PCR amplify the constructed gene 
or domains for cloning into expression vectors.  Both the gene to be inserted and 
the vector are digested with the appropriate restriction enzymes – generally NdeI 
and NotI for pET-24a and pET-28a – according to standard protocol.  Digested 
vector must then be gel-purified to avoid self-ligation, while the insert can be gel- 
or PCR-purified.  Insert and vector are then ligated together using T4 DNA ligase 
overnight at 16oC.  Following purification of the ligation reaction by ethanol 
precipitation, the newly constructed vector is transformed into BL21(DE3) via 
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electroporation and plated on LB agar plates with antibiotic for selection (25 
ug/mL kanamycin for pET vectors in BL21).  Alternatively, Gibson assembly can 
be performed in lieu of restriction digestion and ligation10.  Constructed plasmids 
are first screened using restriction digestion assays to ascertain whether the 
insert has been successfully ligated into the vector.  Constructs are finally 
verified by sequencing at the Johns Hopkins University Sequencing and 
Synthesis Facility or Genewiz. 
A.1.1.  Polymerase Chain Reaction (PCR) 
 Typical PCRs were run under the following conditions: 0.2 mM each 
dNTP, 0.4 μM forward primer, 0.4 μM reverse primer, 3% DMSO, and 1 μL 
template (miniprepped plasmid) in Phusion HF Buffer (New England Biolabs).  
The PCR was performed in an Eppendorf thermocycler, starting with a 2 min 
hold at 94° C.  1 μL Phusion polymerase (New England Biolabs) was added mid-
way through this initial hold.  30 cycles were performed, with a denaturing step 
of 15 s at 94 °C, an annealing step of X s at 63 °C (where X = 30 s/kb of desired 
product), and an elongation step of 30 s at 72 °C, followed by a 5 min hold at 72 
°C.  If necessary, annealing temperatures were optimized from 50-65 °C.  PCR 
products were visualized by agarose gel (typically 1.1%) and purified with a 
GeneJET Gel Extraction Kit (ThermoScientific). 
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A.1.2.  Plasmid assembly by restriction digestion and ligation 
 Inserts (purified PCR products) and vectors (plasmids miniprepped using 
a GeneJET Plasmid Miniprep Kit (Thermo Scientific)) were digested using the 
appropriate restriction enzyme (New England Biolabs) as directed.  Complete 
digestion was confirmed by agarose gel, and digested fragments were purified 
with a GeneJET Gel Extraction Kit (Thermo Scientific).  Digested fragments were 
ligated using T4 DNA Ligase (New England BioLabs) as directed.  The ligated 
plasmid was purified by ethanol precipation.  2 μL pellet paint (Millipore), 10 μL 
3M sodium acetate, and 20 μL ligation reaction were added to 200 μL ice-cold 
ethanol.  The mixture was vortexed thoroughly and centrifuged at 14,000 rpm for 
2 min.  The supernatant was removed and the pellet resuspended in 200 μL ice 
cold ethanol.  The DNA was re-pelleted by another 2 min centrifugation.  The 
supernatant was removed and the pellet thoroughly dried in a Speedvac.  The 
purified DNA was resuspended in 20 μL sterile ddH2O and transformed into E. 
coli BL21(DE3) by electroporation. 
A.1.3.  Plasmid assembly by Gibson assembly 
 Primers to amplify fragments for Gibson assembly were designed using 
NEBBuilder or SnapGene.  Resulting PCR products were purified using a 
GeneJET PCR Purification Kit (Thermo Scientific).  Similarly, the target vector 
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was digested using appropriate restriction enzymes (generally NdeI and NotI-
HF), as described above, and PCR purified.  DNA concentrations were measured 
by A260 using a Cary 50 UV-Vis spectrophotometer.  Equimolar amounts of each 
insert and vector were combined with Gibson Master Mix to reach the following 
final concentrations: 0.08 U T4 exonuclease (New England Biolabs), 0.5 U 
Phusion polymerase (New England Biolabs), 80 U Taq DNA ligase (New 
England Biolabs), 5% PEG-8000, 100 mM Tris HCl pH 7.5, 10 mM MgCl2, 10 mM 
DTT, 0.2 mM each dNTP, 1 mM NAD.  Gibson reactions were incubated at 50 °C 
for 1 h, diluted 5-fold, and transformed into E. coli BL21(DE3) by electroporation. 
A.1.4.  Transformation of E. coli by electroporation 
 Plasmid (2 μL) was added to 18 μL aliquots of electro-competent E. coli 
BL21(DE3) on ice.  This mixture was applied to chilled Potter cuvettes and 
pulsed with a 10 kV/cm electric field for 10 ms at 4 °C.  The cell mixture was then 
incubated in 180 μL LB at 37 °C for 1 h, with shaking.  The resulting inoculum 
was applied to LB agar plates with appropriate antibiotic, and incubated 
overnight at 37 °C.  When transforming purified plasmid, the inoculum was 
streaked using a sterile loop, while 50-100 μL of transformations of ligation or 




A.2.  Heterologous protein expression  
 E. coli BL21 (DE3) cells transformed with the gene of interest were grown 
at 37 oC while shaking in LB supplemented with 25 μg/mL kanamycin.  Once the 
OD600 reached 0.6, flasks were cold shocked in ice water for one hour, until cold 
to the touch.  Protein expression was then induced by addition of 0.5 mM IPTG.  
Cells were induced overnight while shaking at 17 oC.  Cells were then harvested 
by centrifuging at 4000xg for 20 minutes and typically flash frozen in liquid 
nitrogen for storage at -80 oC. 
A.3.  Protein purification 
Cell pellets were thawed and resuspended in a lysis buffer consisting of 50 
mM K/PO4, pH 8, 300 mM NaCl, and 10% glycerol (generally 4 mL lysis buffer 
per gram of cell pellet).  Cells were lysed by sonication, and the resulting lysate 
was cleared by centrifuging at 27,000xg for 30 min.  Cleared lysate was batch 
bound to Ni2+-NTA or Co2+-TALON resin (generally 1 mL resin/1 L culture, 
depending on efficiency of expression) for one hour at 4 oC.  The resin was 
collected by centrifugation at 50xg, washed with lysis buffer and applied to a 
fritted gravity flow column.  The resin was washed and then protein eluted by a 
series of washes of increasing imidazole concentration.  Purified protein was 
dialyzed overnight at 4 oC in appropriate buffer (e.g. 100 mM K/PO4 pH 7 with 
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10% glycerol for in vitro reactions).  A minimum of 100X total protein volume of 
dialysis buffer was used, and proteins were switched into fresh buffer at least 
once.  Protein concentration was measured by absorbance at 280 nm using a Cary 
50 UV-Vis spectrophotometer.  Extinction coefficients were calculated using 
ExPasy ProtParam.  Purity was observed by running all purification fractions on 
SDS-PAGE gels.  If necessary, protein was concentrated using Amicon 3K or 10K 
MWCO Ultracentrifuge filters (Millipore).  Most proteins can be flash frozen in 
liquid nitrogen for storage at -80 oC. 
A.4.  Standard medium recipes 
A.4.1.  Luria-Bertani Broth (LB) 
 10 g/L tryptone, 5 g/L yeast extract, and 5 g/L sodium chloride were 
combined in ddH2O and autoclaved for 25 min.  For agar plates, 7.5 g/L agar was 
added prior to autoclaving.  Autoclaved media was allowed to cool to 
approximately 50 °C prior to addition of antibiotic.  Plates were then poured and 
allowed to set thoroughly prior to storage at 4 °C. 
A.4.2.  Terrific Broth (TB) 
 For each liter of culture 24 g yeast extract, 12 g tryptone, and 8 mL 50% 
glycerol were combined in 900 mL ddH2O and autoclaved for 25 min.  Potassium 
phosphate buffer was prepared and autoclaved separately: 125.4 g/L K2HPO4 and 
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23.1 g/L KH2PO4.  Once sufficiently cooled (approximately 37 °C), 100 mL 
potassium phosphate buffer was added to each 900 mL of media using a sterile 





Appendix B: Supplementary Material to Chapter 2 
 
 
B.1.  Cloning and mutagenesis 
 
All plasmids used in this study are summarized in Table B.1.  Cloning of 
plasmids to express PksA-SAT-KS-MAT (pENKA4) and PT-ACP (pEPTACP), as 
well as a series of active site mutants of PksA-SAT-KS-MAT (see table) has been 
described previously1-2.  Additional mutants and PksA-SAT-KS-MAT-PT-ACP 
were cloned for this study using standard methods.  DNA manipulations were 
carried out in E. coli BL21(DE3).  PksA-SAT-KS-MAT-PT-ACP was amplified 
from a pET-28a vector containing full-length PksA cDNA using pksA5-NheI and 
ACP-3-NotI primers.  The resulting PCR product was ligated into pET28a at 
NheI and NotI sites to give pEPksA-SKMPA.  For the SAT active site mutants, 
overlap extension PCR was used to introduce specific point mutations at Cys117.  
These fragments were amplified from pENKA4 using the primers listed in Table 
B.2.  PCR products were ligated into pET-28a at NcoI and NotI sites to give the  
plasmids listed in Table B.1.  All expression constructs were confirmed by  
automated sequencing (Johns Hopkins University Synthesis and Sequencing  





Appendix Table B.1.  Plasmids used in Chapter 2 
  
Appendix Table B.2.  Primers used in Chapter 2 
 














Plasmid Protein Tag Mol. Wt (kDa) Reference 
pENKA4 SAT-KS-MAT C-His6 144 1 
pEPT-ACP PT-ACP C-His6 59 1 
pENKA4-C117A SAT0-KS-MAT C-His6 144 2 
pENKA4-C117S SAT0-KS-MAT C-His6 144 This study 
pENKA4-C117G SAT0-KS-MAT C-His6 144 This study 
pENKA4-C117N SAT0-KS-MAT C-His6 144 This study 
pEPksA-SKMPA SAT-KS-MAT-PT-ACP 
N-His6 & C-
His6 201 This study 
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B.2.  Synthesis of acyl-SNAC substrates 
All reactions, unless otherwise stated, were performed under a positive N2 
or Ar atmosphere, in anhydrous, freshly distilled solvents.  Commercially 
available compounds were purchased from Sigma-Aldrich or Alfa-Aesar and 
were used without further purification.  All 1H and 13C-NMR spectra were 
acquired on a 300 MHz or 400 MHz Bruker spectrometer and are reported in 
parts per million (δ) referenced against a TMS standard or residual solvent peak.  
All NMR solvents were purchased from Cambridge Isotope Laboratories, Inc.  
Column chromatography was carried out on Silica Gel 60 (Sorbent Technologies, 
200 x 400 mesh).  Exact masses were determined on an Analytical VG-70SE 
Magnetic Sector Mass Spectrometer at the Johns Hopkins University Chemistry 
Department Mass Spectrometry Facility.  ESI-MS spectra were measured at the 
Mass spectrometry facility of Old Dominion University in Norfolk, VA on a 
Bruker Apex-Qe Qh-FTMS instrument.  
 
R OH R OH
Jones O
R SNAC
OA, B or C
 
 
 To a room temperature solution of the alcohol in acetone (200 mM), Jones 
reagent was added dropwise until the red color persisted.  After 15 min, the 
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reaction was quenched with isopropanol, filtered, concentrated, dissolved (5% 
HCl, CH2Cl2), separated, dried and concentrated to afford the desired carboxylic 







2) HSNAC  
 
To a room temperature suspension of N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (1 eq.) in CH2Cl2, under N2, Et3N (1 eq.) was 
added. The carboxylic acid (1 eq.) was added dropwise followed by the addition 
of 4-(dimethylamino)pyridine (0.1 eq.).  After 10 min. N-acetylcysteamine (1 eq.) 
was added dropwise. The resulting solution was allowed to react for 12-14 h then 
poured into a saturated solution of NH4Cl and extracted with CH2Cl2 (3×). The 
combined organic phases were washed with H2O and brine, dried (Na2SO4), 
concentrated and purified by column chromatography to afford the 











2) HSNAC  
A room temperature solution of carboxylic acid (1 eq.) and CDI (1.4 eq.) in 
dry THF were allowed to react for 10 min.  A solution of N-acetylcysteamine (1.1 
eq.) was added and the reaction was allowed to stir at room temperature for 12-
14 h. The solvent was removed under vacuum and the residue was redissolved 
in 10 mL of EtOAc, washed (10 ml of brine), dried (Na2SO4), concentrated and 











To a 0 °C solution of the carboxylic acid (1 equiv) and DMF (cat) in CH2Cl2 
(150 mM), oxalyl chloride (1.1 equiv) was added slowly.  The ice bath was 
removed and the mixture was allowed to warm to room temperature over 2 h, 
then concentrated in vacuo and used immediately without further purification.  
To a 0 °C solution of N-acetylcysteamine (1.0 equiv) and DIPEA (1.1 equiv) in 
CH2Cl2 (350 mM), a 0 °C solution of the acid chloride (1.0 equiv) in CH2Cl2 (500 
mM) was added slowly, and the mixture was allowed to warm to room 
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temperature over 12 h.  The resulting light orange solution was washed (NH4Cl, 
sat, 1x, CuSO4, sat, 1x, NH4Cl, sat, 3x), filtered through a plug of silica gel, 












 To a 0 °C solution of Meldrum’s acid (1.0 equiv) and pyridine (1.0 equiv) 
in CH2Cl2 (350 mM), a 0 °C solution of the acid chloride (1.0 equiv) in CH2Cl2 (350 
mM) was added.  The resulting red solution was allowed to react at 0 °C for one 
hour, then warm to room temperature for 2 h.  The mixture was concentrated in 
vacuo, then dissolved in toluene (200 mM).  N-acetylcysteamine (1.0 equiv) was 
added and the red solution was heated to reflux for 2 h, cooled, washed (NH4Cl, 
sat, 3x, CuSO4, sat, 2x), dried, concentrated and recrystallized to afford the 












S-(2-acetamidoethyl) hexanethioate (5) 







S-(2-acetamidoethyl) butanethioate (6) 
Method B  
1H NMR (400 MHz, CDCl3): δ 6.17 (br s, 1H), 3.38 (app q, J = 6.3, 2H), 2.98 (t, J = 
6.5, 2H), 2.51 (t, J = 7.4, 2H), 1.92 (s, 3H), 1.65 (sext, J = 7.4, 2H), 0.91 (t, J = 7.4, 3H). 
13C NMR (101 MHz, CDCl3): δ 200.0, 170.4, 46.0, 39.7, 28.4, 23.2, 19.2, 13.5.  HR-
ESI-MS: 212.0706 ([M + Na]+, (C8H15NO2S)Na+; calc. 212.0716).  Spectral data 







S-(2-acetamidoethyl) pentanethioate (7) 
Method A 
1H NMR (300 MHz, CDCl3): δ 6.48 (br s, 1H), 3.32 (app q, J = 6.3 Hz, 2H), 2.94 (t, J 
= 6.6 Hz, 2H), 2.49 (t, J = 7.2 Hz, 2H), 1.89 (s, 3H), 1.57 (pent, J = 7.2 Hz, 2H), 1.25 
(hex, J = 7.2 Hz, 2H), 0.83 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 200.1, 
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170.5, 43.8, 39.7, 28.4, 27.7, 23.1, 22.07, 13.7.  HR-ESI-MS calculated exact mass for 
C9H18NO2S: 204.1058, found: 204.1062 [M+H]+.  Spectral data matched that 







S-(2-acetamidoethyl) heptanethioate (8) 
Method A 
1H-NMR (400 MHz, CDCl3): δ 6.07 (br s, 1H), 3.66 (app q, J = 6.8 Hz, 2H), 2.98 (t, J 
= 6.8 Hz, 2H), 2.53 (t, J = 7.6 Hz, 2H), 1.93 (s, 3H), 1.61 (pent, J = 7.6 Hz, 2H), 1.25 
(br m, 6H), 0.84 (t, J = 7.6 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 200.4, 170.4, 
44.3, 39.9, 31.5, 28.7, 28.6, 25.9, 23.3, 22.6, 14.1. HR-ESI-MS: 254.1181 ([M + Na]+, 








S-(2-acetamidoethyl) octanethioate (9) 
Method C  
1H NMR (400 MHz, CDCl3): δ 5.89 (br s, 1H), 3.46 (app q, J = 6.2 Hz, 2H), 3.09 (t, J 
= 6.3 Hz, 2H), 2.52 (t, J = 7.4 Hz, 2H), 1.97 (s, 3H), 1.59 (pent, J = 7.3 Hz, 2H), 1.34–
1.27 (m, 8H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 202.5, 192.6, 
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170.5, 57.3, 43.6, 39.4, 31.3, 29.4, 23.3, 23.3, 22.5, 14.01.  HRFAB m/z calculated 
exact mass for C12H24NO2S 246.1527, found 246.1525 [M+H]+.  Spectral data 








S-(2-acetamidoethyl) 3-oxooctanethioate (10) 







S-(2-acetamidoethyl) 5-bromopentanethioate (11) 
Method B: 76% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 6.05 (br s, 1H), 3.36 (m, 4H), 2.98 (t, J = 8.0 Hz, 2H), 
2.55 (t, J = 8.0 Hz, 2H), 1.92 (s, 3H), 1.82 (m, 4H).  13C NMR (101 MHz, CDCl3): δ 
199.3, 170.4, 42.9, 39.6, 32.8, 31.7, 28.5, 24.1, 23.2.  HRFAB m/z calculated exact 
mass for C9H17NO2S79Br 282.0163, found 282.01662 [M+H]+ (79Br); calculated exact 
mass for C9H17NO2S81Br 284.0142, found 284.0146 [M+H]+ (81Br).  See Figure B.32 








S-(2-acetamidoethyl) 6-bromohexanethioate (12) 
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Method B: 38% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 5.88 (br s, 1H), 3.39 (app q, J = 6.2 Hz, 2H), 3.34 (t, J 
= 6.7 Hz, 2H), 2.99 (t, J = 6.7 Hz, 2H), 2.55 (t, J = 6.7 Hz, 2H), 1.92 (s, 3H), 1.83 (m, 
2H), 1.67 (m, 2H), 1.44 (m, 2H). 13C NMR (101 MHz, CDCl3): δ 199.6, 170.2, 43.7, 
39.6, 33.3, 32.3, 28.5, 27.4, 24.7, 23.2. HRFAB m/z calculated exact mass for 
C10H19NO2S79Br 296.0319, found 296.0324 [M+H]+ (79Br); calculated exact mass for 








S-(2-acetamidoethyl) 5-chloropentanethioate (13) 
Method B: 99% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 5.91 (br s, 1H), 3.51 (m, 2H), 3.41 (app q, J = 6.2 Hz, 
2H), 3.01 (t, J = 6.6 Hz, 2H), 2.58 (m, 2H), 1.92 (s, 3H), 1.80 (m, 4H). 13C NMR (101 
MHz, CDCl3): δ 199.3, 170.2, 44.2, 43.1, 39.6, 31.6, 28.6, 23.2, 22.8. HRFAB m/z 
calculated exact mass for C9H17NO2S35Cl 238.0668, found 238.0676 [M+H]+ (35Cl); 
calculated exact mass for C9H17NO2S37Cl 240.0639, found 240.0639 [M+H]+ (37Cl).  










S-(2-acetamidoethyl) 6-chlorohexanethioate (14) 
Method B: 97% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 5.91 (br s, 1H), 3.49 (t, J = 6.6 Hz, 2H), 3.39 (app q, J 
= 6.2 Hz, 2H), 3.00 (t, J = 6.6 Hz, 2H), 2.57 (t, J = 7.4 Hz, 2H), 1.93 (s, 3H), 1.80 – 
1.60 (m, 4H), 1.45 (m, 2H).  13C NMR (101 MHz, CDCl3): δ 199.8, 170.4, 44.7, 43.8, 
39.7, 32.1, 28.5, 26.1, 25.4, 22.9.  HRFAB m/z calculated exact mass for 
C10H19NO2S35Cl 252.0825, found 252.0823 [M+H]+ (35Cl); calculated exact mass for 








S-(2-acetamidoethyl) 2-methylhexanethioate (15) 
Method A: 87 % of a colorless oil 
1H NMR (400 MHz, CDCl3): δ 5.84 (br s, 1H), 3.43 (app q, J =  6.1 Hz, 2H), 3.02 (t, J 
= 6.4 Hz, 2H), 2.64 (hex, J = 6.8 Hz, 1H), 1.96 (s, 3H), 1.70 (m, 1H), 1.42 (m, 1H), 
1.29 (m, 4H), 1.11 (d, J = 6.8 Hz, 3H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, 
CDCl3): δ 204.9, 170.4, 48.9, 40.1, 34.0, 29.5, 28.3, 23.4, 22.8, 17.9, 14.1. HR-ESI-MS: 








S-(2-acetamidoethyl) 3-methylhexanethioate (16) 
Method C: 95% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 5.87 (br s, 1H), 3.44 (app q, J = 6.1 Hz, 2H), 3.02 (t, J 
= 6.6 Hz, 2H), 2.58 (m, 2H), 1.98 (s, 3H), 1.71 (m, 1H), 1.46 (m, 1H), 1.35 (m, 2H), 
1.16 (m, 1H), 0.87 (t, J = 7.2 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, 
CDCl3): δ 200.0, 170.4, 51.4, 39.9, 38.8, 30.9, 28.4, 23.2, 19.9, 19.5, 14.1.  HRFAB m/z 
calculated exact mass for C11H21NO2S 232.1371, found 232.1369 [M+H]+.  See 





S-(2-acetamidoethyl) 4-methylhexanethioate (17) 
Method C: 86% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 6.00 (br s, 1H), 3.41 (app q, J = 6.0 Hz, 2H), 3.00 (t, J 
= 6.4 Hz, 2H), 2.64 (q, J = 6.8 Hz, 1H), 2.00 (s, 3H), 1.67 (m, 1H), 1.42 (m, 1H), 1.25 
(m, 3H), 1.11 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, 
CDCl3): δ 200.5, 170.5, 42.0, 39.9, 33.9, 32.1, 29.1, 28.4, 23.1, 18.8, 11.2.  HRFAB m/z 
calculated exact mass for C11H21NO2S 232.1371, found 232.1366 [M+H]+.  See 









S-(2-acetamidoethyl) 5-methylhexanethioate (18)  
Method B: 100% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 5.94 (br s, 1H), 3.38 (app q, J = 6.2 Hz, 2H), 2.98 (t, J 
= 6.6 Hz, 2H), 2.53 (app.t, J = 15.2, 7.5 Hz, 2H), 1.93 (s, 3H), 1.62 (m, 2H), 1.51 (m, 
1H), 1.17 (m, 2H), 0.84 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3): δ 200.2, 
170.3, 44.3, 39.7, 38.1, 28.4, 23.5, 24.1, 23.1, 22.0.  HRFAB m/z calculated exact mass 








S-(2-acetamidoethyl) 4-methylpentanethioate (19)  
Method B: 100% of a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 5.94 (br s, 1H), 3.38 (app q, J = 6.2 Hz, 2H), 2.97 (t, J 
= 6.6 Hz, 2H), 2.53 (app t, J = 7.4 Hz, 2H), 1.91 (s, 3H), 1.51 (m, 3H), 0.85 (d, J = 6.2 
Hz, 6H).  13C NMR (101 MHz, CDCl3): δ 200.4, 170.3, 42.3, 39.7, 34.4, 28.4, 27.6, 
23.1, 22.2.  HRFAB m/z calculated exact mass for C10H20NO2S: 218.1215, found: 









S-(2-acetamidoethyl) (E)-hex-2-enethioate (20) 
Method A 
1H NMR (400 MHz, CDCl3): δ 6.92 (dt, J = 15.1, 7.3 Hz, 1H), 6.12 (d, J = 15.5 Hz, 
1H), 5.97 (br s, 1H), 3.44 (app q, J = 6.4 Hz, 2H), 3.08 (t, J = 6.4 Hz, 2H), 2.18 (app 
q, J = 7.2 Hz, 2H), 1.96 (s, 3H), 1.50 (pent, J = 7.4 Hz, 2H), 1.72 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 190.6, 170.5, 146.7, 128.57, 47.7, 40.0, 34.4, 28.4, 23.4, 
21.3.  HR-ESI-MS: 238.0866 ([M + Na]+, C10H17NO2SNa+; calc. 238.0872).  Spectral 





S-(2-acetamidoethyl) (E)-hex-3-enethioate (21) 
Method C 
1H NMR (400 MHz, CDCl3): δ 5.90 (br s, 1H), 5.65 (m, 1H), 5.48 (m, 1H), 3.43 (app 
q, J = 6.3 Hz, 2H), 3.24 (ddd, J = 1.0, 4.4, 6.8 Hz, 1H), 3.02, (t, J = 6.4 Hz, 2H), 2.07 
(m, 2H), 1.96 (s, 3H), 1.00 (t, J = 7.6 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 198.9, 
170.4, 138.3, 119.8, 47.6, 39.7, 28.5, 25.6, 23.2, 13.3.  HRFAB m/z calculated exact 
mass for C10H17NO2S: 216.1058, found: 216.1062 [M+H]+.  Spectral data matched 









S-(2-acetamidoethyl) hex-5-enethioate (22)  
Method A: 24% of a colorless oil 
1H NMR (300 MHz, CDCl3): δ 6.13 (br s, 1H), 5.72 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 
5.02–4.95 (m, 2H), 3.38 (app q, J = 6.3 Hz, 2H), 2.99 (t, J = 6.3 Hz, 2H), 2.55 (t, J = 
7.5 Hz, 2H), 2.05 (q, J = 6.9, CH2), 1.93 (s, 3H), 1.72 (pent, J = 7.5 Hz, 2H). 13C NMR 
(75 MHz, CDCl3): δ 199.4, 170.5, 137.2, 115.5, 43.1, 39.4, 32.6, 28.3, 24.50, 23.0.  HR-
ESI-MS calculated exact mass for C10H18NO2S: 216.1058, found: 216.1059 [M+H]+.  









S-(2-acetamidoethyl) 4-(methylthio)butanethioate (23)  
Method A: 30% of a colorless oil 
1H NMR (400 MHz, CDCl3): δ 5.89 (br s, 1H), 3.42 (app q, J = 6.3 Hz, 2H), 3.04 (t, J 
= 6.3 Hz, 2H), 2.75 (t, J = 6.9 Hz, 2H), 2.44 (t, J = 6.9 Hz, 2H), 2.03 (s, 3H), 1.97 (m, 
2H), 1.96 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 199.3, 170.4, 42.7, 39.6, 33.3, 28.6, 
24.6, 23.4, 15.4. HR-ESI-MS: 258.0589 ([M + Na]+, C9H17NO2S2Na+; calc. 258.0593).  










S-(2-acetamidoethyl) 3-(methylthio)propanethioate (24) 
Method A: 27% of a colorless oil 
1H NMR (400 MHz, CDCl3): δ 6.29 (br s, 1H), 3.36 (app q, J = 6.3 Hz, 2H), 2.99 (t, J 
= 6.5 Hz, 2H), 2.81 (AA’BB’, J ≈ 7.1, 1.9 Hz, 2H), 2.73 (AA’BB’, J ≈ 7.1, 1.9 Hz, 2H), 
2.06 (s, 3H), 1.91 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 197.9, 170.4, 43.4, 39.3, 
29.3, 28.5, 23.1, 15.5.  HR-ESI-MS: 244.0431 ([M + Na]+, C8H15NO2S2Na+; calc. 








S-(2-acetamidoethyl) 2-(ethylthio)ethanethioate (25) 
Method A: colorless oil 
1H NMR (400 MHz, CDCl3): δ 5.89 (br s, 1H), 3.45 (app q, J = 6.4 Hz, 2H), 3.43 (s, 
2H), 3.06 (t, J = 6.4 Hz, 2H), 2.64 (dq, J = 0.8, 7.2 Hz, 2H), 1.97 (s, 3H), 1.27 (dt, J = 
0.8, 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 197.4, 170.3, 41.9, 39.5, 29.1, 27.0, 
23.2, 14.1.  HR-ESI-MS calculated exact mass for C8H16NO2S2: 222.0623, found: 










S-(2-acetamidoethyl) 2-(methylthio)ethanethioate (26) 
Method A: colorless oil  
1H NMR (400 MHz, CDCl3): δ 5.98 (br s, 1H), 3.44 (app q, J = 6.3 Hz, 2H), 3.38 (s, 
2H), 3.06 (t, J = 6.3 Hz, 2H), 2.19 (s, 3H), 1.96 (s, 3H).  13C NMR (101 MHz, CDCl3): 
δ 197.0, 170.4, 44.2, 39.4, 29.1, 23.2, 16.5.  HR-ESI-MS calculated exact mass for 








S-(2-acetamidoethyl) 2-(pentyloxy)ethanethioate (27) 
Method A: 61% of a colorless oil 
1H NMR (300 MHz, CDCl3): δ 6.04 (br s, 1H), 4.10 (s, 2H), 3.54 (t, J = 6.9 Hz, 2H), 
3.41 (app q, J = 6.4 Hz, 2H), 3.03 (t, J = 6.4 Hz, 2H), 1.95 (s, 3H), 1.63 (p, J = 6.9 Hz, 
2H), 1.35 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 201.0, 
170.4, 75.8, 72.9, 39.5, 29.3, 28.1, 27.4, 23.2, 22.5, 14.0.  HR-ESI-MS: 270.1132 ([M + 








S-(2-acetamidoethyl) 2-(ethoxymethoxy)ethanethioate (28) 
Method A colorless oil  
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1H NMR (400 MHz, CDCl3): δ 6.15 (br s, 1H), 4.73 (s, 2H), 4.22 (s, 2H), 3.63 (q, J = 
7.0 Hz, 2H), 3.40 (app q, J = 6.4 Hz, 2H), 3.03 (t, J = 6.4 Hz, 2H), 1.94 (s, 3H), 1.19 (t, 
J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 199.7, 170.5, 95.3, 71.9, 64.1, 39.4, 
27.5, 23.1, 15.0.  HR-ESI-MS calculated exact mass for C9H18NO4S: 236.0957, 








S-(2-acetamidoethyl) 4-cyanobutanethioate (29) 
Method A: 60% of a colorless oil 
1H NMR (300 MHz, CDCl3): δ 5.95 (br s, 1H), 3.42 (app q, J = 6.0 Hz, 2H), 3.01 (t, J 
= 6.0 Hz, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.52 (t, J = 6.9 Hz, 2H), 1.95 (pent, J = 7.2 Hz, 
2H), 1.95 (s, 3H).  13C NMR (75 MHz, CDCl3): δ 198.1, 170.4, 118.9, 42.0, 39.4, 28.9, 
23.3, 21.2, 16.3.  HR-ESI-MS calculated exact mass for C9H15N2O2S: 215.0854, 








S-(2-acetamidoethyl) 4-azidobutanethioate (30) 
Method A: 72% of a colorless oil 
1H NMR (300 MHz, CDCl3): δ 6.17 (br s, 1H), 3.39 (app q, J = 6.3 Hz, 2H), 3.32 (t, J 
= 6.6 Hz, 2H), 3.00 (t, J = 6.3 Hz, 2H), 2.65 (t, J = 7.2 Hz, 2H), 1.93 (s, 3H), 1.88 
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(pent, J = 6.6 Hz, 3H).  13C NMR (75 MHz, CDCl3): δ 198.6, 170.5, 50.4, 40.8, 39.4, 
28.6, 24.7, 23.1.  HR-ESI-MS: 253.0735 ([M + Na]+, C8H14N4O2SNa+; calc. 253.0711).  








S-(2-acetamidoethyl) cyclopropanecarbothioate (31) 
Method C 
1H NMR (400 MHz, CDCl3): δ 6.08 (br s, 1H), 3.41 (app q, J = 6.1 Hz, 2H), 3.03 (t, J 
= 6.4 Hz, 2H), 2.02 (sym m, 1H), 1.95 (s, 3H), 1.15 (sym m, 2H), 1.35 (m, 2H), 0.97 
(sym m, 2H). 13C-NMR (101 MHz, CDCl3): δ 199.9, 170.3, 39.8, 31.1, 28.5, 22.8, 
23.2, 22.7, 11.1.  HR-ESI-MS calculated exact mass for C8H14NO2S: 188.0745, 







S-(2-acetamidoethyl) 2-methylcyclopropane-1-carbothioate (32) 
Method C: 72% of a colorless oil 
As a 3:1 mixture of diastereomers.  Major: 1H NMR (400 MHz, CDCl3): δ 5.99 (br 
s, 1H), 3.42 (app q, J = 6.0 Hz, 2H), 3.02 (t, J = 6.8 Hz, 2H), 1.95 (s, 3H), 1.76 (sym 
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m, 1H), 1.55 (b m, 1H), 1.35 (m, 1H), 1.13 (d, J = 6.0 Hz, 3H), 0.82 (sym m, 1H). 
Minor: 1H NMR (400 MHz, CDCl3): δ 5.99 (br s, 1H), 3.42 (app q, J = 6.0 Hz, 2H), 
3.06 (m, 2H), 2.10 (b m, 1H) 1.95 (s, 3H), 1.48 (b m, 1H), 1.14 (d, J = 6.0 Hz, 3H), 
1.11 (m, 1H), 1.10 (m, 1H).  Major: 13C-NMR (101 MHz, CDCl3): δ 199.2, 170.3, 
39.9, 31.4, 28.5, 23.2, 20.4, 19.6, 17.9.  Minor: 13C-NMR (101 MHz, CDCl3): δ 197.7, 
170.3, 40.1, 28.6, 28.3, 23.2, 19.6, 16.3, 11.9.  HR-ESI-MS calculated exact mass for 







S-(2-acetamidoethyl) but-2-ynethioate (33) 
Method A: colorless prisms 
1H NMR (400 MHz, CDCl3): δ 6.01 (br s, 1H), 3.45 (app q, J = 6.3 Hz, 2H), 3.10 (t, J 
= 6.3 Hz, 2H), 2.05 (s, 3H), 1.97 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 176.6, 170.4, 
92.5, 77.9, 39.3, 29.3, 23.2, 4.3.  HR-ESI-MS calculated exact mass for C8H12NO2S: 












1H NMR (300 MHz, CDCl3): δ 7.96 (d, J = 4.9 Hz, 2H), 7.58 (d, J = 3.8 Hz, 1H), 7.46 
(dd, J = 4.7, 3.8 Hz, 2H), 6.01 (br s, 1H), 3.51 (app q, J ≈ 6.0 Hz, 2H), 3.23 (t, J = 6.0 
Hz, 2H), 1.97 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 192.4, 170.5, 136.8, 133.8, 128.8, 
127.4, 39.8, 28.7, 23.4. HR-ESI-MS: 246.0554 ([M + Na]+, C11H13NO2SNa+; calc. 





























Appendix Figure B.1.  Full structures of all starter units assayed in this paper 
and the resulting enzymatic products.  See following figures (Appendix Figure 





















Peak Compound Core 
Structure 






1 35 B C5H11 260, 288 309.1342 Hex+5Mal -H2O +H2O C16H20O6 
2 36 B CH2COC5H11 262, 290 351.1434 Hex+6Mal -H2O +H2O C18H22O7 
3 37 A CH2COC5H11 220, 288 333.1337 Hex+6Mal -2H2O +H2O C18H20O6 
4 38 C C5H11 220, 286 183.1027 Hex+2Mal - O-C C10H14O3 
5 39a,b D/E C5H11 224, 278, 
306 
357.1342 Hex+7Mal -H2O O-C C20H20O6 
6 40 F CH2COC5H11 248, 270, 
340, 468 
371.1124 Hex+7Mal -2H2O O-C, [O] C20H18O7 
7 4 G CH2COC5H11 270, 280, 
390 
357.1332 Hex+7Mal -2H2O O-C C20H20O6 
Appendix Figure B.2.  Product profile for starter unit 5 reaction (S-(2-acetamidoethyl) hexanethioate) 
 
Peak Compound Core 
Structure 
R UV max [M+H]+ Chain 
Length 
Dehydration Release Mol. 
Formula 
1 41 C C3H7 232, 284 155.0712 But+2Mal - O-C C8H10O5 
2 42 G CH2COCH2COCH2COCH3 270, 
280, 390 
385.0917 10Mal -2H2O O-C C20H16O8 
3 43a,b D/E C3H7 224, 
278, 306 
329.1027 But+7Mal -2H2O O-C C18H16O6 
4 44 G CH2COCH2COC3H7 270, 
280, 390 
371.1130 But+8Mal -2H2O O-C C20H18O7 
5 44 G CH2COCH2COC3H7 270, 
280, 390 
371.1128 But+8Mal -2H2O O-C C20H18O7 




Peak Compound Core 
Structure 






1 45 B C4H9 260, 288 295.1184 Pent+5Mal -H2O + H2O C15H18O6 
2 46 B CH2COC4H9 262, 288 337.1285 Pent+6Mal -H2O + H2O C17H20O7 
3 47 C C4H9 220, 286 169.0872 Pent+2Mal - O-C C9H12O3 
4 48a,b D/E C4H9 224, 278, 
306 
343.1178 Pent+7Mal -2H2O O-C C19H18O6 
5 49 F CH2COC4H9 246, 270, 
336, 468 
357.0974 Pent+7Mal -2H2O O-C, [O] C19H16O7 
6 50 G CH2COC4H9 272, 280, 
390 
343.1174 Pent+7Mal -2H2O O-C C19H18O6 
Appendix Figure B.4.  Product profile for starter unit 7 reaction (S-(2-acetamidoethyl) pentanethioate) 
Peak Compound Core 
Structure 






1 51 A C6H13 262, 288 305.1391 Hept+5Mal -2H2O +H2O C17H20O5 
2 52 B C6H13 260, 288 323.1494 Hept+5Mal -H2O +H2O C17H22O6 
3 53 B CH2COC6H13 262, 288 365.1602 Hept+6Mal -H2O +H2O C19H24O7 
4 54 A CH2COC6H13 222, 288 347.1497 Hept+6Mal -2H2O +H2O C19H22O6 
5 55 C CH2COC6H13 224, 286 239.1288 Hept+3Mal - O-C C13H18O4 
6 56 C C6H13 220, 286 197.1183 Hept+2Mal - O-C C11H16O3 
7 57 G CH2COC6H13 270, 280, 
390 
371.1493 Hept+7Mal -2H2O O-C C21H22O6 
8 58 G C6H13 270, 280, 
390 
329.1403 Hept+6Mal -2H2O O-C C19H20O5 




Peak Compound Core 
Structure 






1 59 A C7H15 262, 288 319.1548 Oct+5Mal -2H2O +H2O C18H22O5 
2 60 B C7H15 260, 288 337.1651 Oct+5Mal -H2O +H2O C18H24O6 
3 61 C CH2COC7H15 220, 286 253.1443 Oct+3Mal - O-C C14H20O4 
4 62 C C7H15 220, 286 211.1339 Oct+2Mal - O-C C12H18O3 
5 63 G C7H15 270, 280, 
390 
343.1538 Oct+6Mal -H2O O-C C20H22O5 
Appendix Figure B.6.  Product profile for starter unit 9 reaction (S-(2-acetamidoethyl) octanethioate) 
Peak Compound Core 
Structure 






1 35 B C5H11 260, 288 309.1342 Oct+4Mal -H2O +H2O C16H20O6 
2 36 B CH2COC5H11 262, 288 351.1435 Oct+5Mal -H2O +H2O C18H22O7 
3 37 A CH2COC5H11 220, 288 333.1336 Oct+5Mal -2H2O +H2O C18H20O6 
4 38 C C5H11 218, 286 183.1025 Oct+Mal - O-C C10H14O3 
5 39a,b D/E C5H11 224, 278, 310 357.1337 Oct+6Mal -2H2O O-C C20H20O6 
6    234, 248, 280, 
304 
333.1341 Oct+5Mal   C18H20O6 
7 40 F CH2COC5H11 246, 264, 340, 
468 
371.1127 Oct+6Mal -2H2O O-C, [O] C20H18O7 
8 4 G CH2COC5H11 270, 280, 390 357.1332 Oct+6Mal -2H2O O-C C20H20O6 






Peak Compound Core 
Structure 




1 64 B C4H8Br 262, 290 373.0296 Br-Pent+5Mal -H2O +H2O C15H17BrO6 
2 65 B CH2COC4H8Br 262, 290 415.0380 Br-Pent+6Mal -H2O +H2O C17H19BrO7 
3 66 C C4H8Br 220, 286 246.9974 Br-Pent+2Mal - O-C C9H11BrO3 
4 67 F CH2COC4H8Br 246, 268, 
338, 468 
435.0079 Br-Pent+7Mal -2H2O O-C, [O] C19H15BrO7 
5 68 G CH2COC4H8Br 272, 280, 
388 
421.0273 Br-Pent+7Mal -2H2O O-C C19H17BrO6 
Appendix Figure B.8.  Product profile for starter unit 11 reaction (S-(2-acetamidoethyl) 5-
bromopentanethioate) 
Peak Compound Core 
Structure 






1 69 B C5H10Br 260, 288 387.0440 Br-Hex 
+5Mal 
-H2O +H2O C16H19BrO6 
2 70 B CH2COC5H10Br 262, 288 429.0569 Br-Hex 
+6Mal 
-H2O +H2O C18H21BrO7 
3 71 C C5H10Br 220, 286 261.0121 Br-Hex 
+2Mal 
- O-C C10H13BrO3 




  C18H19BrO6 




-2H2O O-C, [O] C20H17BrO7 




-2H2O O-C C20H19BrO6 





Peak Compound Core 
Structure 




1 74 B C4H8Cl 262, 288 329.0812 Cl-Pent+5Mal -H2O +H2O C15H17ClO6 
2 75 B CH2COC4H8Cl 262, 288 371.0872 Cl-Pent+6Mal -H2O +H2O C17H19ClO7 
3 76 C C4H8Cl 220, 286 203.0479 Cl-Pent+2Mal - O-C C9H11ClO3 
4    218, 286 245.0481    C11H13ClO4 
5 77 F CH2COC4H8Cl 246, 264, 338, 
468 
391.0569 Cl-Pent+7Mal -2H2O O-C, [O] C19H15ClO7 
6 78 G CH2COC4H8Cl 272, 280, 390 377.0784 Cl-Pent+7Mal -2H2O O-C C19H17ClO6 
Appendix Figure B.10.  Product profile for starter unit 13 reaction (S-(2-acetamidoethyl) 5-
chloropentanethioate) 
Peak Compound Core 
Structure 




1 79 B C5H10Cl 260, 288 343.0923 Cl-Hex+5Mal -H2O +H2O C16H19ClO6 
2 80 B CH2COC5H10Cl 262, 288 385.1041 Cl-Hex+6Mal -H2O +H2O C18H21ClO7 
3 81 C C5H10Cl 220, 286 217.0627 Cl-Hex+2Mal - O-C C10H13ClO3 
4    218, 234, 278, 
300 
367.0952 Cl-Hex+6Mal   C18H19ClO6 
5 82 F CH2COC5H10Cl 246, 270, 330, 
468 
405.0741 Cl-Hex+7Mal -2H2O O-C, [O] C20H17ClO7 
6 83 G CH2COC5H10Cl 270, 280, 390 391.0914 Cl-Hex+7Mal -2H2O O-C C20H19ClO6 







Peak Compound Core 
Structure 






1 42 G CH2COCH2COCH2COCH3 272, 280, 
390 
385.0911 10Mal -2H2O O-C C20H16O8 




-2H2O O-C C21H22O6 
Appendix Figure B.12.  Product profile for starter unit 15 reaction (S-(2-acetamidoethyl) 2-
methylhexanethioate) 
Peak Compound Core 
Structure 






1 42 G CH2COCH2COCH2COCH3 270, 280, 
390 
385.0905 10Mal -2H2O O-C C20H16O8 
2 85 B CH2COCH2CH(CH3)C3H7 266, 288 365.1596 Me-
Hex+6Mal 
-H2O +H2O C19H24O7 
3    240, 288, 
336 
197.1178    C11H16O3 




-2H2O O-C C21H22O6 




-2H2O O-C C21H22O6 










Peak Compound Core 
Structure 






1 88 B C2H4CH(CH3) 
C2H5 
260, 288 323.1493 Me-Hex 
+5Mal 
-H2O +H2O C17H22O6 
2 89 B CH2CO 
C2H4CH(CH3)C2H5 
262, 288 365.1594 Me-Hex 
+6Mal 
-H2O +H2O C19H24O7 
3 90 C CH2COC2H4CH(CH3) 
C2H5 
220, 284 239.1281 Me-Hex 
+3Mal 
- O-C C13H18O4 
4 91a,b D/E C2H4CH(CH3) 
C2H5 
224, 278, 310 371.1492 Me-Hex 
+7Mal 
-2H2O O-C C21H22O6 
5 92 G CH2COC2H4CH(CH3) 
C2H5 
270, 280, 390 371.1486 Me-Hex 
+7Mal 
-2H2O O-C C21H22O6 
Appendix Figure B.14.  Product profile for starter unit 17 reaction (S-(2-acetamidoethyl) 4-
methylhexanethioate) 
 
Peak Compound Core 
Structure 






1 93 B C3H6C(CH3)2 260, 288 323.1488 Me-Hex 
+5Mal 
-H2O +H2O C17H22O6 
2 94 B CH2COC3H6C(CH3)2 266, 288 365.1590 Me-Hex 
+6Mal 
-H2O +H2O C19H24O7 
4 95 C C3H6C(CH3)2 224, 284 197.1179 Me-Hex 
+2Mal 
- O-C C11H16O3 
5 96 G CH2COC3H6C(CH3)2 270, 280, 390 371.1487 Me-Hex 
+7Mal 
-2H2O O-C C21H22O6 







Peak Compound Core 
Structure 




1 97 B C2H4C(CH3)2 260, 288 309.1338 Me-Pent+5Mal -H2O +H2O C16H20O6 
2 98 B CH2COC2H4C(CH3)2 262, 288 351.1435 Me-Pent+6Mal -H2O +H2O C18H22O7 
3 99 C CH2COC2H4C(CH3)2 220, 284 225.1127 Me-Pent+3Mal - O-C C12H16O4 
4 100 C C2H4C(CH3)2 220, 286 183.1024 Me-Pent+2Mal - O-C C10H14O3 
5 101a,b D/E C2H4C(CH3)2 232, 278, 
304 
357.1339 Me-Pent+7Mal -2H2O O-C C20H20O6 
6 102 F CH2COC2H4C(CH3)2 246, 270, 
330, 468 
371.1121 Me-Pent+7Mal -2H2O O-C, [O] C20H18O7 
7 103 G CH2COC2H4C(CH3)2 270, 280, 
390 
357.1349 Me-Pent+7Mal -2H2O O-C C20H20O6 
Appendix Figure B.16.  Product profile for starter unit 19 reaction (S-(2-acetamidoethyl) 4-
methylpentanethioate) 
Peak Compound Core 
Structure 






1 104a,b D/E CHCHC3H7 226, 262 355.1176 Hex+7Mal -2H2O O-C C20H18O6 
2 105 H CHCHC3H7 222, 264, 304, 
374 
355.1179 Hex+7Mal -2H2O +H2O, C-C C20H18O6 
3 106 G CH2COCHCHC3H7 270, 280, 390 355.1184 Hex+7Mal -2H2O O-C C20H18O6 










Peak Compound Core 
Structure 






1    218, 268, 
382 
349.1281 Hex+6Mal   C18H20O7 
2    228, 284 331.1187 Hex+6Mal   C18H18O6 
3 107 C CH2CHCHC2H5 220, 288 181.0874 Hex+2Mal - O-C C10H12O3 
4 108a,b D/E* CH2CHCHC2H5 224, 280 373.1280 Hex+7Mal -H2O O-C C20H20O7 
5 109 H CH2CHCHC2H5 222, 264, 
304, 374 
355.1182 Hex+7Mal -2H2O C-C C20H18O6 
6 110 G CH2COCH2CHCHC2H5 270, 280, 
390 
355.1183 Hex+7Mal -2H2O O-C C20H18O6 
Appendix Figure B.18.  Product profile for starter unit 21 reaction (S-(2-acetamidoethyl) (E)-hex-3-
enethioate). *108a,b consist of hydrated versions of cores D, E. 
 
Peak Compound Core 
Structure 






1    272, 280, 390 490.1537    ? 
2 111 C C3H6CHCH2 220, 286 181.0865 Hex+2Mal - O-C C10H12O3 
3 112a,b D/E C3H6CHCH2 224, 278, 310 355.1177 Hex+7Mal -2H2O O-C C20H18O6 
4    270, 280, 390 331.1183 Hex+6Mal   C18H18O6 
5 113 G CH2COC3H6CHCH2 270, 280, 390 355.1182 Hex+7Mal -2H2O C-O C20H18O6 






Peak Compound Core 
Structure 






1 114 C C3H6SCH3 220, 286 201.0591 ‘Hex’+2Mal - O-C C9H12O3S 
2 115 F CH2COC3H6SCH3 246, 270, 330, 
468 
389.0688 ‘Hex’+7Mal -2H2O O-C, [O] C19H16O7S 
3 116 G CH2COC3H6SCH3 270, 280, 390 375.0899 ‘Hex’+7Mal -2H2O O-C C19H18O6S 





Peak Compound Core 
Structure 






1 117 C C2H4SCH3 220, 286 187.0428 ‘Pent’+2Mal - O-C C8H10O3S 
2 118a,b D/E C2H4SCH3 224, 280, 388 361.0740 ‘Pent’+7Mal -2H2O O-C C18H16O6S 
3 119 G CH2COC2H4SCH3 270, 280, 390 361.0744 ‘Pent’+7Mal -2H2O O-C C18H16O6S 











Peak Compound Core 
Structure 






1 120 C CH2SC2H5 222, 288 187.0433 ‘Pent’+2Mal - O-C C8H10O3S 
2 121a,b D/E* CH2SC2H5 224, 282 379.0844 ‘Pent’+7Mal -H2O O-C C18H18O7S 
3 122a,b D/E CH2SC2H5 224, 278 361.0744 ‘Pent’+7Mal -2H2O O-C C18H16O6S 
4 123 G CH2COCH2SC2H5 270, 280, 390 361.0744 ‘Pent’+7Mal -2H2O O-C C18H16O6S 
Appendix Figure B.22.  Product profile for starter unit 25 reaction (S-(2-acetamidoethyl) 2-
(ethylthio)propanethioate).  *129a,b are hydrated versions of 130 a,b 
 
Peak Compound Core 
Structure 






1 124 C CH2SCH3 236, 288 173.0273 ‘But’+2Mal - O-C C7H8O3S 
2 125 G CH2COCH2COCH2SCH3 272, 280, 
390 
389.0678 ‘But’+8Mal -2H2O O-C C19H16O7S 
















Peak Compound Core 
Structure 






1 126 B CH2OC5H11 262, 288 339.1443 ‘Oct’+5Mal -H2O +H2O C17H22O7 
2 127 B CH2COCH2OC5H11 262, 288 381.1544 ‘Oct’+6Mal -H2O +H2O C19H24O8 
3    234, 278, 
300 
363.1441 ‘Oct’+6Mal   C19H22O7 
4 128 G CH2COCH2OC5H11 270, 280, 
390 
387.1476 ‘Oct’+7Mal -2H2O O-C C21H22O7 
5 129 G CH2OC5H11 270, 280, 
390 
345.1339 ‘Oct’+6Mal -2H2O O-C C19H20O6 
Appendix Figure B.24.  Product profile for starter unit 27 reaction (S-(2-acetamidoethyl) 2-
(pentyloxy)ethanethioate) 
 
Peak Compound Core 
Structure 






1 130a,b D/E CH2OCH2OC2H5 232, 280 375.1074 ‘Hept’+7Mal -2H2O O-C C19H18O8 
2 131 G CH2CO 
CH2OCH2OC2H5 
270, 280, 390 375.1076 ‘Hept’+7Mal -2H2O O-C C19H18O8 











Peak Compound Core 
Structure 






















2 134a,b D/E* C3H6CN 224, 280 372.1071 Cyanobut+7Mal -H2O O-C C19H17NO7 
3 135 F CH2COC3H6CN 226, 270, 390 368.0763 Cyanobut+7Mal -2H2O O-C, [O] C19H13NO7 
4    234, 266, 350 396.1095 Cyanobut+8Mal   C21H17NO7 
5 136 G CH2COC3H6CN 270, 280, 390 354.0964 Cyanobut+7Mal -2H2O O-C C19H15NO6 
Appendix Figure B.26.  Product profile for starter unit 29 reaction (S-(2-acetamidoethyl) 4-
cyanobutanethioate).  *142a,b consist of hydrated versions of cores D, E 
 
Peak Compound Core 
Structure 
























2 139 G CH2COC3H6N3 270, 280, 390 370.1022 Azidobut+7Mal -2H2O O-C C18H15N3O6 












Peak Compound Core 
Structure 






1 42 G CH2COCH2COCH2COCH3 270, 280, 
390 
385.0923 10Mal -2H2O O-C C20H16O8 
2 140 G CH2COCH2COC3H5 280, 390 369.0964    +8Mal -2H2O O-C C20H16O7 
Appendix Figure B.28.  Product profile for starter unit 31 reaction (S-(2-acetamidoethyl) 
cyclopropanecarbothioate) 
 
Peak Compound Core 
Structure 






1 42 G CH2COCH2COCH2COCH3 270, 280, 
390 
385.0921 10Mal -2H2O O-C C20H16O8 
2 141 G CH2COCH2COC3H4CH3 280, 390 383.1123    +8Mal -2H2O O-C C21H18O7 

















Peak Compound Core 
Structure 






1 42 G CH2COCH2COCH2COCH3 270, 280, 
390 
385.0914 10Mal -2H2O O-C C20H16O8 
Appendix Figure B.30.  Product profile for starter unit 33 reaction (S-(2-acetamidoethyl) but-2-ynethioate) 
Peak Compound Core 
Structure 






1 34 N/A  245, 274 224.0749    C11H13NO2S 
Appendix Figure B.31.  Product profile for starter unit 34 reaction (S-(2-acetamidoethyl) benzothioate) 
Peak Compound Core 
Structure 






1 42 G CH2COCH2COCH2COCH3 270, 280, 
390 
385.0912 10Mal -2H2O O-C C20H16O8 



















































































Appendix Figure B.33. Purified proteins used in this study separated by SDS-PAGE 
and stained with Coomassie Blue. BenchMark Protein Ladder (Invitrogen) was used 
as a molecular weight standard (indicated in kDa). (A) 12% SDS-PAGE of wild-type 
PksA SAT-KS-MAT and PT-ACP.  (B) 12% SDS-PAGE of PksA SAT-KS-MAT 







Appendix Figure B.34.  NMR spectra of S-(2-acetamidoethyl) 5-bromopentanethioate (11) 







Appendix Figure B.35.  NMR spectra of S-(2-acetamidoethyl) 6-bromohexanethioate (12) A)  







Appendix Figure B.36.  NMR spectra of S-(2-acetamidoethyl) 5-chloropentanethioate (13) 







Appendix Figure B.37.  NMR spectra of S-(2-acetamidoethyl) 6-chlorohexanethioate (14) A)  







Appendix Figure B.38.  NMR spectra of S-(2-acetamidoethyl) 2-methylhexanethioate (15) 







Appendix Figure B.39.  NMR spectra of S-(2-acetamidoethyl) 3-methylhexanethioate (16) 







Appendix Figure B.40.  NMR spectra of S-(2-acetamidoethyl) 4-methylhexanethioate 







Appendix Figure B.41.  NMR spectra of S-(2-acetamidoethyl) 5-methylhexanethioate (18) 







Appendix Figure B.42.  NMR spectra of S-(2-acetamidoethyl) 4-methylpentanethioate (19) 







Appendix Figure B.43.  NMR spectra of S-(2-acetamidoethyl) hex-5-enethioate (22) A)  1H 







Appendix Figure B.44.  NMR spectra of S-(2-acetamidoethyl) 4-(methylthiol)butanethioate 







Appendix Figure B.45.  NMR spectra of S-(2-acetamidoethyl) 3-(methylthio)propanethioate 







Appendix Figure B.46.  NMR spectra of S-(2-acetamidoethyl) 2-(ethylthio)ethanethioate 







Appendix Figure B.47.  NMR spectra of S-(2-acetamidoethyl) 2-(methylthio)ethanethioate 







Appendix Figure B.48.  NMR spectra of S-(2-acetamidoethyl) 2-(pentyloxy)ethanethioate 







Appendix Figure B.49.  NMR spectra of S-(2-acetamidoethyl) 2-







Appendix Figure B.50.  NMR spectra of S-(2-acetamidoethyl) 4-cyanobutanethioate (29) (A)  







Appendix Figure B.51.  NMR spectra of S-(2-acetamidoethyl) 4-azidobutanethioate (30) (A)  








Appendix Figure B.52.  NMR spectra of S-(2-acetamidoethyl) 2-methylcyclopropane-1-








Appendix Figure B.53.  NMR spectra of S-(2-acetamidoethyl) but-2-ynethioate (33)  A)  1H 
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Appendix C: Supplementary Material for Chapter 3 
C.1.  Supplementary figures 
 
Appendix Figure C.1.  Integration of loading domains in PKS.  (a)  Sequence alignment of 34 
SAT-KS linker sequences of NR-PKS.  All sequences are labelled as “protein name (organism 
abbreviation) Uniprot number”.  (b)  Superposition of the CazM SAT (black) onto the SAT 
domain of CTB1 SAT-KS-MAT (light grey) shows a similar location of the SAT C-terminal linker 
ending (dark red/light red for CazM/CTB1), which points towards the N-terminus of the KS in 
CTB1.  (c)  Superposition of the loading domain of the AVES1 avermectin modPKS (black) onto 
the SAT domain of CTB1 SAT-KS-MAT reveals differences in C-terminal linker organization.  (d)  
Superposition of the AVES1 loading domain onto CTB1-MAT shows that the AVES1 post-loading 
domain linker contains an α-helix that matches the linker architecture of MAT in CTB1 (and AT 






Appendix Figure C.2.  Cryo-EM data processing scheme.  (a)  2D- and 3D-classification and 
sorting scheme for reconstructions of CTB1-SAT°-KS-MAT°=ACP2 dimers as well as monomers. 
3D-class distributions are indicated below the models. FSC plots (corrected for effects of the 
mask) used for determining resolution based on the 0.143 criterion30 is shown below the final 
models.  (b,c)  3D (b) and 2D (c) angular distribution plot based on the alignment used for the 
final reconstruction. (d) Local resolution map of the final reconstruction at 7.1 Å resolution shows 
a resolution below 5 Å in the central KS region, decreasing towards the lateral MAT domains to 
217 
 
around 10 Å. (e) The final map reveals features of secondary structure elements as well as linkers. 
All maps are contoured at 7.1σ. 
 
 
Appendix Figure C.3.  Crosslinking and cryo-EM sample preparation. (a) Crosslinking time course in 
high (50 mM Tris pH 7.5, 250 mM NaCl) and low (50 mM Tris pH 7.5) salt buffer as well as for two 
different CTB1-SAT°-KS-MAT°:ACP2 ratios. Crosslinking proceeds faster in low salt buffer and at higher 
excess of ACP2. (b,c) Drift corrected and dose filtered cryo-EM micrographs reveal clearly recognizable 
shapes for monomeric (b) and dimeric (c) particles. (d) Denaturating SDS-PAGE analysis with Coomassie 











Appendix Figure C.4.  Conformational variability in the cryo-EM structure of CTB1-SAT0-KS-
MAT0=ACP2. (a.b)  KS-based C2 symmetry differences map of the final reconstruction at 7.1 Å 
resolution, contoured at 7.1σ (green: positive, red: negative). The potential ACP2 binding region 
on the KS surface is less ordered on the side lacking ACP2 density. (b) An unmasked map of the 
final reconstruction contoured at 3σ and colored by distance to the atomic model shows 



















Appendix Figure C.5.  Structural comparison between CTB1-SAT-KS-MAT and CTB1-SAT°-KS-
AT°=ACP2. (a)  Superposition on the central KS dimer. Transparent cartoon representation of 
CTB1 is shown in white (CTB1 SAT-KS-MAT) and black (CTB1 SAT°-KS-MAT°=ACP2). Selected 
helices are shown in light (CTB1 SAT-KS-MAT) and dark (CTB1 SAT°-KS-MAT°=ACP2) domain 
colors. (b) Schematic representation of relative domain motions. Distances are derived by 
domain-wise Cα-r.m.s.d. calculations. (c, d) Structural differences at the MAT-SAT interface in the 
cryo-EM reconstruction are shown for the unsharpened map. While the side with visualized 








Appendix Figure C.6.  CTB1 SAT-KS-MAT alignment of regions interfacing ACP2 and 
phylogeny. All sequences are labelled as “protein name (organism abbreviation) Uniprot 
number”. (a)  Sequence alignment of regions relevant for ACP2 interaction. *indicates interface 
mutants that reduce activity. (b)  Phylogenetic analysis of NR-PKS indicates three main clades 
with one clustering around CTB1. Distance unit is given as accepted amino-acid substitutions per 
site and indicated by scale bar. 
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Appendix Figure C.7.  Comparison of KS-ACP interactions in PKS and FAS. (a) ACP interactions 
with multienzyme KS domains have been observed in the hetero-dodecameric yFAS and PikAIII 
modPKS. (b)  Superposition of the architecturally distinct yFAS-KS with CTB1-KS-LD°=ACP2. 
The divergent ACP of yFAS consists of a C-terminal four-helix bundle extension (white) and the 
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conserved four-helix bundle at the N-terminus, which interacts with the KS in a similar position 
as observed for ACP2 in CTB1. ACP-interfacing residues in CTB1 are indicated by blue spheres 
(see Figure 3.8) (c)  Derivation of the length of a fully extended crosslink between ACP2 and KS 
in CTB1. The defined length of the phosphopantetheine cofactor bridges a distance of approx. 
27 Å between the ACP-Ser and the KS-Cys Cα atoms for functional ACP interaction with active 
sites. (d,e)  Superpositions of PikAIII with ACP4 (d) and ACP5 (e) on CTB1-KS-LD=ACP2 show 
the relative locations of the ACP binding interfaces. The LD5 arrangement in PikAIII is invers to 
CTB1. (f-i)  Cα-Cα solvent accessible surface (SAS) distances between the ACP anchor and the KS 
active site cysteine in CTB1 (f), yFAS (g), and PikAIII with ACP4 (h) and ACP5 (i) are indicated. 
Solvent accessible surface paths are indicated by tubes of spheres and colored according to the 
agreement (green) or disagreement (red) with the length of the Ppant cofactor. The path for ACP5 
to KS5 in PikAIII (i) is only accessible in the absence of the post-(M)AT linker, which was not 
resolved in the cryo-EM structure. An additional miniaturized-sideview is indicated. 
Corresponding euclidian distances are given in the panels. Domain colors are indicated in the 




















C.2.  Supplementary tables 
Appendix Table C.1.  X-ray crystallographic (a) and cryo-EM (b) data collection and refinement 
statistics.  Resolution cutoff in (a) was determined by CC1/2 criterion1.  Highest resolution shell is 
shown in parentheses. 
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Appendix Table C.2.  Structural comparison and interface analysis of CTB1 SAT-KS-MAT.  (a) Cα 
r.m.s. deviations obtained for structural comparison of crystallized CTB1 domains with their 
closest structural neighbors in the PDB and of multienzyme PKSs and FASs (to the best of our 
knowledge).  For structures with several protomers, only the best matches are reported.  *Q-score 
225 
 
based, †trans-AT PKS.  (b) Interfaces in the crystal structures of CTB1 SAT-KS-MAT.  §Interface 
with the second protomer. 




pECTB1-NKA62 SAT-KS-MAT pET-24a C-His6 140150 138200 
pECTB1-SKM-C119A-S1010A SAT°-KS-MAT° pET-24a C-His6 140150 138200 
p28CTB1-ACP2 ACP2 pET-28a N-His6 11970 5500 
pECTB1-SKM-R461A SAT-KS-MAT-R461A pET-24a C-His6 140150 138200 
pECTB1-SKM-R461E SAT-KS-MAT-R461E pET-24a C-His6 140150 138200 
pECTB1-SKM-R658A SAT-KS-MAT-R658A pET-24a C-His6 140150 138200 
pECTB1-SKM-R658E SAT-KS-MAT-R658E pET-24a C-His6 140150 138200 
pECTB1-SKM-R879A SAT-KS-MAT-R879A pET-24a C-His6 140150 138200 
pECTB1-SKM-R879E SAT-KS-MAT-R879E pET-24a C-His6 140150 138200 
pECTB1-PT2 PT pET-24a C-His6 41240 26150 
pECTB1-TE2 TE pET-28a N-His6 33630 38055 
pECTB1-ACP2-E1794A ACP2-E1794A pET-28a N-His6 11970 5500 
pECTB1-ACP2-E1794R ACP2-E1794R pET-28a N-His6 11970 5500 
pECTB1-ACP2-E1795A ACP2-E1795A pET-28a N-His6 11970 5500 
pECTB1-ACP2-E1795R ACP2-E1795R pET-28a N-His6 11970 5500 
pECTB1-ACP2-E1802A ACP2-E1802A pET-28a N-His6 11970 5500 
pECTB1-ACP2-E1802R ACP2-E1802R pET-28a N-His6 11970 5500 
pECTB1-ACP2-D1806A ACP2-D1806A pET-28a N-His6 11970 5500 
pECTB1-ACP2-D1806R ACP2-D1806R pET-28a N-His6 11970 5500 
pECTB1-ACP2-D1811A ACP2-D1811A pET-28a N-His6 11970 5500 
pECTB1-ACP2-D1811R ACP2-D1811R pET-28a N-His6 11970 5500 
pECTB1-ACP2-D1815A ACP2-D1815A pET-28a N-His6 11970 5500 
pECTB1-ACP2-D1815R ACP2-D1815R pET-28a N-His6 11970 5500 
pECTB1-ACP1 ACP1 pET-28a N-His6 11160 N/A 
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Appendix D:  Supplementary Material to Chapter 4 
 
D.1.  CTB gene sequences 
 mRNA sequences from C. beticola are shown. 





























































































































































































































































































































































































D.2.  CTB protein sequences 





































































































D.2.10.  CTB10 
MGSIGEPNRLLCWSIYVTKKPDQSEEDHHNHVSKVNAPMMIPFLKKYGIVRYTVKHNDAHSKPKQAALMAG
QPEENVLAYDTVFEMIVKDIESIQTMQKDEEFLRTTIPDHFNFADMTRSKGSLTWIEEFTF* 
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